FIELD OF THE INVENTION
[0001] The present invention relates to photochromic materials that include a photochromic
compound that includes a photochromic substituent selected from photochromic pyrans,
photochromic oxazines and photochomic fulgides (e.g., an indeno-fused naphthopyran)
and at least one pendent silane group bonded to the photochromic substituent. The
pendent silane groups are selected from certain pendent siloxy-silane groups and/or
pendent alkoxy-silane groups. The photochromic materials of the present invention
provide a desirable combination of molar absorption coefficients, activation times,
fade times and linear fade relative to comparable photochromic materials (e.g., the
photochromic substituents thereof alone). The photochromic materials of the present
invention have improved compatibility with compositions into which they may be incorporated,
for example, coating compositions, such as urethane coating compositions.
BACKGROUND OF THE INVENTION
[0002] In response to certain wavelengths of electromagnetic radiation (or "actinic radiation"),
photochromic materials, such as indeno-fused naphthopyrans, typically undergo a transformation
from one form or state to another form, with each form having a characteristic or
distinguishable absorption spectrum associated therewith. Typically, upon exposure
to actinic radiation, many photochromic materials are transformed from a closed-form,
which corresponds to an unactivated (or bleached, e.g., substantially colorless) state
of the photochromic material, to an open-form, which corresponds to an activated (or
colored) state of the photochromic material. In the absence of exposure to actinic
radiation, such photochromic materials are reversibly transformed from the activated
(or colored) state, back to the unactivated (or bleached) state. Compositions and
articles, such as eyewear lenses, that contain photochromic materials or have photochromic
materials applied thereto (e.g., in form of a photochromic coating composition) typically
display colorless (e.g., clear) and colored states that correspond to the colorless
and colored states of the photochromic materials contained therein or applied thereto.
[0003] Upon exposure to actinic radiation (e.g., sunlight), the photochromic material typically
is transformed from the unactivated (or bleached) state to the activated (or colored)
state over a period of time that is referred to as an activation time. Correspondingly,
when exposure to actinic radiation is halted (e.g., due to shielding of sunlight),
the photochromic material typically is transformed from the activated (or colored)
state to the unactivated (or bleached) state over a period of time that is referred
to as a fade time. It is generally desirable that the activation time and the fade
time associated with a photochromic material in each case be minimized. In addition,
it is desirable that the fade rate associated with a photochromic material be substantially
linear. With photochromic eyewear, such as photochromic lenses, a linear fade rate
allows the wearer's eyes to adjust more smoothly and less noticeably to the wearer
as the lenses transform from a colored to a bleached state.
[0004] The amount of a photochromic material required to achieve a desired optical effect
when incorporated into a composition or article typically depends, at least in part,
on the amount of actinic radiation that the photochromic material is capable of absorbing
on a per molecule basis. The amount of actinic radiation that a particular photochromic
material absorbs on a per molecule basis is quantitatively referred with regard to
the molar absorption coefficient (or "extinction coefficient") of the photochromic
material. Photochromic materials having a relatively high molar absorption coefficient
are more likely to transform from a closed-form to an open-form upon exposure to actinic
radiation, than photochromic materials having a relatively lower molar absorption
coefficient. Correspondingly, photochromic materials having a higher molar absorption
coefficient may be used in lower concentrations in photochromic compositions and articles,
than photochromic materials having a lower molar absorption coefficient, without compromising
the desired optical effect.
[0005] In some applications, a photochromic material having a relatively high and desirable
molar absorption coefficient may have limited solubility in the composition or material
into which it is to be incorporated (e.g., a coating composition). As such, compositions
or materials in which the photochromic material has low solubility, may be capable
of having incorporated therein only a limited and relatively low amount of photochromic
material. With a limited and relatively low amount of photochromic material incorporated
therein, the resulting photochromic composition would have reduced photochromic properties
(e.g., having reduced absorbance when fully activated), than if more photochromic
material were capable of being incorporated therein. Accordingly, increasing the solubility
of a photochromic material in a particular composition, such as a coating composition,
may be desirable in some applications.
[0006] It would be desirable to develop new photochromic materials that provide a desirable
combination of molar absorption coefficients, activation times, fade times and linear
fade relative to comparable photochromic materials. In addition, it would also be
desirable that such newly developed photochromic materials have improved solubility
in certain compositions, for example coating compositions.
[0007] JP-A-2000 226571 discloses photochromic compounds having pendant groups which might be regarded as
being similar to the those of general formula I of present invention, but its photochromic
moiety is not selected from pyrans, oxazines and fulgides.
SUMMARY OF THE INVENTION
[0008] In accordance with the present invention, there is provided a photochromic material
comprising,
a photochromic compound comprising a photochromic substituent selected from photochromic
pyrans, photochromic oxazines and photochomic fulgides and at least one pendent silane
group bonded to said photochromic substituent, each pendent silane group being selected
independently from the group consisting of,
- (i) pendent silane groups represented by the following general formula I,

wherein Z for each n is independently Si or C, R is selected from hydrogen or C1-C10 hydrocarbyl, each R1 is independently selected from C1-C10 hydrocarbyl and halo substituted C1-C10 hydrocarbyl, m is 0 or 1, n is 2 or 3, provided that the sum of m and n is 3, and
L is a bond or a divalent linking group comprising at least one divalent moiety selected
from the group consisting of divalent organic moieties, divalent inorganic moieties
and combinations thereof,
- (ii) pendent silane groups represented by the following general formula II,

and combinations thereof,
wherein Z, R, R
1, m, n and L are each independently as described with regard to general formula (I),
R
a is a divalent linking group selected from divalent organic moieties, R
b is selected from hydrogen or C
1-C
10 hydrocarbyl, t is 0, 1 or 2, and y is 1, 2 or 3, provided that the sum of t and y
is 3.
[0009] As used herein and in the claims, the term "actinic radiation" means electromagnetic
radiation that is capable of transforming a photochromic material from one form or
state to another.
[0010] As used herein, the term "photochromic" means capable of exhibiting a light-induced
reversible change of color, for example, exhibiting a reversible change of color in
response to at least actinic radiation. Further, as used herein the term "photochromic
material" means any substance that is adapted to display photochromic properties,
i.e. adapted to change color in response to light, for example, actinic radiation,
and which includes at least one photochromic compound.
[0011] As used herein and in the claims, the term "photochromic substituent" and similar
terms, such as "photochromic moiety" and "photochromic substrate," means a photochromic
group that by itself has photochromic properties in the absence of one or more pendent
silane groups bonded thereto. The photochromic compounds of the present invention
have enhanced properties (e.g., improved matrix solubility and/or improved optical
density and/or improved fade rates) relative to the photochromic substituents thereof
alone. It should be understood that the at least one pendent silane group bonded to
the photochromic substituent of the photochromic compound can be bonded directly to
the "core" photochromic moiety (for example, at one of the numbered positions of the
photochromic compound represented by general formula (III) hereinbelow), or, where
applicable, bonded to a substituent which is bonded directly to the core photochromic
moiety (e.g. subsitutent R
5, R
6, R
7, R
8, R
9, R
10, R
11, and/or R
12 described with respect to the photochromic compound represented by general formula
(III) hereinbelow).
[0012] The term "closed-form absorption spectrum," as used herein and in the claims, means
the absorption spectrum of a photochromic material in the closed-form or unactivated
state of the photochromic material, and more particularly, the wavelength(s) of electromagnetic
radiation that cause a photochromic material to undergo the desired closed-form to
open-form transformation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013]
Figure 1 is a representative schematic diagram of a synthetic reaction scheme for
making an intermediate material that may be used in forming photochromic materials
according to the present invention;
Figure 2 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of an indeno-fused naphthopyran to which a pendent silane group may
be bonded to form a photochromic compound according to the present invention;
Figure 3 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of indeno-fused naphthopyrans having a hydroxyl group at Position-13
thereof, to which a pendent silane group may be bonded to from a photochromic compound
according to the present invention;
Figure 4 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of an indeno-fused naphthopyran having a methylenol group at Position-13
thereof, to which a pendent silane group may be bonded to from a photochromic compound
according to the present invention;
Figure 5 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to a Position-13
hydroxyl of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 3;
Figure 6 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to a Position-13
methylenol group of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 4;
Figure 7 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to a B group of
an indeno-fused naphthopyran prepared in accordance with the synthetic reaction scheme
of Figure 2;
Figure 8 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to each of the
B and B' groups of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 2;
Figure 9 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to a Position-13
hydroxyl of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 3;
Figure 10 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to Position-11
of an indeno-fused naphthopyran prepared in accordance with the synthetic reaction
scheme of Figure 2;
Figure 11 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (I) is bonded to a Position-13
hydroxyl of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 3; and
Figure 12 is a representative schematic diagram of a synthetic reaction scheme depicting
the preparation of a photochromic compound according to the present invention in which
a pendent silane group represented by general formula (II) is bonded to a Position-13
hydroxyl of an indeno-fused naphthopyran prepared in accordance with the synthetic
reaction scheme of Figure 3.
DETAILED DESCRIPTION OF THE INVENTION
[0014] The photochromic material of the present invention includes a photochromic compound
that includes a photochromic substituent selected from photochromic pyrans, photochromic
oxazines and photochomic fulgides having bonded thereto at least one pendent silane
selected from one or more of the pendent silanes represented by general formulas (I)
and/or (II). The R group of formulas (I) and/or (II) may in each case and for each
m be independently selected from hydrogen, C
1-C
10 hydrocarbyl.
[0015] As used herein and in the claims the term "hydrocarbyl" and similar terms, such as
"hydrocarbyl substituent," means: linear or branched C
1-C
20 alkyl (e.g., linear or branched C
1-C
10 alkyl); linear or branched C
2-C
20 alkenyl (e.g., linear or branched C
2-C
10 alkenyl); linear or branched C
2-C
20 alkynyl (e.g., linear or branched C
2-C
10 alkynyl); C
3-C
12 cycloalkyl (e.g., C
3-C
10 cycloalkyl); C
3-C
12 heterocycloalkyl (having at least one hetero atom in the cyclic ring); C
5-C
18 aryl (including polycyclic aryl groups) (e.g., C
5-C
10 aryl); C
5-C
18 heteroaryl (having at least one hetero atom in the aromatic ring); and C
6-C
24 aralkyl (e.g., C
6-C
10 aralkyl).
[0016] Representative alkyl groups include but are not limited to methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, heptyl,
octyl, nonyl and decyl. Representative alkenyl groups include but are not limited
to vinyl, allyl and propenyl. Representative alkynyl groups include but are not limited
to ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, and 2-butynyl. Representative cycloalkyl
groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
and cyclooctyl substituents. Representative heterocycloalkyl groups include but are
not limited to tetrahydrofuranyl, tetrahydropyranyl and piperidinyl. Representative
aryl groups include but are not limited to phenyl and naphthyl. Representative heteroaryl
groups include but are not limited to furanyl, pyranyl and pyridinyl. Representative
aralkyl groups include but are not limited to benzyl, and phenethyl.
[0017] The term hydrocarbyl as used herein and in the claims is inclusive of halohydrocarbyl
(or halo substituted hydrocarbyl) substituents. By halohydrocarbyl (or halo substituted
hydrocarbyl) is meant that at least one hydrogen atom of the hydrocarbyl (e.g., of
the alkyl, alkenyl, alkynyl, cycloalky, aryl and aralkyl groups) is replaced with
a halogen atom selected from chlorine, bromine, fluorine and iodine. The degree of
halogenation can range from at least one hydrogen atom being replaced by a halogen
atom (e.g., a fluoromethyl group) to full halogenation (perhalogenation) wherein all
replaceable hydrogen atoms on the hydrocarbyl group have been replaced by a halogen
atom (e.g., trifluoromethyl or perfluoromethyl). Perhalohydrocarbyl groups as used
herein and in the claims include perhalogenated phenyl and alkyl groups.
[0018] The R
1 groups of the pendent silane groups represented by formulas (I) and/or (II) may in
each case and for each n be independently selected from C
1-C
10 hydrocarbyl and halo substituted C
1-C
10 hydrocarbyl. The terms hydrocarbyl and halo substituted hydrocarbyl relative to R
1 are as described previously herein with regard to R. Typically, each R of formulas
(I) and (II) is independently selected from hydrogen or linear or branched C
1-C
10 alkyl (e.g., methyl and ethyl), and more typically from hydrogen or methyl. Typically,
each R
1 of formulas (I) and (II) is selected independently from linear or branched C
1-C
10 alkyl (e.g., methyl or ethyl), and more typically is methyl. In an embodiment of
the present invention for the pendent silane groups represented by formulas (I) and
(II), m is 0, n is 3 and each R
1 is independently methyl or ethyl.
[0019] The R
b group of the pendent silane group represented by formula (II) may be selected from
hydrogen or C
1-C
10 hydrocarbyl. The term hydrocarbyl relative to R
b is as described previously herein with regard to R. Typically, each R
b of formula (II) is selected from hydrogen or linear or branched C
1-C
10 alkyl (e.g., methyl or ethyl), and more typically hydrogen or methyl. In an embodiment
of the present invention, for the pendent silane group represented by formula (II):
t is 0 and y is 3; m is 0 and n is 3; and each R
1 is independently methyl or ethyl.
[0020] The divalent linking group L of the pendent silane groups represented by formulas
(I) and (II) may in each case independently be a bond or a divalent linking group
comprising at least one divalent moiety selected from one or more divalent organic
moieties and/or one or more divalent inorganic moieties. The divalent linking group
L may comprise a plurality of divalent organic moieties and a plurality of divalent
inorganic moieties. As used herein and in the claims, the term "divalent organic moieties/moiety"
and similar terms, such as "divalent organic group(s)" may also be described as "divalent
hydrocarbylene moieties." More particularly, as used herein and in the claims, the
term "divalent organic moieties/moiety" and similar terms, such as "divalent organic
group(s)" means substituted or unsubstituted linear or branched C
1-C
20 alkylene, substituted or unsubstituted linear or branched C
2-C
20 alkenylene, substituted or unsubstituted, linear or branched C
2-C
10 alkynyl, substituted or unsubstituted C
3-C
10 cycloalkylene, substituted or unsubstituted C
3-C
10 heterocycloalkylene (having at least one hetero atom in the cyclic ring), substituted
or unsubstituted arylene (e.g., C
6-C
18 aryl, including polycyclic arylene groups), substituted or unsubstituted heteroarylene
(having at least one hetero atom in the cyclic arylene ring or rings).
[0021] With regard to the divalent organic moieties from which the divalent linking group
L may be selected, representative divalent alkylene groups include but are not limited
to methylene (-CH
2-), ethylene (-CH
2CH
2-), propylene (-CH
2CH
2CH
2-), isopropylene (e.g., -CH
2CH(CH
3)-), butylene (-CH
2CH
2CH
2CH
2-), isobutylene, sec-butylene, tert-butylene, pentylene, neopentylene, hexylene, heptylene,
octylene, nonylene and decylene. Representative divalent alkenylene groups include
but are not limited to vinylene (-CH=CH-), and propenylene (e.g., -C(CH
3)=CH-). Representative divalent alkynylene groups include but are not limited to ethynylene
(-CC-), propynylene (-CC-CH
2-), and butynylene (e.g., -CC-CH(CH
2)-). Representative divalent cycloalkylene groups include but are not limited to cyclopropylene,
cyclobutylene, cyclopentylene, cyclohexylene, and cyclooctylene. Representative divalent
heterocycloalkylene groups include but are not limited to tetrahydrofuranylene, tetrahydropyranylene
and piperidinylene. Representative divalent arylene groups include but are not limited
to phenylene, naphthylene and anthracenylene. Representative divalent heteroarylene
groups include but are not limited to furanylene, pyranylene and pyridinylene. Representative
divalent aralkylene groups include but are not limited to benzylene, and phenethylene.
[0022] The term "substituted" with regard to the various divalent moieties from which the
divalent organic moiety may be selected means that at least one of the substitutable
hydrogens of the divalent organic moiety is substituted with another group. For example,
a substituted C
1-C
20 alkylene group may be substituted with at least one substituent selected from alkenyl
groups, alkynyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups and
heteroaryl groups. Examples of substituents of the substituted divalent organic moieties
include, but are not limited to: alkyl groups (e.g., methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, heptyl, octyl, nonyl
and decyl); alkenyl groups (e.g., vinyl, allyl and propenyl); alkynyl groups (e.g.,
ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, and 2-butynyl); cycloalkyl groups (e.g.,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl); heterocycloalkyl
groups (e.g., tetrahydrofuranyl, tetrahydropyranyl and piperidinyl); aryl groups (e.g.,
phenyl, biphenyl, naphthyl and anthracenyl); arakyl groups (e.g., benzyl and phenethyl)
and heteroaryl groups (e.g., furanyl, pyranyl and pyridinyl); halo or halogen groups
(e.g., chloro, bromo, fluoro and iodo); ketones (e.g., hydrocarbyl ketones); carboxylic
acid esters (e.g., hydrocarbyl carboxylates); hydroxyl; thiol; amino groups (e.g.,
-NH
2); ethers (e.g., hydrocarbyl ethers); thio ethers (e.g., hydrocarbyl thio ethers);
and combinations thereof.
[0023] The term "unsubstituted" with regard to the various divalent moieties from which
the divalent organic moiety may be selected means that none of the substitutable hydrogens
of the divalent organic moiety are substituted with another group (e.g., a halogen).
[0024] Additional divalent groups from which the divalent organic moieties, of the divalent
linking group L of the pendent silane groups represented by formulas (I) and (II),
may be selected include, but are not limited to: -N(R
2)-; -C(R
3)(R
4)-C(O)-O-; -C(R
5)(R
6)-C(O)-N(R
7)-; -C(O)-N(R
7)-;

and -R
9-O-. With these additional divalent organic moieties, R
2, R
3, R
4, R
5, R
6 and R
7 may each independently be selected from substituted or unsubstituted, linear or branched
C
1-C
20 alkyl, substituted or unsubstituted C
3-C
10 cycloalkyl, substituted or unsubstituted C
3-C
10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl. The R
3, R
4, R
5 and R
6 groups may each independently also be hydrogen. When R
2 and R
7 are each hydrogen, the related divalent linking groups, -N(R
2)- and -C(O)-N(R
7)-, are characterized herein more so as divalent inorganic linking groups, as further
recited and categorized below.
[0025] With regard to the divalent organic moiety represented by the following general formula,

the R
8 group, for each p, may independently be selected from substituted or unsubstituted,
linear or branched C
1-C
20 alkylene, substituted or unsubstituted, linear or branched C
2-C
20 alkenylene, substituted or unsubstituted, linear or branched C
2-C
20 alkynylene, and substituted or unsubstituted C
3-C
10 cycloalkylene (in which the terms substituted, unsubstituted, alkylene, alkenylene,
alkynylene and cycloalkylene are as described previously herein). The subscript "p"
may be an integer of at least 1, for example from 1 to 100, or 1 to 50, or 1 to 25
or 1 to 10, inclusive of the recited numbers.
[0026] With regard to the divalent organic moiety -R
9-O-, R
9 may be selected from, for example, substituted or unsubstituted, linear or branched
C
1-C
20 alkylene, substituted or unsubstituted, linear or branched C
2-C
20 alkenylene, substituted or unsubstituted, linear or branched C
2-C
20 alkynylene, substituted or unsubstituted C
3-C
10 cycloalkylene, and substituted or unsubstituted arylene (in which the terms substituted,
unsubstituted, alkylene, alkenylene, alkynylene and cycloalkylene are as described
previously herein).
[0027] The divalent inorganic linking group, of the divalent linking group L of the pendent
silane groups represented by formulas (I) and (II), may be selected from, for example,
at least one of: -O-; -S-; Si(R
1)
2- in which each R
1 is independently as described with regard to formulas (I) and (II); -NH-; -C(O)-;
-C(O)-O-; -O-C(O)-O-; -C(O)-NH-;-NH-C(O)-O-; -NH-C(O)-S-; -NH-C(S)-O-; and -NH-C(S)-S-.
[0028] The divalent linking group R
a of the pendent silane group represented by general formula (II) is selected from
divalent organic moieties. The divalent organic moieties from which divalent linking
group R
a may be selected include one or more of those classes and examples of divalent organic
moieties as recited previously herein with regard to the divalent linking group L.
For example, the divalent linking group R
a may be selected from linear or branched C
1-C
10 alkylene, eg., methylene (-CH
2-), ethylene (-CH
2CH
2-), propylene (-CH
2CH
2CH
2-), isopropylene (e.g., -CH
2CH(CH
3)-), butylene (-CH
2CH
2CH
2CH
2-), isobutylene, sec-butylene, tert-butylene, pentylene, neopentylene, hexylene, heptylene,
octylene, nonylene and decylene.
[0029] In an embodiment of the present invention, the divalent linking group L of the pendent
silane groups represented by general formulas (I) and (II) in each case independently
comprises at least one divalent moiety selected from -O-, -S-, -Si(R
1)
2-, -N(R
2)-, -C(O)-, -C(O)-O-, -O-C(O)-O-, -C(R
3)(R
4)-C(O)-O-, -C(R
5)(R
6)-C(O)-N(R
7)-, -C(O)-N(R
7)-, -NH-C(O)-O-, -NH-C(O)-S-, -NH-C(S)-O-, -NH-C(S)-S-,

-R
9-O-, substituted or unsubstituted, linear or branched C
1-C
20 alkylene, substituted or unsubstituted, linear or branched C
2-C
20 alkenylene, substituted or unsubstituted, linear or branched C
2-C
20 alkynylene, substituted or unsubstituted C
3-C
10 cycloalkylene, substituted or unsubstituted C
3-C
10 heterocycloalkylene, substituted or unsubstituted arylene, substituted or unsubstituted
heteroarylene, and combinations of two or more thereof. The R
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8 and R
9 groups are each as described previously herein. The subscript p is as described previously
herein (e.g., from 1 to 100). In this particular embodiment, the divalent linking
group R
a of formula (II) is selected from linear or branched C
1-C
10 alkylene.
[0030] Each divalent linking group L may be formed from, or composed of, a single divalent
organic moiety, a single divalent inorganic moiety, combinations of two or more divalent
organic moieties, combinations of two or more divalent inorganic moieties, or combinations
of one or more divalent organic moieties and one or more divalent inorganic moieties
(in each case selected from, for example, those classes and examples of divalent linking
groups as recited previously herein). For example, a divalent linking group represented
by the following general formula,
-O-C(O)-R
9-C(O)-O-,
may be described as being composed of: a divalent organic moiety -O-C(O)-; for example,
a divalent substituted or unsubstituted, linear or branched C
1-C
20 or C
1-C
10 alkylene group for -R
9-; and another divalent organic moiety -O-C(O)-. For purposes of further illustration,
a divalent linking group represented by the following general formula,
-O-C(O)-R
9-C(O)-NH-,
may be described as being composed of: a divalent organic moiety -O-C(O)-; for example,
a divalent substituted or unsubstituted, linear or branched C
1-C
20 or C
1-C
10 alkylene group for -R
9-; and a further divalent organic moiety -C(O)-N(R
7)-, where R
7 is hydrogen. An example of a combination of a divalent arylene moiety (e.g., phenylene)
and a divalent heterocycloalkyl moiety (e.g., N-piperidinylene), is represented by
the following general formula,

[0031] In a further embodiment, the divalent linking group L, of the pendent silane groups
represented by general formulas (I) and (II), in each case independently comprises
at least one divalent moiety selected from -O-, -Si(R
1)
2-,-C(O)-O-,

-R
9-O-, substituted or unsubstituted, linear or branched C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, linear or branched C
2-C
10 alkynylene, -O-C(O)-R
9-C(O)-O-, -O-C(O)-R
9-C(O)-NH-,

and combinations of two or more thereof. With this particular embodiment, R
8 for each p is independently selected from substituted or unsubstituted, linear or
branched C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, and linear or branched C
2-C
10 alkynylene, and p is from 1 to 10. Each divalent R
9 group, in this particular embodiment, is selected independently from substituted
or unsubstituted, linear or branched C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, linear or branched C
2-C
10 alkynylene, substituted or unsubstituted C
3-C
10 cycloalkylene, and substituted or unsubstituted arylene.
[0033] In this particular embodiment, R
8 for each p is independently selected from substituted or unsubstituted, linear or
branched C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, and linear or branched C
2-C
10 alkynylene. Each divalent R
9 group, in this particular embodiment, is selected independently from substituted
or unsubstituted, linear or branched C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, linear or branched C
2-C
10 alkynylene, substituted or unsubstituted C
3-C
10 cycloalkylene, and substituted or unsubstituted arylene. Each divalent R
10 group is independently selected from substituted or unsubstituted, linear or branched
C
1-C
10 alkylene, substituted or unsubstituted, linear or branched C
2-C
10 alkenylene, substituted or unsubstituted, linear or branched C
2-C
10 alkynylene, substituted or unsubstituted C
3-C
10 cycloalkylene, and substituted or unsubstituted arylene. Regarding the subscripts:
p is from 1 to 10; p' is from 1 to 10 (e.g., from 2 to 10), and q is from 1 to 10.
[0034] For purposes of further illustrating that each divalent linking group L may be formed
from, or composed of, combinations of those classes and examples of divalent linking
groups as recited previously herein, the following divalent linking group,

may be described as being composed of the following divalent moieties:

-O-C(O)-R
9-C(O)-NH-; and, for example, a substituted or unsubstituted, linear or branched C
1-C
20 or C
1-C
10 alkylene group for -R
10-.
[0035] Similarly, the following divalent linking group,

may be described as being composed of the following divalent moieties:

and for example, a substituted or unsubstituted, linear or branched C
1-C
20 or C
1-C
10 alkylene group for -R
10-.
[0036] In a particular embodiment of the present invention, for the pendent silane groups
represented by formulas (I) and (II): each R
1 is independently linear or branched C
1-C
10 alkyl (e.g., methyl or ethyl); each R is independently hydrogen or linear or branched
C
1-C
10 alkyl (e.g., methyl or ethyl); and R
b, of formula (II) is hydrogen or linear or branched C
1-C
10 alkyl (e.g., hydrogen, methyl or ethyl).
[0037] Non-limiting examples of pendent silane groups, of the photochromic materials of
the present invention, are described in further detail herein with reference to the
following general formulas, in which the symbol PC represents a photochromic substituent
to which the various pendent silane groups are bonded. In the following general formulas,
while a single pendent silane group is depicted as being bonded to the photochromic
substituent, a plurality of (e.g., 2 or more) pendent silane groups, which may be
the same or different, may be bonded to the photochromic substituent.
[0038] A photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (1),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (1a),

[0039] Another photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (2),

in which m is 0, n is 3, Z is C, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (1a),

[0040] A further photochromic compound according to the present invention, in which the
pendent silane group is represented by general formula (I), is represented by the
following general formula (3),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (3a),
(3a) -CH
2-O-.
[0041] In an embodiment, a photochromic compound according to the present invention having
a pendent silane group represented by general formula (I), is represented by the following
general formula (4),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (4a),
(4a) -(CH
2)
11-O-.
[0042] In another embodiment, a photochromic compound according to the present invention
having a pendent silane group represented by general formula (I), is represented by
the following general formula (5),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (5a),
(5a) -O-Si(CH
3)
2-CH
2CH
2-.
[0043] In a further embodiment, a photochromic compound according to the present invention
having a pendent silane group represented by general formula (I), is represented by
the following general formula (6),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (6a),

[0044] A photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (7),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (7a),

[0045] Another photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (8),

in which m is 1, R is methyl, n is 2, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (8a),

[0046] A further photochromic compound according to the present invention, in which the
pendent silane group is represented by general formula (I), is represented by the
following general formula (9),

in which m is 1, R is methyl, n is 2, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (9a),

[0047] In an embodiment, a photochromic compound according to the present invention having
a pendent silane group represented by general formula (I), is represented by the following
general formula (10),

in which m is 1, R is methyl, n is 2, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (10a),

[0048] A photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (11),

in which m is 1, R is methyl, n is 2, Z is Si, one R
1 is methyl, the remaining R
1 groups are each -CH
2CH
2CF
2CF
2CF
2CF
3, and L is a divalent linking group represented by the following general formula (11a),

[0049] In another embodiment, a photochromic compound according to the present invention
having a pendent silane group represented by general formula (I), is represented by
the following general formula (13),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (13a),

[0050] A further photochromic compound according to the present invention, in which the
pendent silane group is represented by general formula (I), is represented by the
following general formula (14),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (14a),

[0051] A photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (I), is represented by the following
general formula (15),

in which m is 0, n is 3, Z is Si, each R
1 is methyl, and L is a bond.
[0052] A photochromic compound according to the present invention, in which the pendent
silane group is represented by general formula (II), is represented by the following
general formula (16),

in which t is 0, y is 3, m is 0, n is 3, Z is Si, each R
1 is methyl, R
a is -CH
2CH
2-, and L is a divalent linking group represented by the following general formula
(1a),

[0053] A further photochromic compound according to the present invention, in which the
pendent silane group is represented by general formula (II), is represented by the
following general formula (17),

in which t is 0, y is 3, m is 0, n is 3, Z is Si, each R
1 is methyl, R
a is -CH
2CH
2-, and L is a bond.
[0054] The photochromic substituent of the photochromic compound of the present invention
is selected from photochromic pyrans (including photochromic spiropyrans), photochromic
oxazines (including spiro-oxazines), photochromic fulgides and combinations (e.g.,
mixtures) of two or more thereof.
[0055] Examples of photochromic pyrans, include but are not limited to: benzopyrans; naphthopyrans,
e.g., naphtho[1,2-b]pyrans, naphtho[2,1-b]pyrans; indenonaphthopyrans, such as those
disclosed in
U.S. Pat. No. 5,645,767 at col. 2, line 16 to col. 12, line 57; heterocyclic-fused naphthopyrans, such as
those disclosed in
U.S. Pat. No. 5,723,072 at col. 2, line 27 to col. 15, line 55;
U.S. Pat. No. 5,698,141 at col. 2, line 11 to col. 19, line 45,
U.S. Pat. No. 6,153,126 at col. 2, line 26 to col. 8, line 60, and
U.S. Pat. No. 6,022,497 at col. 2, line 21 to col. 11, line 46, spiro-9-fluoreno[1,2-b]pyrans; phenanthropyrans;
quinolinopyrans; fluoroanthenopyrans; and spiropyrans, e.g., spiro(benzindoline)naphthopyrans,
spiro(indoline)benzopyrans, spiro(indoline)naphthopyrans, and spiro(indoline)pyrans.
Further examples of naphthopyrans, include but are not limited to those described
in
U.S. Pat. No. 5,658,501 at col. 1, line 64 to col. 13, line 17. Spiro(indoline)pyrans are also described
in the text,
Techniques in Chemistry, Volume III, "Photochromism", Chapter 3, Glenn H. Brown, Editor,
John Wiley and Sons, Inc., New York, 1971.
[0056] Examples of photochromic oxazines include, but are not limited to, benzoxazines;
naphthoxazines; and spiro-oxazines, e.g., spiro(indoline)naphthoxazines, spiro(indoline)pyridobenzoxazines,
spiro(benzindoline)pyridobenzoxazines, spiro(benzindoline)naphthoxazines, spiro(indoline)benzoxazines,
spiro(indoline)fluoranthenoxazines, and spiro(indoline)quinoxazines.
[0057] Examples of thermally reversible photochromic fulgides include, but are not limited
to, those fulgides that are disclosed in
U.S. Pat. No. 4,685,783 at col. 1, line 57 to col. 5, line 27.
[0058] The photochromic substituent of the photochromic materials and compounds according
to the present invention, may include combinations (e.g., mixtures) of two or more
of any of the classes and examples of photochromic substituents/moieties described
herein-above.
[0059] In a particular embodiment of the present invention, the photochromic substituent
of the photochromic compound is selected from one or more indeno-fused naphthopyrans.
At least one position of the indeno-fused naphthopyran has a pendent silane group
represented by formulas (I) and/or (II) bonded thereto. (It should be understood that
for purposes of the present invention, the at least one pendent silane group can be
bonded directly to the "core" photochromic substituent or bonded to a substituent
which is bonded directly to the core photochromic substituent as described in more
detail below.) As will be discussed in further detail herein, an indeno-fused naphthopyran
typically has 10 to 12 available positions to which a pendent silane group may be
bonded. Two of the 10 to 12 available positions of an indeno-fused naphthopyran may
have two pendent silane groups bonded thereto. While all available positions of the
indeno-fused naphthopyran may have a pendent silane group represented by formulas
(I) and/or (II) bonded thereto, typically at least one and less than all available
positions of the indeno-fused naphthopyran have a pendent silane group bonded thereto.
In an embodiment, the indeno-fused naphthopyran has 1 or 2 pendent silane groups represented
by formulas (I) and/or (II) bonded thereto.
[0060] In an embodiment, the photochromic material includes, as the photochromic substituent
of the photochromic compound, an indeno-fused naphthopyran, for example as represented
by the following general formula (III), in which the ring atoms are numbered as shown,

The B and B' groups of the indeno-fused naphthopyran represented by general formula
(III) are each independently selected from substituted and unsubstituted aromatic
groups, and substituted and unsubstituted heteroaromatic groups, or B and B' taken
together form an unsubstituted or substituted fluoren-9-ylidene.
[0061] The indeno-fused naphthopyran represented by general formula (III) has at least one
pendent silane group represented by formula (I) and/or formula (II) bonded thereto.
As discussed previously herein, the B and B' groups of the indeno-fused naphthopyran
are each independently selected from aromatic groups, heteroaromatic groups, or together
form a fluoren-9-ylidene group. As such, the pendent silane group(s) may be described
as: (i) being bonded to a B group and/or a B' group; or (ii) the divalent linking
group L of the pendent silane group includes a divalent aromatic, or heteroaromatic
or fluoren-9-ylidene moiety that is bonded directly to the 3 position of the indeno-fused
naphthopyran represented by general formula (III).
[0062] As was mentioned previously, the at least one pendent silane group can be bonded
directly to the indeno-fused naphthopyran at the positions numerically designated
in general formula (III), and/or the at least one pendent silane group can be bonded,
where applicable, to one of the substitutents (e.g. R
5, R
6, R
7, R
8, R
9, R
10, R
11, or R
12) which is bonded directly to the indeno-fused naphthopyran.
[0063] While indeno-fused naphthopyrans according to the present invention have bonded thereto
at least one pendent silane group (e.g., 1 or 2 pendent silane group) represented
by general formulas (I) and/or (II), the 1 and 2 positions of the indeno-naphthopyran,
e.g., represented by general formula (III), are each typically free of a pendent silane
group bonded thereto. With the indeno-fused naphthopyrans according to the present
invention, for example as represented by general formula (III): (a) at least one of
R
5, R
6, R
7, R
8, R
9, R
10, R
11, R
12, R
13 and R
14 is a pendent silane group represented by formula (I) and/or formula (II), as described
previously herein; and/or (b) at least one of B and B' has bonded thereto at least
one pendent silane group represented by general formula (I) and/or general formula
(II).
[0064] The indeno-fused naphthopyran represented by general formula (III) may be referred
to as an indeno[2',3':3,4]naphtho[1,2-b]pyran. The indeno-naphthopyran may be selected
from one or more indeno[2',3':3,4]naphtho[1,2-b]pyrans represented by general formula
(III), and/or one or more indeno[1',2':4,3]naphtho[2,1-b]pyrans represented by the
following general Formula-(IV), in which the ring atoms are numbered as shown,

The R
5 through R
14, B and B' groups of the indeno[1',2':4,3]naphtho[2,1-b]pyran represented by the following
general Formula-(IV) are each as described herein with regard to the indeno[2',3':3,4]naphtho[1,2-b]pyran
represented by general formula (III). While indeno-fused naphthopyrans according to
the present invention have bonded thereto at least one pendent silane group (e.g.,
1 or 2 pendent silane group) represented by general formulas (I) and/or (II), the
3 and 4 positions of the indeno[1',2':4,3]naphtho[2,1-b]pyran represented by general
formula (IV) are each typically free of a pendent silane group bonded thereto.
[0065] While the indeno-naphthopyran may be selected from one or more indeno[2',3':3,4]naphtho[1,2-b]pyrans
represented by general formula (III), and/or one or more indeno[1',2':4,3]naphtho[2,1-b]pyrans
represented by general Formula-(IV), it is typically selected from indeno[2',3':3,4]naphtho[1,2-b]pyrans
represented by general formula (III).
[0066] With the indeno-fused naphthopyrans according to the present invention, for example
as represented by general formulas (III) and/or (IV), R
5, R
6, R
7, R
8, R
9, R
10, R
11 and R
12 may each independently be selected in each case from: a reactive substituent; a compatibilizing
substituent; hydrogen; fluoro; chloro; C
1-C
6 alkyl; C
3-C
7 cycloalkyl; substituted or unsubstituted phenyl; -OR
10' or -OC(=O)R
10', wherein R
10' is hydrogen, C
1-C
6 alkyl, phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkyl substituted phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkoxy substituted phenyl(C
1-C
3)alkyl, (C
1-C
6)alkoxy(C
2-C
4)alkyl, C
3-C
7 cycloalkyl, or mono(C
1-C
4)alkyl substituted C
3-C
7 cycloalkyl. The phenyl substituents (i.e., the substituents of the substituted phenyl)
may be selected from hydroxyl, halogen, carbonyl, C
1-C
6 alkoxycarbonyl, cyano, halo(C
1-C
6)alkyl, C
1-C
6 alkyl or C
1-C
6 alkoxy.
[0067] Alternatively or in addition to the previously recited classes and examples, R
5, R
6, R
7, R
8, R
9, R
10, R
11 and R
12 may each independently be selected in each case from: -N(R
11')R
12', wherein R
11' and R
12' are each independently hydrogen, C
1-C
8 alkyl, phenyl, naphthyl, furanyl, benzofuran-2-yl, benzofuran-3-yl, thienyl, benzothien-2-yl,
benzothien-3-yl, dibenzofuranyl, dibenzothienyl, benzopyridyl, fluorenyl, C
1-C
8 alkylaryl, C
3-C
20 cycloalkyl, C
4-C
20 bicycloalkyl, C
5- C
20 tricycloalkyl or C
1- C
20 alkoxyalkyl, wherein said aryl group is phenyl or naphthyl, or R
11' and R
12' come together with the nitrogen atom to form a C
3-C
20 hetero-bicycloalkyl ring or a C
4-C
20 hetero-tricycloalkyl ring.
[0068] Each R
5, R
6, R
7, R
8, R
9, R
10, R
11 and R
12 group may independently be selected in each case from, a nitrogen containing ring
substituent represented by the following general (or graphic) formula VA:

With the nitrogen ring substituent represented by general formula VA, each -Y- is
independently chosen for each occurrence from -CH
2-, -CH(R
13')-, -C(R
13')
2-, -CH(aryl)-, -C(aryl)
2-, and -C(R
13')(aryl)-, and Z is -Y-, -O-, -S-, -S(O)-, -SO
2-, -NH-, -N(R
13')-, or -N(aryl)-, wherein each R
13' is independently C
1-C
6 alkyl, each aryl is independently phenyl or naphthyl, m is an integer 1, 2 or 3,
and p is an integer 0, 1, 2, or 3 and provided that when p is 0, Z is -Y-.
[0069] Additionally, each R
5, R
6, R
7, R
8, R
9, R
10, R
11 and R
12 group may independently be selected in each case from a nitrogen containing ring
substituent represented by general formula (VB) and/or general formula (VC):

For the nitrogen containing ring substituents represented by general formulas (VB)
and (VC), R
15, R
16, and R
17 are each independently selected from hydrogen, C
1-C
6 alkyl, phenyl, or naphthyl, or the groups R
15 and R
16 together form a ring of 5 to 8 carbon atoms and each R
d is independently for each occurrence selected from C
1-C
6 alkyl, C
1-C
6 alkoxy, fluoro or chloro, and Q is an integer 0, 1, 2, or 3.
[0070] Each R
5, R
6, R
7, R
8, R
9, R
10, R
11 and R
12 group may also independently be selected in each case from unsubstituted, mono-,
or di-substituted C
4-C
18 spirobicyclic amine, or unsubstituted, mono-, and di-substituted C
4-C
18 spirotricyclic amine. The substituents of the spirobicyclic amines and the spirotricyclic
amines may in each case be independently selected from aryl, C
1-C
6 alkyl, C
1-C
6 alkoxy, or phenyl(C
1-C
6)alkyl.
[0071] In an embodiment of the present invention, R
6 and R
7, of the indeno-fused naphthopyran, may together form a group represented by the following
general formula (VD) or general formula (VE),

With the groups represented by general formulas (VD) and (VE), T and T' are each independently
oxygen or the group -NR
11-, where R
11, R
15, and R
16 are each as set forth and described previously herein.
[0072] The R
13 and R
14 groups of the indeno-fused naphthopyran according to the present invention, e.g.,
the indeno[2',3':3,4]naphtho[1,2-b]pyran represented by general formula (III), and/or
the indeno[1',2':4,3]naphtho[2,1-b]pyran represented by general formula-(IV), may
each be independently selected from: a reactive substituent; a compatibilizing substituent;
hydrogen; hydroxy; C
1-C
6 alkyl; hydroxy(C
1-C
6 )alkyl; C
3-C
7 cycloalkyl; allyl; substituted or unsubstituted phenyl; substituted or unsubstituted
benzyl; chloro; fluoro; the group -C(=O)W', wherein W' is hydrogen, hydroxy, C
1-C
6 alkyl, C
1-C
6 alkoxy, the unsubstituted, mono-or di-substituted aryl groups phenyl or naphthyl,
phenoxy, mono- or di-( C
1-C
6)alkoxy substituted phenoxy, mono- or di-(C
1-C
6)alkoxy substituted phenoxy, amino, mono(C
1-C
6)alkylamino, di(C
1-C
6)alkylamino, phenylamino, mono- or di-( C
1-C
6)alkyl substituted phenylamino, or mono- or di-(C
1-C
6)alkoxy substituted phenylamino. The phenyl, benzyl, or aryl group substituents (e.g.,
the substituents of the substituted phenyl, substituted benzyl and substituted aryl
groups) are each independently selected from C
1-C
6 alkyl or C
1-C
6 alkoxy.
[0073] The R
13 and R
14 groups of the indeno-fused naphthopyran according to the present invention may each
independently also be an -OR
18 group, in which R
18 is selected from C
1-C
6 alkyl, phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkyl substituted phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkoxy substituted phenyl(C
1-C
3)alkyl, C
1-C
6 alkoxy(C
2-C
4)alkyl, C
3-C
7 cycloalkyl, mono(C
1-C
4)alkyl substituted C
3-C
7 cycloalkyl, C
1-C
6 chloroalkyl, C
1-C
6 fluoroalkyl, allyl, or the group -CH(R
19)Y', wherein R
19 is hydrogen or C
1-C
3 alkyl and Y' is CN, CF
3, or COOR
20, wherein R
20 is hydrogen or C
1-C
3 alkyl, or R
18 is the group, - C(=O)W", wherein W" is hydrogen, C
1-C
6 alkyl, C
1-C
6 alkoxy, the unsubstituted, mono- or di-substituted aryl groups phenyl or naphthyl,
phenoxy, mono-, or di-( C
1-C
6)alkyl substituted phenoxy, mono- or di-(C
1-C
6)alkoxy substituted phenoxy, amino, mono(C
1-C
6)alkylamino, di(C
1-C
6)alkylamino, phenylamino, mono- or di-(C
1-C
6)alkyl substituted phenylamino, or mono- or di-(C
1-C
6)alkoxy substituted phenylamino. The phenyl, benzyl, or aryl group substituents (e.g.,
the substituents of the substituted phenyl, substituted benzyl and substituted aryl
groups) are each independently selected from C
1-C
6 alkyl or C
1-C
6 alkoxy.
[0074] The R
13 and R
14 groups of the indeno-fused naphthopyran of the present invention may each independently
also be a mono-substituted phenyl, in which the phenyl has a substituent located at
the para position thereof. The substituent of the mono-substituted phenyl may be:
a dicarboxylic acid residue or derivative thereof, a diamine residue or derivative
thereof, an amino alcohol residue or derivative thereof, a polyol residue or derivative
thereof, -CH
2-, -(CH
2)
t-, or -[O-(CH
2)
t]
k-, in which (t) is selected from an integer of 2, 3, 4, 5 or 6, and k is an integer
selected from 1 to 50. The substituent of the mono-substituted phenyl is connected
to an aryl group on another photochromic material.
[0075] Alternatively, R
13 and R
14 may together form an oxo group, a spiro-carbocyclic group containing 3 to 6 carbon
atoms, or a spiro-heterocyclic group containing 1 to 2 oxygen atoms and 3 to 6 carbon
atoms including the spirocarbon atom. The spiro-carbocyclic and spiro-heterocyclic
groups are annellated with 0, 1 or 2 benzene rings.
[0076] The B and B' groups of the indeno-fused naphthopyran of the present invention may
each be independently selected from: a substituted phenyl; a substituted aryl; a substituted
9-julolidinyl; a substituted heteroaromatic group chosen from pyridyl, furanyl, benzofuran-2-yl,
benzofuran-3-yl, thienyl, benzothien-2-yl, benzothien-3-yl, dibenzofuranyl, dibenzothienyl,
carbazoyl, benzopyridyl, indolinyl, and fluorenyl, wherein the phenyl, aryl, 9-julolidinyl,
or heteroaromatic substituent is the reactive substituent R; an unsubstituted, mono-,
di-, or tri-substituted phenyl or aryl group; 9-julolidinyl; or an unsubstituted,
mono- or di-substituted heteroaromatic group chosen from pyridyl, furanyl, benzofuran-2-yl,
benzofuran-3-yl, thienyl, benzothien-2-yl, benzothien-3-yl, dibenzofuranyl, dibenzothienyl,
carbazoyl, benzopyridyl, indolinyl, and fluorenyl.
[0077] The phenyl, aryl and heteroaromatic substituents (i.e., the substituents of the substituted
phenyl, aryl and heteroaromatic groups) of the B and B' groups may each be independently
selected from: hydroxyl, a group -C(=O)R
21, wherein R
21 is -OR
22, - N(R
23)R
24, piperidino, or morpholino, wherein R
22 is allyl, C
1-C
6 alkyl, phenyl, mono(C
1-C
6)alkyl substituted phenyl, mono(C
1-C
6)alkoxy substituted phenyl, phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkyl substituted phenyl(C
1-C
3)alkyl, mono(C
1-C
6)alkoxy substituted phenyl(C
1-C
3)alkyl, C
1-C
6 alkoxy(C
2-C
4)alkyl or C
1-C
6 haloalkyl, R
23 and R
24 are each independently C
1-C
6 alkyl, C
5-C
7 cycloalkyl, phenyl or substituted phenyl, the phenyl substituents being C
1-C
6 alkyl or C
1-C
6 alkoxy, and said halo substituent is chloro or fluoro, aryl, mono(C
1-C
12)alkoxyaryl, di(C
1-C
12)alkoxyaryl, mono(C
1-C
12)alkylaryl, di(C
1-C
12)alkylaryl, haloaryl, C
3-C
7 cycloalkylaryl, C
3-C
7 cycloalkyl, C
3-C
7 cycloalkyloxy, C
3-C
7 cycloalkyloxy(C
1-C
12)alkyl, C
3-C
7 cycloalkyloxy(C
1-C
12)alkoxy, aryl(C
1-C
12)alkyl, aryl(C
1-C
12)alkoxy, aryloxy, aryloxy(C
1-C
12)alkyl, aryloxy(C
1-C
12)alkoxy, mono- or di(C
1-C
12)alkylaryl(C
1-C
12)alkyl, mono- or di-(C
1-C
12)alkoxyaryl(C
1-C
12)alkyl, mono- or di-(C
1-C
12)alkylaryl(C
1-C
12)alkoxy, mono- or di-(C
1-C
12)alkoxyaryl(C
1-C
12)alkoxy, amino, mono- or di-(C
1-C
12)alkylamino, diarylamino, piperazino, N-(C
1-C
12)alkylpiperazino, N-arylpiperazino, aziridino, indolino, piperidino, morpholino, thiomorpholino,
tetrahydroquinolino, tetrahydroisoquinolino, pyrrolidyl, C
1-C
12 alkyl, C
1-C
12 haloalkyl, C
1-C
12 alkoxy, mono(C
1-C
12)alkoxy(C
1-C
12 )alkyl, acryloxy, methacryloxy, or halogen.
[0078] The B and B' groups may also each independently be an unsubstituted or mono-substituted
group chosen from pyrazolyl, imidazolyl, pyrazolinyl, imidazolinyl, pyrrolinyl, phenothiazinyl,
phenoxazinyl, phenazinyl, and acridinyl. The substituents of these mono-substituted
groups are each independently selected from C
1-C
12 alkyl, C
1-C
12 alkoxy, phenyl, or halogen.
[0079] In addition, the B and B' groups may each be independently selected from a group
represented by the following general formulas (VIA) or (VIB),

Independently with each of general formulas (VIA) and (VIB), K is -CH
2- or -O-, and M is -O- or substituted nitrogen, provided that when M is substituted
nitrogen, K is -CH
2-. The substituted nitrogen substituents are hydrogen, C
1-C
12 alkyl, or C
1-C
12 acyl. Each R
25 is independently selected for each occurrence from C
1-C
12 alkyl, C
1-C
12 alkoxy, hydroxy, and halogen, and each u is independently an integer ranging from
0 to 2. The R
26 and R
27 groups are each independently hydrogen or C
1-C
12 alkyl.
[0080] Each B and B' group may independently be a group represented by the following general
formula (VII),

[0081] With the group represented by general formula (VII), R
28 is hydrogen or C
1-C
12 alkyl, and R
29 is an unsubstituted, mono- or di-substituted group chosen from naphthyl, phenyl,
furanyl, and thienyl. The substitutents of the mono- or di-substituted naphthyls,
phenyls, furanyls, and thienyls, are in each case independently selected from C
1-C
12 alkyl, C
1-C
12 alkoxy, or halogen.
[0082] The B and B' groups may together form a member selected from, a fluoren-9-ylidene,
a mono-substituted fluoren-9-ylidene, or a di-substituted fluoren-9-ylidene. The substituents
of the mono-substituted fluoren-9-ylidene, and the di-substituted fluoren-9-ylidene
may in each case be independently selected from C
1-C
12 alkyl, C
1-C
12 alkoxy, or halogen.
[0083] As discussed previously herein, the indeno-fused naphthopyrans of the photochromic
material according to the present invention, for example as represented by general
formulas (III) and/or (IV): (a) at least one of R
5, R
6, R
7, R
8, R
9, R
10, R
11, R
12, R
13 and R
14 is a pendent silane group represented by formula (I) and/or formula (II), as described
previously herein; and/or (b) at least one of B and B' has bonded thereto at least
one pendent silane group represented by formula (I) and/or formula (II). Typically,
at least one and, at the same time, less than all available positions of the indeno-fused
naphthopyran have a pendent silane group bonded thereto. In an embodiment, for example,
the indeno-fused naphthopyran of the photochromic material according to the present
invention has bonded thereto 1 or 2 pendent silane groups represented by formula (I)
and/or formula (II).
[0084] In an embodiment, with the indeno-fused naphthopyran of the photochromic material
of the present invention: (i) at least one of R
11, R
13 and R
14 is a pendent silane group represented by formulas (I) and/or (II); and/or (ii) at
least one of B and B' has bonded thereto at least one pendent silane group, represented
by formulas (I) and/or (II). The indeno-fused naphthopyran typically has bonded thereto
1 or 2 of such pendent silane groups.
[0085] In a particular embodiment the indeno-fused naphthopyran has bonded thereto one (i.e.,
a single) pendent silane group represented by general formula (I) or (II). More particularly,
with the indeno-fused naphthopyran of this embodiment: the R
11 group is the pendent silane group; R
5, R
8, R
9, R
10 and R
12 are each hydrogen; R
6 and R
7 are each independently selected from hydrogen, linear or branched C
1-C
6 alkyl, and -OR
10' where R
10' is C
1-C
6 alkyl; R
13 and R
14 are each independently selected from linear or branched C
1-C
6 alkyl, and C
3-C
7 cycloalkyl; and B and B' are each independently selected from aryl substituted with
C
1-C
6 alkoxy, and aryl substituted with morpholino.
[0086] In a further embodiment, the indeno-fused naphthopyran has bonded thereto one (i.e.,
a single) pendent silane group represented by general formula (I) or (II), and, in
particular, the R
13 group thereof is the pendent silane group. The remaining groups of the indeno-fused
naphthopyran, in which R
13 is a pendent silane group are described as follows: R
5, R
8, R
9, R
10 and R
12 are each hydrogen; R
6 and R
7 are each independently selected from hydrogen, C
1-C
6 alkyl, and -OR
10' where R
10' is C
1-C
6 alkyl, R
11 is selected from hydrogen, halogen (e.g., fluoro, chloro, bromo or iodo), and C
1-C
6 alkyl; R
14 is selected from C
1-C
6 alkyl, and C
3-C
7 cycloalkyl; and B and B' are each independently selected from aryl substituted with
C
1-C
6 alkoxy, and aryl substituted with morpholino.
[0087] A non-limiting example of an indeno-fused naphthopyran according to the present invention
in which the R
13 group is the pendent silane group, as described above, is represented by the following
general formula 20b.

In general formula (20b), the R
13 group is a pendent silane group represented by general formula (I) in which, m is
0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by general formula (5a),
(5a) -O-Si(CH
3)
2-CH
2CH
2-.
With further reference to general formula (20b), R
5, R
7 R
8, R
9, R
10 and R
12 are each hydrogen; R
6, R
11 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0088] A further example of an indeno-fused naphthopyran according to the present invention
in which the R
13 group is the pendent silane group, as described above, is represented by the following
general formula 20c.

In general formula (20c), the R
13 group is a pendent silane group represented by general formula (I) in which, m is
0, n is 3, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by general formula (3a),
(3a) -CH
2-O-
With further reference to general formula (20c), R
5, R
7 R
8, R
9, R
10 and R
12 are each hydrogen; R
6, R
11 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0089] Another non-limiting example of an indeno-fused naphthopyran according to the present
invention in which the R
13 group is the pendent silane group, as described above, is represented by the following
general formula 20d.

In general formula (20d), the R
13 group is a pendent silane group represented by general formula (II) in which, t is
0, y is 3, m is 1, n is 2, Z is Si, R is methyl, each R
1 is methyl, R
a is -CH
2CH
2-, and L is a divalent linking group represented by general formula (1a),

With further reference to general formula (20d), R
5, R
7 R
8, R
9, R
10 and R
12 are each hydrogen; R
6, R
11 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0090] In an embodiment of the present invention, the indeno-fused naphthopyran has bonded
thereto one (i.e., a single) pendent silane group represented by general formula (I)
or (II), and in particular, B or B' has the pendent silane group bonded thereto.
[0091] With regard to this particular embodiment, the various groups of the indeno-fused
naphthopyran, in which B or B' has a pendent silane group bonded thereto are described
as follows: R
5, R
8, R
9, R
10 and R
12 are each hydrogen; R
6 and R
7 are each independently selected from hydrogen, halogen, C
1-C
6 alkyl, and -OR
10' where R
10' is C
1-C
6 alkyl, R
11 is selected from hydrogen, halogen, and C
1-C
6 alkyl; R
13 and R
14 are each independently selected from C
1-C
6 alkyl, and C
3-C
7 cycloalkyl; and B and B' are each independently selected from aryl, aryl substituted
with C
1-C
6 alkoxy, aryl substituted with morpholino and aryl substituted with piperidinyl.
[0092] A further non-limiting example of an indeno-fused naphthopyran according to the present
invention in which B or B' has a pendent silane group bonded thereto, as described
above, is represented by the following general formula 20f.

In general formula (20f), the B group (or substituent) has bonded thereto a pendent
silane group represented by general formula (I) in which, m is 0, n is 3, Z is Si,
each R
1 is methyl, and L is a divalent linking group represented by the following general
formula,
-O-CH
2CH
2O-.
With further reference to general formula (20f), R
5, R
6, R
7 R
8, R
9, R
10, R
11 and R
12 are each hydrogen; R
13 and R
14 are each methyl; B' is a phenyl group substituted with a methoxy group; and B is
a phenyl group. The pendent silane group represented by general formula (I) is bonded
to the piperidinyl group of the piperidinyl substituted phenyl that is the B group
in this particular embodiment.
[0093] In an embodiment of the present invention, the indeno-fused naphthopyran has bonded
thereto two pendent silane groups represented by general formula (I) or (II), and
in particular, B and B' each have a pendent silane group bonded thereto. With regard
to this particular embodiment, the various groups of the indeno-fused naphthopyran,
in which B and B' each have a pendent silane group bonded thereto are described as
follows: R
5, R
8, R
9, R
10 and R
12 are each hydrogen; R
6 and R
7 are each independently selected from hydrogen, halogen, C
1-C
6 alkyl, and -OR
10' where R
10' is C
1-C
6 alkyl; R
11 is selected from hydrogen, halogen (e.g., fluoro, chloro, bromo or iodo), and C
1-C
6 alkyl; R
13 and R
14 are each independently selected from C
1-C
6 alkyl, and C
3-C
7 cycloalkyl; and B and B' are each independently selected from aryl, aryl substituted
with C
1-C
6 alkoxy, aryl substituted with morpholino and aryl substituted with piperidinyl.
[0094] A non-limiting example of an indeno-fused naphthopyran according to the present invention
in which B and B' each have a pendent silane group bonded thereto, as described above,
is represented by the following general formula 20g.

In general formula (20g), B and B' each have bonded thereto a pendent silane group
represented by general formula (I) in which and in each case, m is 0, n is 3, Z is
Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula,
-O-CH
2CH
2O-.
With further reference to general formula (20g), R
5, R
6, R
7 R
8, R
9, R
10, R
11 and R
12 are each hydrogen; R
13 and R
14 are each methyl; B and B' are each a phenyl group. Each pendent silane group represented
by general formula (I) is bonded to the phenyl group of each B and B'.
[0095] As previously discussed, the indeno-fused naphthopyrans according to present invention
may include at least one of a reactive substituent and/or a compatibilizing substituent.
Any one or more of the groups R
5 through R
14, B and B' of the indeno-fused naphthopyran (e.g., represented by general formulas-III
and/or -IV) may include at least one of a reactive substituent and/or a compatibilizing
substituent. If the photochromic compound includes multiple reactive substituents
and/or multiple compatibilizing substituents, each reactive substituent and each compatibilizing
substituent may be independently chosen.
[0096] The reactive substituent and the compatibilizing substituent may each independently
be represented in each case by one of:
| -A'-D-E-G-J (XIII); |
-G-E-G-J (XVI); |
-D-E-G-J (XIX); |
| -A'-D-J (XIV); |
-D-G-J (XVII); |
-D-J (XX); |
| -A'-G-J (XV); |
-G-J (XVIII); and |
-A'-J (XXI). |
[0097] With formulas (XIII) through (XXI), non-limiting examples of groups that -A'-may
represent according to various non-limiting embodiments disclosed herein include -
O-, -C(=O)-, -CH
2-, -OC(=O)- and -NHC(=O)-, provided that if -A'- represents -O-, - A'- forms at least
one bond with -J.
[0098] Non-limiting examples of groups that -D- may represent according to various non-limiting
embodiments include a diamine residue or a derivative thereof, wherein a first amino
nitrogen of said diamine residue may form a bond with -A'-, the group that extends
the pi-conjugated system of the indeno-fused naphthopyran bonded at the 11-position
thereof, or a substituent or an available position on the indeno-fused naphthopyran,
and a second amino nitrogen of said diamine residue may form a bond with -E-, -G-
or -J; and an amino alcohol residue or a derivative thereof, wherein an amino nitrogen
of said amino alcohol residue may form a bond with -A'-, the group that extends the
pi-conjugated system of the indeno-fused naphthopyran bonded at the 11-position thereof,
or a substituent or an available position on the indeno-fused naphthopyran, and an
alcohol oxygen of said amino alcohol residue may form a bond with -E-, -G- or -J.
Alternatively, according to various non-limiting embodiments disclosed herein the
amino nitrogen of said amino alcohol residue may form a bond with -E-, -G- or -J,
and said alcohol oxygen of said amino alcohol residue may form a bond with -A'-, the
group that extends the pi-conjugated system of the indeno-fused naphthopyran bonded
at the 11-position thereof, or a substituent or an available position on the indeno-fused
naphthopyran.
[0099] Non-limiting examples of suitable diamine residues that -D- may represent include
an aliphatic diamine residue, a cyclo aliphatic diamine residue, a diazacycloalkane
residue, an azacyclo aliphatic amine residue, a diazacrown ether residue, and an aromatic
diamine residue. More particular, illustrative and non-limiting examples of diamine
residues that may be used in conjunction with various non-limiting embodiments disclosed
herein include the following:

[0100] Non-limiting examples of suitable amino alcohol residues that -D- may represent include
an aliphatic amino alcohol residue, a cyclo aliphatic amino alcohol residue, an azacyclo
aliphatic alcohol residue, a diazacyclo aliphatic alcohol residue and an aromatic
amino alcohol residue. More particular, illustrative and non-limiting examples of
amino alcohol residues that may be used in conjunction with various non-limiting embodiments
disclosed herein include the following:

[0101] With continued reference to formulas (XIII) through (XXI) above, according to various
non-limiting embodiments disclosed herein, -E- may represent a dicarboxylic acid residue
or a derivative thereof, wherein a first carbonyl group of said dicarboxylic acid
residue may form a bond with -G- or -D-, and a second carbonyl group of said dicarboxylic
acid residue may form a bond with -G-. Non-limiting examples of suitable dicarboxylic
acid residues that -E- may represent include an aliphatic dicarboxylic acid residue,
a cycloaliphatic dicarboxylic acid residue and an aromatic dicarboxylic acid residue.
More particular, illustrative and non-limiting examples of dicarboxylic acid residues
that may be used in conjunction with various non-limiting embodiments disclosed herein
include the following:

[0102] According to various non-limiting embodiments disclosed herein, -G- may represent
a group represented by the following general formula,
-[(OC
2H
4)
x(OC
3H
6)
y(OC
4H
8)
z]-O-
in which x, y and z are each independently chosen and range from 0 to 50, and a sum
of x, y, and z ranges from 1 to 50; a polyol residue or a derivative thereof, wherein
a first polyol oxygen of said polyol residue may form a bond with -A'-, -D-, -E-,
or a substituent or an available position on the indeno-fused naphthopyran, and a
second polyol oxygen of said polyol may form a bond with -E- or -J; or a combination
thereof, wherein the first polyol oxygen of the polyol residue forms a bond with a
group -[(OC
2H
4)
x(OC
3H
6)
y(OC
4H
8)
z]- (i.e., to form the group -[(OC
2H
4)
x(OC
3H
6)
y (OC
4H
8)
z]-O-), and the second polyol oxygen forms a bond with -E- or -J. Non-limiting examples
of suitable polyol residues that -G- may represent include an aliphatic polyol residue,
a cyclo aliphatic polyol residue and an aromatic polyol residue.
[0103] More particular, illustrative and non-limiting examples of polyols from which the
polyol residues that -G- may represent may be formed according to various non-limiting
embodiments disclosed herein include (a) low molecular weight polyols having an average
molecular weight less than 500, such as, but not limited to, those set forth in
U.S. Patent No. 6,555,028 at col. 4, lines 48-50, and col. 4, line 55 to col. 6, line 5; (b) polyester polyols,
such as, but not limited to, those set forth in
U.S. Patent No. 6,555,028 at col. 5, lines 7-33; (c) polyether polyols, such as but not limited to those set
forth in
U.S. Patent No. 6,555,028 at col. 5, lines 34-50; (d) amide-containing polyols, such as, but not limited to,
those set forth in
U.S. Patent No. 6,555,028 at col. 5, lines 51-62; (e) epoxy polyols, such as, but not limited to, those set
forth in
U.S. Patent No. 6,555,028 at col. 5 line 63 to col. 6, line 3; (f) polyhydric polyvinyl alcohols, such as,
but not limited to, those set forth in
U.S. Patent No. 6,555,028 at col. 6, lines 4-12; (g) urethane polyols, such as, but not limited to those set
forth in
U.S. Patent No. 6,555,028 at col. 6, lines 13-43; (h) polyacrylic polyols, such as, but not limited to those
set forth in
U.S. Patent No. 6,555,028 at col. 6, lines 43 to col. 7, line 40; (i) polycarbonate polyols, such as, but not
limited to, those set forth in
U.S. Patent No. 6,555,028 at col. 7, lines 41-55; and (j) mixtures of such polyols.
[0104] With further reference to formulas (XIII) through (XXI), according to various non-limiting
embodiments disclosed herein, -J may represent a group -K, wherein -K represents a
group such as, but not limited to, -CH
2COOH, -CH(CH
3)COOH, -C(O)(CH
2)
wCOOH, -C
6H
4SO
3H, -C
5H
10SO
3H, -C
4H
8SO
3H, -C
3H
6SO
3H, -C
2H
4SO
3H and -SO
3H, wherein "w" ranges from 1 to 18. According to other non-limiting embodiments -J
may represent hydrogen that forms a bond with an oxygen or a nitrogen of linking group
to form a reactive moiety such as -OH or -NH. For example, according to various non-limiting
embodiments disclosed herein, -J may represent hydrogen, provided that if -J represents
hydrogen, -J is bonded to an oxygen of -D- or -G-, or a nitrogen of -D-.
[0105] According to still further non-limiting embodiments, -J may represent a group -L
or residue thereof, wherein -L may represent a reactive moiety. For example, according
to various non-limiting embodiments disclosed herein -L may represent a group such
as, but not limited to, acryl, methacryl, crotyl, 2-(methacryloxy)ethylcarbamyl, 2-(methacryloxy)ethoxycarbonyl,
4-vinylphenyl, vinyl, 1-chlorovinyl or epoxy. As used herein, the terms acryl, methacryl,
crotyl, 2-(methacryloxy)ethylcarbamyl, 2-(methacryloxy)ethoxycarbonyl, 4-vinylphenyl,
vinyl, 1-chlorovinyl, and epoxy refer to the following structures:

[0106] As previously discussed, -G- may represent a residue of a polyol, which is defined
herein to include hydroxy-containing carbohydrates, such as those set forth in
U.S. Patent No. 6,555,028 at col. 7, line 56 to col. 8, line 17. The polyol residue may be formed, for example
and without limitation herein, by the reaction of one or more of the polyol hydroxyl
groups with a precursor of -A'-, such as a carboxylic acid or a methylene halide,
a precursor of polyalkoxylated group, such as polyalkylene glycol, or a hydroxyl substituent
of the indeno-fused naphthopyran. The polyol may be represented by q-(OH)
a and the residue of the polyol may be represented by the formula -O-q-(OH)
a-1, wherein q is the backbone or main chain of the polyhydroxy compound and "a" is at
least 2.
[0107] Further, as discussed above, one or more of the polyol oxygens of -G- may form a
bond with -J (i.e., forming the group -G-J). For example, although not limiting herein,
wherein the reactive and/or compatibilizing substituent comprises the group -G-J,
if -G-represents a polyol residue and -J represents a group -K that contains a carboxyl
terminating group, -G-J may be produced by reacting one or more polyol hydroxyl groups
to form the group -K (for example as discussed with respect to Reactions B and C at
col. 13, line 22 to col. 16, line 15 of
U.S. Patent No. 6,555,028) to produce a carboxylated polyol residue. Alternatively, if -J represents a group
-K that contains a sulfo or sulfono terminating group, although not limiting herein,
-G-J may be produced by acidic condensation of one or more of the polyol hydroxyl
groups with HOC
6H
4SO
3H; HOC
5H
10SO
3H; HOC
4H
8SO
3 H; HOC
3H
6SO
3H; HOC
2H
4SO
3H; or H
2SO
4, respectively. Further, although not limiting herein, if -G- represents a polyol
residue and -J represents a group -L chosen from acryl, methacryl, 2-(methacryloxy)ethylcarbamyl
and epoxy, -L may be added by condensation of the polyol residue with acryloyl chloride,
methacryloyl chloride, 2-isocyanatoethyl methacrylate or epichlorohydrin, respectively.
[0108] Methods of synthesizing the photochromic compounds according to the present invention
that include indeno-fused naphthopyrans are described here with reference to the general
reaction schemes summarized and depicted in Figures 1 through 12 of the drawings.
With reference to Figure 1, there is depicted a reaction scheme for making substituted
7H-benzo[C]fluoren-5-ol compounds, that may be further reacted as shown in Figure
2 to form indeno-fused naphthopyrans to which may be bonded pendent silane groups
represented by formulas (I) and/or (II) so as to form the photochromic compounds of
the photochromic materials according to the present invention.
[0109] The synthetic reaction schemes depicted in Figures 1-12 are presented for purposes
of illustration, and as such are not intended to be limiting with regard to the scope
of the present invention.
[0110] With reference to Figure 1, a solution of benzoyl chloride that may have one or more
γ-substituents, represented by structure (a) in Figure 1, and benzene, represented
by structure (b) in Figure 1, which may have one or more γ
1- substituents, in methylene chloride are added to a reaction flask. Suitable γ-substituents
include, for example those groups as described previously herein with regard to R
9, R
10, R
11 and R
12, depending on what position a particular γ-substituent is bonded to, or a precursor
thereof (e.g., a halogen group that may be later substituted with a group that may
optionally be further modified). Suitable γ
1-substituents include, for example and without limitation, those groups as described
previously herein with regard to R
5, R
6, R
7 and R
8, depending on what position a particular γ
1-substituent is bonded to, or a precursor thereof (e.g., a halogen group that may
be later substituted with a group that may optionally be further modified). The subscripts
n and m may each be independently selected from 0 to 4. Anhydrous aluminum chloride
catalyzes the Friedel-Crafts acylation to give an optionaly substituted benzophenone
represented by structure (c) in Figure 1. This material is then reacted via a Stobbe
reaction with dimethyl succinate to produce a mixture of half-esters, one of which
is represented by structure (d) in Figure 1. Thereafter the half-esters are reacted
in acetic anhydride and toluene at an elevated temperature to produce, after recrystallization,
a mixture of optionally substituted naphthalene compounds, one of which is represented
by structure (e) in Figure 1. The mixture of optionally substituted naphthalene compounds
is then reacted with methyl magnesium chloride to produce a mixture of optionally
substituted naphthalene compounds, one of which is represented by structure (f) in
Figure 1. The mixture of optionally substituted naphthalene compounds is then cyclized
with dodecylbenzene sulfonic acid to provide a mixture of 7H-benzo[C]fluoren-5-ol
compounds, one of which is represented by structure (g) in Figure 1.
[0111] As depicted in Figure 2, the 7H-benzo[C]fluoren-5-ol compound represented by structure
(g) may be reacted with a propargyl alcohol represented by structure (h) to produce
the indeno-fused naphthopyran represented by structure (i) in Figure 2.
[0112] Further, non-limiting examples of methods of forming benzofurano-fused naphthopyrans,
indolo-fused naphthopyrans, and/or benzothieno-fused naphthopyrans that may be useful
(with appropriate modifications that will be recognized by skilled artisans) in forming
the benzofurano-fused naphthopyrans, indolo-fused naphthopyrans and/or benzothieno-fused
naphthopyrans according to various non-limiting embodiments disclosed herein are set
forth in
U.S. Patent No. 5,651,923 at col. 6, line 43 to col. 13, line 48;
U.S. Patent No. 6,018,059 at column 6, line 1, to column 7, line 64; and
U.S. Patent No. 6,392,043 at column 6, line 5, to column 10, line 10.
[0113] The preparation of an indeno-fused naphthopyran having a hydroxyl group at Position-13
is described with reference to Figure 3. The optionally substituted naphthalene compound
represented by structure (e) of Figure 1 is reacted with sodium hydroxide in the presence
of water and alcohol, and then acid to form the hydroxyl and carboxylic acid functional
compound represented by structure (j), which is then reacted with phosphoric acid
under conditions of elevated temperature to form the cyclic fused ring ketone represented
by structure (k). The cyclic fused ring ketone represented by structure (k) is then
reacted with a propargyl alcohol represented by structure (h) to produce the ketone
intermediate represented by structure (1), which may be reacted with Grignard reagent
to produce the indeno-fused naphthopyran represented by structure (m), which has at
Position-13: a hydroxyl group; and an R-group, which is a residue of the Grignard
reagent. Alternatively, the ketone intermediate represented by structure (1), may
be reacted with lithium aluminum hydride (LAH) to form the indeno-fused naphthopyran
represented by structure (n), which has at Position-13: a hydroxyl group; and a hydrogen.
[0114] The preparation of an indeno-fused naphthopyran having a methylol group (-CH
2-OH) at Position-13 is described with reference to Figure 4. The ketone intermediate
represented by structure (l) of Figure 3 is converted by means of Wolf-Kinsher reduction
to the indeno-fused naphthopyran represented by structure (o), which has two hydrogens
at Position-13 thereof. The indeno-fused naphthopyran represented by structure (o)
is reacted with a halohydrocarbyl represented by RX, which is typically an alkylhalo,
in the presences of n-butyl lithium to form the indeno-fused naphthopyran represented
by structure (p), in which one of the Position-13 hydrogens has been substituted with
the R-group of the RX reactant. The remaining Position-13 hydrogen of the indeno-fused
naphthopyran represented by structure (p) is then converted to a carboxylic acid group
by exposure to n-butyl lithium in the present of CO
2, followed by an esterification reaction to form the indeno-fused naphthopyran represented
by structure (q) having a carboxylic acid ester group at Position-13. The Position-13
carboxylic acid ester of the indeno-fused naphthopyran represented by structure (q)
is reduced in the presence of lithium aluminum hydride (LAH)to form the indeno-fused
naphthopyran represented by structure (r), which has a methylol group (-CH
2-OH) at Position-13 thereof.
[0115] Preparation of the photochromic compound according to the present invention, represented
by general formula (20b) is generally described as follows with reference to Figure
5. An indeno-fused naphthopyran (m-1) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 3, having a Position-13 hydroxyl
group, is reacted with a chlorosilane represented by general formula (Si-1) in the
presence of triethyl amine (TEA) and 4-(dimethylamino)-pyridine (4-DMAP) to form a
photochromic compound according to the present invention represented by general formula
(20b). The photochromic compound represented by general formula (20b) is as described
previously herein.
[0116] Preparation of the photochromic compound according to the present invention, represented
by general formula (20c) is generally described as follows with reference to Figure
6. An indeno-fused naphthopyran (r-1) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 4, having a Position-13 methylol
group (-CH
2-OH), is reacted with a chlorosilane represented by general formula (Si-2) in the
presence of triethyl amine (TEA) and 4-(dimethylamino)-pyridine (4-DMAP) to form a
photochromic compound according to the present invention represented by general formula
(20c). The photochromic compound represented by general formula (20c) is as described
previously herein.
[0117] Preparation of the photochromic compound according to the present invention, represented
by general formula (20e) is generally described as follows with reference to Figure
7. An indeno-fused naphthopyran (i-1) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 2, in which B is a phenyl group
substituted with a 3-methylol-piperidinyl group, is reacted with a chlorosilane represented
by general formula (Si-2) in the presence of triethyl amine (TEA) and 4-(dimethylamino)-pyridine
(4-DMAP) to form a photochromic compound according to the present invention represented
by general formula (20e). The photochromic compound represented by general formula
(20e) is as described previously herein.
[0118] Preparation of the photochromic compound according to the present invention, represented
by general formula (20g) is generally described as follows with reference to Figure
8. An indeno-fused naphthopyran (i-2) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 2, in which B and B' are each 4-(2-hydroxy-ethoxy)-phenyl,
is reacted with a chlorosilane represented by general formula (Si-2) in the presence
of triethyl amine (TEA) and 4-(dimethylamino)-pyridine (4-DMAP) to form a photochromic
compound according to the present invention represented by general formula (20g).
The photochromic compound represented by general formula (20g) is as described previously
herein.
[0119] Preparation of a photochromic compound according to the present invention, represented
by general formula (20h) is generally described as follows with reference to Figure
9. An indeno-fused naphthopyran (m-1) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 3, having a Position-13 hydroxyl
group, is reacted with triethylene glycol in the presence of para-toluenesulfonic
acid (PTSA) to form an intermediate indeno-fused naphthopyran represented by structure
(m-1a) having a hydroxyl functional triethyleneglycol ether bonded to Position-13
thereof, which is then reacted with succinic anhydride, under art-recognized conditions,
to form the carboxylic acid functional indeno-fused naphthopyran intermediate represented
by structure (m-1b). The carboxylic acid functional indeno-fused naphthopyran intermediate
represented by structure (m-1b) is then reacted with the hydroxyl functional silane
represented by structure (Si-3), in the presence of dicyclohexyl carbodiimide (DCC)
and 4-(dimethylamino)-pyiridine (4-DMAP), to from a photochromic compound according
to the present invention represented by general formula (20h).
[0120] In Figure 9, the photochromic compound represented by general formula (20h) includes
a pendent silane group represented by general formula (I), in which, m is 1, n is
2, R is methyl, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (20h-L), in which n is from 1 to 4,

With further reference to formula (20h), R
5, R
7 R
8, R
9, R
10 and R
12 are each hydrogen; R
6, R
11 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0121] Preparation of a photochromic compound according to the present invention, represented
by general formula (20i) is generally described as follows with reference to Figure
10. An indeno-fused naphthopyran represented by structure (i-3) prepared in accordance
with the reaction scheme depicted in and described with reference to Figure 2, having
a 2,5-dioxypyrrolidin-1-yl-carboxylate group at Position-11 thereof, is reacted with
an amine functional silane represented by general formula (Si-4) in the presence of
pyridine to form a photochromic compound according to the present invention represented
by general formula (20i).
[0122] In Figure 10, the photochromic compound represented by general formula (20i) includes
a pendent silane group represented by general formula (I), in which, m is 1, n is
2, R is methyl, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (20i-L),
(20i-L) -C(O)-NH-(CH
2)
3-
With further reference to formula (20i), R
5, R
8, R
9, R
10 and R
12 are each hydrogen; R
6 and R
7 are each methoxy; R
13 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0123] Preparation of a photochromic compound according to the present invention, represented
by general formula (20j) is generally described as follows with reference to Figure
11. An indeno-fused naphthopyran represented by structure (m-1) prepared in accordance
with the reaction scheme depicted in and described with reference to Figure 3, having
a hydroxy group at Position-13 thereof, is reacted with 3-hydroxy-1-propene, in the
presence of paratoluenesulfonic acid (PTSA) and methyl cyanide (MeCN) to form a indeno-fused
naphthopyran intermediate represented by structure (m-1c) having a 1-propenoxy group
at Position-13 thereof. The indeno-fused naphthopyran intermediate represented by
structure (m-1c) is then reacted with the silane represented by general formula (Si-5),
in the presence of platinum catalyst (Pt) and toluene, to form the photochromic compound
according to the present invention represented by general formula (20j).
[0124] In Figure 11, the photochromic compound represented by general formula (20j) includes
a pendent silane group represented by general formula (I), in which, m is 1, n is
2, R is methyl, Z is Si, each R
1 is methyl, and L is a divalent linking group represented by the following general
formula (20j-L),
(20j-L) -O-(CH
2)
3-
With further reference to formula (20j) of Figure 11, R
5, R
7 R
8, R
9, R
10 and R
12 are each hydrogen; R
6, R
11 and R
14 are each methyl; and B and B' are each a phenyl group substituted with a methoxy
group.
[0125] Preparation of the photochromic compound according to the present invention, represented
by general formula (20d) is generally described as follows with reference to Figure
12. An indeno-fused naphthopyran (m-1) prepared in accordance with the reaction scheme
depicted in and described with reference to Figure 3, having a Position-13 hydroxyl
group, is reacted with triethyleneglycol in the presence of para-toluenesulfonic acid
(PTSA) to form an intermediate indeno-fused naphthopyran represented by structure
(m-1a) having a hydroxyl functional triethyleneglycol ether bonded to Position-13
thereof. The intermediate indeno-fused naphthopyran represented by structure (m-1a)
is then reacted with a trivinylchlorosilane represented by structure (Si-6) in the
presence of triethylamine (TEA) and 4-(dimethylamino)-pyridine, to form the tri-vinyl
functional indeno-fused naphthopyran intermediate represented by structure (m-1d),
which is then reacted with the silane represented by structure (Si-5), in the presence
of platinum (Pt) and toluene, to form a photochromic compound according to the present
invention represented by general formula (20d). The photochromic compound represented
by general formula (20d) is as described previously herein.
[0126] The present invention also provides photochromic compositions (e.g., photochromic
articles and photochromic coatings) that include a photochromic material according
to the present invention, and an organic material. The photochromic materials according
to the present invention may be incorporated into at least a portion of an organic
material, such as a polymeric, oligomeric or monomeric material, to form a photochromic
composition, which may be used, for example and without limitation, as or to form
photochromic articles, such as optical elements, and photochromic coating compositions
that may be applied to various substrates. As used herein the terms "polymer" and
"polymeric material" refer to homopolymers and copolymers (e.g., random copolymers,
block copolymers, and alternating copolymers), as well as blends and other combinations
thereof. As used herein the terms "oligomer" and "oligomeric material" refer to a
combination of two or more monomer units that is capable of reacting with additional
monomer unit(s). As used herein the term "incorporated into" means physically and/or
chemically combined with. For example, the photochromic materials according to the
present invention may be physically combined with at least a portion of an organic
material, for example and without limitation, by mixing or imbibing the photochromic
material into the organic material; and/or chemically combined with at least a portion
of an organic material, for example and without limitation, by copolymerization or
otherwise bonding the photochromic material to the organic material.
[0127] The photochromic materials according to the present invention may each be used alone,
in combination with other photochromic materials according to various non-limiting
embodiments disclosed herein, or in combination with an appropriate complementary
conventional photochromic material. For example, the photochromic materials according
to the present invention may be used in conjunction with conventional photochromic
materials having activated absorption maxima within the range of 300 to 1000 nanometers.
Further, the photochromic materials according to the present invention may be used
in conjunction with a complementary conventional polymerizable or a compatibilized
photochromic material, such as for example, those disclosed in
U.S. Patent Nos. 6,113,814 (at col. 2, line 39 to col. 8, line 41), and
6,555,028 (at col. 2, line 65 to col. 12, line 56).
[0128] The photochromic compositions of the present invention may contain a mixture of photochromic
materials. For example, although not limiting herein, mixtures of photochromic materials
may be used to attain certain activated colors such as a near neutral gray or near
neutral brown. See, for example,
U.S. Patent No. 5,645,767, col. 12, line 66 to col. 13, line 19, which describes the parameters that define
neutral gray and brown colors.
[0129] The present invention relates to a photochromic composition that includes an organic
material, in which the organic material is a polymeric material, an oligomeric material
and/or a monomeric material, and a photochromic material according to the present
invention incorporated into at least a portion of the organic material. According
to various non-limiting embodiments disclosed herein, the photochromic material may
be incorporated into a portion of the organic material by at least one of blending
and bonding the photochromic material with the organic material or a precursor thereof.
As used herein with reference to the incorporation of photochromic materials into
an organic material, the terms "blending" and "blended" mean that the photochromic
material is intermixed or intermingled with the at least a portion of the organic
material, but not bonded to the organic material. Further, as used herein with reference
to the incorporation of photochromic materials into an organic material, the terms
"bonding" or "bonded" mean that the photochromic material is linked to a portion of
the organic material or a precursor thereof. For example, although not limiting herein,
the photochromic material may be linked to the organic material through a reactive
substituent.
[0130] When the organic material of the photochromic compositions of the present invention
is a polymeric material, the photochromic material of the present invention may be
incorporated into at least a portion of the polymeric material or at least a portion
of the monomeric material or oligomeric material from which the polymeric material
is formed. For example, photochromic materials according to various non-limiting embodiments
disclosed herein that have a reactive substituent may be bonded to an organic material
such as a monomer, oligomer, or polymer having a group with which a reactive moiety
may be reacted, or the reactive moiety may be reacted as a co-monomer in the polymerization
reaction from which the organic material is formed, for example, in a copolymerization
process.
[0131] As discussed previously herein, photochromic compositions according to various non-limiting
embodiments of the present invention may include an organic material chosen from a
polymeric material, an oligomeric material and/or a monomeric material. Examples of
polymeric materials that may be used in conjunction with various non-limiting embodiments
disclosed herein include, without limitation: polymers of bis(allyl carbonate) monomers;
diethylene glycol dimethacrylate monomers; diisopropenyl benzene monomers; ethoxylated
bisphenol A dimethacrylate monomers; ethylene glycol bismethacrylate monomers; poly(ethylene
glycol) bismethacrylate monomers; ethoxylated phenol bismethacrylate monomers; alkoxylated
polyhydric alcohol acrylate monomers, such as ethoxylated trimethylol propane triacrylate
monomers; urethane acrylate monomers; vinylbenzene monomers; and styrene. Other non-limiting
examples of suitable polymeric materials include polymers of polyfunctional, e.g.,
mono-, di- or multi-functional, acrylate and/or methacrylate monomers; poly(C
1-C
12 alkyl methacrylates), such as poly(methyl methacrylate); poly(oxyalkylene)dimethacrylate;
poly(alkoxylated phenol methacrylates); cellulose acetate; cellulose triacetate; cellulose
acetate propionate; cellulose acetate butyrate; poly(vinyl acetate); poly(vinyl alcohol);
poly(vinyl chloride); poly(vinylidene chloride); polyurethanes; polythiourethanes;
thermoplastic polycarbonates; polyesters; poly(ethylene terephthalate); polystyrene;
poly(alpha-methylstyrene); copolymers of styrene and methyl methacrylate; copolymers
of styrene and acrylonitrile; polyvinylbutyral; and polymers of diallylidene pentaerythritol,
particularly copolymers with polyol (allyl carbonate) monomers, e.g., diethylene glycol
bis(allyl carbonate), and acrylate monomers, e.g., ethyl acrylate, butyl acrylate.
Also contemplated are copolymers of the aforementioned monomers, combinations, and
blends of the aforementioned polymers and copolymers with other polymers, e.g., to
form interpenetrating network products.
[0132] Photochromic compositions according to the present invention may possess transparency,
in which case the organic material(s) may be selected from one or more transparent
polymeric materials. For example, the polymeric material may be an optically clear
polymeric material prepared from a thermoplastic polycarbonate resin, such as a resin
derived from bisphenol A and phosgene, which is commercially available under the trademark,
LEXAN
®; a polyester, such as the material commercially available under the trademark, MYLAR
®; a poly(methyl methacrylate), such as the material commercially available under the
trademark, PLEXIGLAS
®; and polymerizates of a polyol(allyl carbonate) monomer, especially diethylene glycol
bis(allyl carbonate), which monomer is commercially available under the trademark
CR-39
®; and polyurea-polyurethane (polyurea urethane) polymers, which are prepared, for
example, by the reaction of a polyurethane oligomer and a diamine curing agent, a
composition for one such polymer being commercially available under the trademark
TRIVEX
® by PPG Industries, Inc. Other non-limiting examples of suitable polymeric materials
include polymerizates of copolymers of a polyol (allyl carbonate), e.g., diethylene
glycol bis(allyl carbonate), with other copolymerizable monomeric materials, such
as, but not limited to: copolymers with vinyl acetate, copolymers with a polyurethane
having terminal diacrylate functionality, and copolymers with aliphatic urethanes,
the terminal portion of which contain allyl or acrylyl functional groups. Still other
suitable polymeric materials include, without limitation, poly(vinyl acetate), polyvinylbutyral,
polyurethane, polythiourethanes, polymers chosen from diethylene glycol dimethacrylate
monomers, diisopropenyl benzene monomers, ethoxylated bisphenol A dimethacrylate monomers,
ethylene glycol bismethacrylate monomers, poly(ethylene glycol) bismethacrylate monomers,
ethoxylated phenol bismethacrylate monomers and ethoxylated trimethylol propane triacrylate
monomers, cellulose acetate, cellulose propionate, cellulose butyrate, cellulose acetate
butyrate, polystyrene and copolymers of styrene with methyl methacrylate, vinyl acetate
and acrylonitrile. According to one non-limiting embodiment, the polymeric material
may be an optical resin commercially available from PPG Industries, Inc., under the
CR-designation, e.g., CR-307, CR-407, and CR-607.
[0133] In an embodiment, the organic material of the photochromic compositions according
to the present invention, is a polymeric material that may be chosen from poly(carbonate);
copolymers of ethylene and vinyl acetate; copolymers of ethylene and vinyl alcohol;
copolymers of ethylene, vinyl acetate, and vinyl alcohol (such as those that result
from the partial saponification of copolymers of ethylene and vinyl acetate); cellulose
acetate butyrate; poly(urethane); poly(acrylate); poly(methacrylate); epoxies; aminoplast
functional polymers; poly(anhydride); poly(urea urethane); N-alkoxymethyl(meth)acrylamide
functional polymers; poly(siloxane); poly(silane); and combinations and mixtures thereof.
[0134] Photochromic articles (e.g., optical elements) according to the present invention,
more particularly, include a photochromic material that further includes a photochromic
compound having bonded thereto at least one pendent silane group represented by general
formula (I) and/or general formula (II), as described previously herein. The photochromic
compound of the photochromic material may include one or more indeno-fused naphthopyrans,
for example as described previously herein with regard to general formulas (III) and/or
(IV).
[0135] Examples of photochromic articles according to the present invention include, but
are not limited to, optical elements, displays, windows (or transparencies), mirrors,
and liquid crystal cells. As used herein the term "optical" means pertaining to or
associated with light and/or vision. The optical elements according to the present
invention may include, without limitation, ophthalmic elements, display elements,
windows, mirrors, and liquid crystal cell elements. As used herein the term "ophthalmic"
means pertaining to or associated with the eye and vision. Non-limiting examples of
ophthalmic elements include corrective and non-corrective lenses, including single
vision or multi-vision lenses, which may be either segmented or non-segmented multi-vision
lenses (such as, but not limited to, bifocal lenses, trifocal lenses and progressive
lenses), as well as other elements used to correct, protect, or enhance (cosmetically
or otherwise) vision, including without limitation, magnifying lenses, protective
lenses, visors, goggles, as well as, lenses for optical instruments (for example,
cameras and telescopes). As used herein the term "display" means the visible or machine-readable
representation of information in words, numbers, symbols, designs or drawings. Non-limiting
examples of display elements include screens, monitors, and security elements, such
as security marks. As used herein the term "window" means an aperture adapted to permit
the transmission of radiation there-through. Non-limiting examples of windows include
automotive and aircraft transparencies, windshields, filters, shutters, and optical
switches. As used herein the term "mirror" means a surface that specularly reflects
a large fraction of incident light. As used herein the term "liquid crystal cell"
refers to a structure containing a liquid crystal material that is capable of being
ordered. One non-limiting example of a liquid crystal cell element is a liquid crystal
display.
[0136] Photochromic articles according to the present invention, such as optical elements,
may include a substrate and a photochromic material according to the present invention
that is connected to at least a portion of the substrate. As used herein, the term
"connected to" means associated with, either directly, or indirectly by means of another
material or structure.
[0137] Photochromic articles according to the present invention may include, as discussed
above, a substrate that may include one or more polymeric materials. The photochromic
material of the present invention may be connected to at least a portion of the substrate
by: incorporating the photochromic material into at least a portion of the polymeric
material of the substrate; or by incorporating the photochromic material into at least
a portion of the oligomeric or monomeric material from which the substrate is formed.
For example, according to one non-limiting embodiment, the photochromic material may
be incorporated into the polymeric material of the substrate by a cast-in-place method
or by imbibition. The imbibition and the cast-in-place methods are discussed in further
detail herein below.
[0138] In the imbibition method, the photochromic material is typically diffused into the
polymeric material of a previously formed or fabricated article, such as a substrate
or previously applied coating/film. Imbibition may be performed by immersing the polymeric
material of a previously formed or fabricated article in a solution containing the
photochromic material, with or without heating. Thereafter, although not required,
the photochromic material may be bonded with the polymeric material (e.g., of the
substrate or coating).
[0139] With cast-in-place methods, the photochromic material may be mixed with: a polymer
and/or oligomer composition in solution or melt form; or monomer composition in liquid
form, so as to form a castable photochromic composition. The castable photochromic
composition is then typically introduced into the cavity of a mold (e.g., a lens mold).
The castable photochromic composition is then set within the mold so as to form a
photochromic article.
[0140] With photochromic articles according to the present invention that include a substrate,
the photochromic material may be connected to at least a portion of the substrate
as part of a coating that is connected to at least a portion of the substrate. The
substrate may be a polymeric substrate or an inorganic substrate (such as, but not
limited to, a glass substrate). The photochromic material may be incorporated into
at least a portion of a coating composition prior to application of the coating composition
to the substrate. Alternatively, a coating composition may be applied to the substrate,
at least partially set, and thereafter the photochromic material may be imbibed into
at least a portion of the coating. As used herein, the terms "set" and "setting" include,
without limitation, curing, polymerizing, cross-linking, cooling, and drying.
[0141] Photochromic articles according to the present invention may be formed by art-recognized
in-mold coating (or in-mold casting) methods. With in-mold coating methods, a photochromic
coating composition according to the present invention, which may be a liquid coating
composition or a powder coating composition, is applied to at least a portion of the
interior surface of a mold, and then at least partially set. Thereafter, a polymer
solution or melt, or oligomeric or monomeric solution or mixture is cast or molded
within the mold cavity and in contact with the previously applied photochromic coating
composition, and at least partially set. The resulting photochromic article is then
removed from the mold. Non-limiting examples of powder coatings in which the photochromic
materials according to various non-limiting embodiments disclosed herein may be employed
are set forth in U.S. Patent No. 6,068,797 at col. 7, line 50 to col. 19, line 42.
[0142] Photochromic articles according to the present invention may also be formed by art-recognized
over-mold methods. Over-mold methods typically involve forming a substrate within
a mold, and then forming an interior space between the substrate and an interior surface
of the mold, into which a photochromic coating composition is then subsequently introduced
(e.g., injected) and then set (e.g., cured). Alternatively, over-mold methods may
involve introducing a previously formed substrate into a mold, such that an interior
space is defined between the substrate and an interior mold surface, and thereafter
a photochromic coating composition is introduced (e.g., injected) into the interior
space.
[0143] Photochromic articles according to the present invention may also be formed by means
of art-recognized lamination methods. With lamination methods, a film comprising the
photochromic material according to the present invention may be adhered or otherwise
connect to a portion of the substrate, with or without an adhesive and/or the application
of heat and pressure. Thereafter, if desired, a second substrate may be applied over
the first substrate and the two substrates may be laminated together (i.e., by the
application of heat and pressure) to form an element wherein the film comprising the
photochromic material is interposed between the two substrates. Methods of forming
films comprising a photochromic material may include for example and without limitation,
combining a photochromic material with a polymeric solution or oligomeric solution
or mixture, casting or extruding a film therefrom, and, if required, at least partially
setting the film. Additionally or alternatively, a film may be formed (with or without
a photochromic material) and imbibed with the photochromic material.
[0144] The coating composition comprising the photochromic material may be connected to
at least a portion of the substrate of the photochromic article by art-recognized
methods, such as applying a coating composition comprising the photochromic material
to at least a portion of a surface of the substrate, and at least partially setting
the coating composition. Additionally or alternatively, the coating comprising the
photochromic material may be connected to the substrate, for example, through one
or more additional coatings. For example, while not limiting herein, according to
various non-limiting embodiments, an additional coating composition may be applied
to a portion of the surface of the substrate, at least partially set, and thereafter
the coating composition comprising the photochromic material may be applied over the
additional coating and at least partially set. Non-limiting and art-recognized methods
of applying coatings compositions to substrates are discussed herein below.
[0145] Examples of additional coatings and films that may be used in conjunction with the
photochromic coatings and articles according to the present invention, include, but
are not limited to: primer coatings and films (which typically reside under the photochromic
coating); protective coatings and films (which are typically applied over the photochromic
coating), including transitional coatings and films and abrasion resistant coatings
and films; anti-reflective coatings and films; conventional photochromic coatings
and films; polarizing coatings and films; and combinations thereof. As used herein
the term "protective coating or film" refers to coatings or films that can prevent
wear or abrasion, provide a transition in properties from one coating or film to another,
protect against the effects of polymerization reaction chemicals and/or protect against
deterioration due to environmental conditions such as moisture, heat, ultraviolet
light, oxygen, etc.
[0146] Examples of primer coatings and films that may be used in conjunction with the photochromic
coatings and/or with/to-form photochromic articles according to the present invention
include, but are not limited to coatings and films that include coupling agents, at
least partial hydrolysates of coupling agents, and mixtures thereof. As used herein
"coupling agent" means a material having a group capable of reacting, binding and/or
associating with a group on a surface. Coupling agents according to various non-limiting
embodiments disclosed herein may include organometallics such as silanes, titanates,
zirconates, aluminates, zirconium aluminates, hydrolysates thereof and mixtures thereof.
As used herein the phrase "at least partial hydrolysates of coupling agents" means
that some to all of the hydrolyzable groups on the coupling agent are hydrolyzed.
Other non-limiting examples of primer coatings that are suitable for use in conjunction
with the various non-limiting embodiments disclosed herein include those primer coatings
described
U.S. Patent 6,025,026 at col. 3, line 3 to col. 11, line 40 and
U.S. Patent 6,150,430 at col. 2, line 39 to col. 7, line 58.
[0147] As used herein, the term "transitional coating and film" means a coating or film
that aids in creating a gradient in properties between two coatings or films, or a
coating and a film. For example, although not limiting herein, a transitional coating
may aid in creating a gradient in hardness between a relatively hard coating and a
relatively soft coating. Non-limiting examples of transitional coatings include radiation-cured,
acrylate-based thin films as described in
U.S. Patent Application Publication 2003/0165686 at paragraphs 79-173.
[0148] As used herein the term "abrasion resistant coating and film" refers to a protective
polymeric material that demonstrates a resistance to abrasion that is greater than
a standard reference material, e.g., a polymer made of CR-39
® monomer available from PPG Industries, Inc, as tested in a method comparable to ASTM
F-735 Standard Test Method for Abrasion Resistance of Transparent Plastics and Coatings
Using the Oscillating Sand Method. Non-limiting examples of abrasion resistant coatings
include, for example, abrasion-resistant coatings comprising organosilanes, organosiloxanes,
abrasion-resistant coatings based on inorganic materials such as silica, titania and/or
zirconia, organic abrasion-resistant coatings of the type that are ultraviolet light
curable, oxygen barrier-coatings, UV-shielding coatings, and combinations thereof.
[0149] Non-limiting examples of antireflective coatings and films include a monolayer, multilayer
or film of metal oxides, metal fluorides, or other such materials, which may be deposited
onto the articles disclosed herein (or onto films that are applied to the articles),
for example, through vacuum deposition, sputtering, etc. Non-limiting examples of
conventional photochromic coatings and films include, but are not limited to, coatings
and films comprising conventional photochromic materials. Non-limiting examples of
polarizing coatings and films include, but are not limited to, coatings and films
comprising dichroic compounds that are known in the art.
[0150] Additional coating compositions (e.g., primers and over-coats) that may be used with
photochromic coating compositions according to the present invention and/or to form
photochromic articles according to the present invention, may be applied to / formed:
on a substrate prior to application of the photochromic coating; and/or over a previously
applied photochromic coating. For example, a primer coating may be formed on the substrate
prior to applying a photochromic coating composition according to the present invention.
Additionally or alternatively, an additional coating or film may be applied (e.g.,
as an over-coat or over-coating) at least partially over a previously applied photochromic
coating composition according to the present invention. For example, a transitional
coating may be formed over a previously applied photochromic coating composition according
to the present invention, and an abrasion resistant coating may then be applied over
the transitional coating.
[0151] Photochromic coating compositions according to the present invention include: a photochromic
compound (e.g., an indeno-fused naphthopyran represented by general formulas III and/or
IV) having bonded thereto at least one pendent silane group represented by general
formulas (I) and/or (II) as described previously herein; a curable resin composition;
and optionally a solvent. The photochromic coating composition may be in the form
of art-recognized liquid coatings and powder coatings. The photochromic coating compositions
of the present invention may be thermoplastic or thermosetting coating compositions.
In an embodiment, the photochromic coating composition is a curable or thermosetting
coating composition.
[0152] The curable resin composition of the curable photochromic coating compositions according
to the present invention typically include: a first reactant (or component) having
functional groups, e.g., an epoxide functional polymer reactant; and a second reactant
(or component) that is a crosslinking agent having functional groups that are reactive
towards and that can form covalent bonds with the functional groups of the first reactant.
The first and second reactants of the curable resin composition of the curable photochromic
coating composition may each independently comprise one or more functional species,
and are each present in amounts sufficient to provide cured photochromic coatings
having a desirable combination of physical properties, e.g., smoothness, optical clarity,
solvent resistance and hardness.
[0153] Examples of curable resin compositions that may be used with the curable photochromic
coating compositions according to the present invention include, but are not limited
to: curable resin compositions comprising epoxide functional polymer (e.g., (meth)acrylic
polymers containing residues of glycidyl (meth)acrylate) and epoxide reactive crosslinking
agent (e.g., containing active hydrogens, such as hydroxyls, thiols and amines); and
curable resin compositions comprising hydroxy functional polymer and capped (or blocked)
isocyanate functional crosslinking agent.
[0154] In an embodiment, the curable resin composition of the photochromic coating composition
of the present invention is a curable urethane (or polyurethane) resin composition.
Curable urethane resin compositions useful in the photochromic coating compositions
of the present invention typically include: an active hydrogen functional polymer,
such as a hydroxy functional polymer; and a capped (or blocked) isocyanate functional
crosslinking agent. Hydroxy functional polymers that can be used in such compositions
include, but are not limited to, art-recognized hydroxy functional vinyl polymers,
hydroxy functional polyesters, hydroxy functional polyurethanes and mixtures thereof.
[0155] Vinyl polymers having hydroxy functionality can be prepared by free radical polymerization
methods that are known to those of ordinary skill in the art. In an embodiment of
the present invention, the hydroxy functional vinyl polymer is prepared from a majority
of (meth)acrylate monomers and is referred to herein as a "hydroxy functional (meth)acrylic
polymer."
[0156] Hydroxy functional polyesters useful in curable photochromic coating compositions
comprising capped isocyanate functional crosslinking agent can be prepared by art-recognized
methods. Typically, diols and dicarboxylic acids or diesters of dicarboxylic acids
are reacted in a proportion such that the molar equivalents of hydroxy groups is greater
than that of carboxylic acid groups (or esters of carboxylic acid groups) with the
concurrent removal of water or alcohols from the reaction medium.
[0157] Hydroxy functional urethanes can be prepared by art-recognized methods, for example,
as previously described herein. Typically one or more difunctional isocyanates are
reacted with one or more materials having two active hydrogen groups (e.g., diols
or dithiols), such that the ratio of active hydrogen groups to isocyanate groups is
greater than 1, as is known to the skilled artisan.
[0158] By "capped (or blocked) isocyanate crosslinking agent" is meant a crosslinking agent
having two or more capped isocyanate groups that can decap (or deblock) under cure
conditions, e.g., at elevated temperature, to form free isocyanate groups and free
capping groups. The free isocyanate groups formed by decapping of the crosslinking
agent are preferably capable of reacting and forming substantially permanent covalent
bonds with the active hydrogen groups of the active hydrogen functional polymer (e.g.,
with the hydroxy groups of a hydroxy functional polymer).
[0159] It is desirable that the capping group of the capped isocyanate crosslinking agent
not adversely affect the curable photochromic coating composition upon decapping from
the isocyanate (i.e., when it becomes a free capping group). For example, it is desirable
that the free capping group neither become trapped in the cured film as gas bubbles
nor excessively plastisize the cured film. Capping groups useful in the present invention
preferably have the characteristics of being nonfugitive or capable of escaping substantially
from the forming coating prior to its vitrification. Typically, the free capping groups
escape substantially from the forming (e.g., curing) coating prior to its vitrification.
[0160] Classes of capping groups of the capped isocyanate crosslinking agent may be selected
from: hydroxy functional compounds, e.g., linear or branched C
2-C
8 alcohols, ethylene glycol butyl ether, phenol and p-hydroxy methylbenzoate; 1H-azoles,
e.g., 1H-1,2,4-triazole and 1H-2,5-dimethyl pyrazole; lactams, e.g., e-caprolactam
and 2-pyrolidinone; ketoximes, e.g., 2-propanone oxime and 2-butanone oxime. Other
suitable capping groups include, morpholine, 3-aminopropyl morpholine and N-hydroxy
phthalimide.
[0161] The isocyanate or mixture of isocyanates of the capped isocyanate crosslinking agent
has two or more isocyanate groups (e.g., 3 or 4 isocyanate groups). Examples of suitable
isocyanates that may be used to prepare the capped isocyanate crosslinking agent include,
monomeric diisocyanates, e.g., α, α'-xylylene diisocyanate, α, α, α', α'-tetramethylxylylene
diisocyanate and 1-isocyanato-3-isocyanatomethyl-3,5,5-trimethylcyclohexane (isophorone
diisocyanate or IPDI), and dimers and trimers of monomeric diisocyanates containing
isocyanurate, uretidino, biruet or allophanate linkages, e.g., the trimer of IPDI.
[0162] The capped isocyanate crosslinking agent may also be selected from oligomeric capped
isocyanate functional adducts. As used herein, by "oligomeric capped polyisocyanate
functional adduct" is meant a material that is substantially free of polymeric chain
extension. Oligomeric capped polyisocyanate functional adducts can be prepared by
art-recognized methods from, for example, a compound containing three or more active
hydrogen groups, e.g., trimethylolpropane (TMP), and an isocyanate monomer, e.g.,
1-isocyanato-3,3,5-trimethyl-5-isocyanatomethylcyclohexane (IPDI), in a molar ratio
of 1:3, respectively. In the case of TMP and IPDI, by employing art-recognized starved
feed and/or dilute solution synthesis techniques, an oligomeric adduct having an average
isocyanate functionality of 3 can be prepared (e.g., "TMP-3IPDI"). The three free
isocyanate groups per TMP-3IPDI adduct are then capped with a capping group, e.g.,
a linear or branched C
2-C
8 alcohol.
[0163] To catalyze the reaction between the isocyanate groups of the capped polyisocyanate
crosslinking agent and the hydroxy groups of the hydroxy functional polymer, one or
more catalysts are typically present in the curable photochromic coating composition
in amounts of from, for example, 0.1 to 5 percent by weight, based on total resin
solids of the composition. Classes of useful catalysts include but are not limited
to, metal compounds, in particular, organic tin compounds, e.g., tin(II) octanoate
and dibutyltin(IV) dilaurate, and tertiary amines, e.g., diazabicyclo[2.2.2]octane.
[0164] Curable photochromic coating compositions according to the present invention, which
include hydroxy functional polymer and capped isocyanate functional crosslinking agent,
typically have present therein hydroxy functional polymer in an amount of from 55
percent to 95 percent by weight, based on total resin solids weight of the composition,
e.g., from 75 percent to 90 percent by weight, based on total resin solids weight
of the composition. The capped isocyanate functional crosslinking agent is typically
present in the curable resin composition in an amount corresponding to the balance
of these recited ranges, i.e., 5 to 45, particularly 10 to 25, percent by weight.
[0165] With the curable urethane resin compositions of the curable photochromic coating
compositions of the present invention, the equivalent ratio of isocyanate equivalents
in the capped isocyanate crosslinking agent to hydroxy equivalents in the hydroxy
functional polymer is typically within the range of 1:3 to 3:1, e.g., 1:2 to 2:1.
While equivalent ratios outside of this range can be employed, they are generally
less desirable due to performance deficiencies in cured photochromic films obtained
therefrom. Curable photochromic coating compositions according to the present invention
that include hydroxy functional polymer and capped isocyanate functional crosslinking
agent are typically cured at a temperature of from 120°C to 190°C over a period of
from 10 to 60 minutes.
[0166] Photochromic coating compositions according to the present invention may optionally
further include a solvent. Examples of suitable solvents include, but art not limited
to, acetates, alcohols, ketones, glycols, ethers, aliphatics, cycloaliphatics and
aromatics. Examples of acetates include, but are not limited to, ethyl acetate, butyl
acetate, and glycol acetate. Examples of ketones include, but are not limited to,
methyl ethyl ketone and methyl-N-amyl ketone. Examples of aromatics include, but are
not limited to, are toluene, naphthalene and xylene. In an embodiment, one or more
solvents are added to each of the first reactant and the second reactant. Suitable
solvent blends can include, for example, one or more acetates, propanol and its derivatives,
one or more ketones, one or more alcohols and/or one or more aromatics. If present,
the solvent is typically present in an amount of from 5 to 60 percent by weight, or
5 to 40 percent by weight, or 10 to 25 percent by weight, based on the total weight
of the photochromic coating composition (inclusive of the solvent weight).
[0167] Curable photochromic coating compositions according to the present invention may
optionally contain additives such as waxes for flow and wetting, flow control agents,
e.g., poly(2-ethylhexyl)acrylate, adjuvant resin to modify and optimize coating properties,
antioxidants and ultraviolet (UV) light absorbers. Examples of useful antioxidants
and UV light absorbers include those available commercially from Ciba-Geigy under
the trademarks IRGANOX and TINUVIN. These optional additives, when used, are typically
present in amounts up to 20 percent by weight (e.g., from 0.5 to 10 percent by weight),
based on total weight of resin solids of the curable resin composition.
[0168] Photochromic compositions, articles and coating compositions according to the present
invention may further include art-recognized additives that aid or assist in the processing
and/or performance of the compositions or articles. Non-limiting examples of such
additives include photoinitiators, thermal initiators, polymerization inhibitors,
solvents, light stabilizers (such as, but not limited to, ultraviolet light absorbers
and light stabilizers, such as hindered amine light stabilizers (HALS)), heat stabilizers,
mold release agents, rheology control agents, leveling agents (such as, but not limited
to, surfactants), free radical scavengers, adhesion promoters (such as hexanediol
diacrylate and coupling agents), and combinations and mixtures thereof.
[0169] The photochromic materials according to the present invention may be used in amounts
(or ratios) such that the organic material or substrate (e.g., photochromic articles
and photochromic coatings) into which the photochromic materials are incorporated
or otherwise connected exhibits desired optical properties. For example, the amount
and types of photochromic materials may be selected such that the organic material
or substrate may be clear or colorless when the photochromic material is in the closed-form
(i.e., in the bleached or unactivated state) and may exhibit a desired resultant color
when the photochromic material is in the open-form (that is, when activated by actinic
radiation). The precise amount of the photochromic material to be utilized in the
various photochromic compositions and articles described herein is not critical provided
that a sufficient amount is used to produce the desired effect. The particular amount
of the photochromic material used may depend on a variety of art-recognized factors,
such as but not limited to, the absorption characteristics of the photochromic material,
the color and intensity of the color desired upon activation, and the method used
to incorporate or connect the photochromic material to the substrate. Although not
limiting herein, according to various non-limiting embodiments disclosed herein, the
amount of the photochromic material that is incorporated into an organic material
may range from 0.01 to 40 weight percent (e.g., from 0.05 to 15, or from 0.1 to 5
weight percent), based on the weight of the organic material.
Examples
[0170] Part 1 describes the preparation of the propargyl alcohols (PA) 1-23. Part 2 describes
the preparation of the naphthols (N) 1-27. Part 3 describes the preparation of intermediate
photochromic compounds, the majority of which were used as Comparative Examples (CE)
1-78. Part 4 describes the preparation of Examples 1-87 utilizing the materials of
Parts 1,2 & 3. Part 5 describes the photochromic performance testing and results of
the Examples and Comparative Examples. Part 6 describes the preparation and testing
of polyurethane coatings containing Example 25 and Comparative Example 78. The results
reported in Tables 1 and 2 showed that the compounds of the present invention demonstrated
improved photochromic performance over the comparative examples with a higher sensitivity,
higher ΔOD at saturation and/or a faster Fade Half Life ("T1/2"), i.e., a lower value.
[0171] The patent examples referred to in Parts 1-4 of
U.S. Patents: 5,458,814;
5,645,767;
7,465,415;
7,527,754; and
7,557,208; and
U.S. Patent Publications: 2006/0228557 and
2008/0103301 are incorporated herein by reference.
[0172] In the following parts, the acronyms used herein mean as follows:
EtOAc - ethyl acetate;
DCM - dichloromethane;
DHP - 3,4-dihydro-2H-pyran;
DMAP or 4-DMAP - 4-dimethylaminopyridine;
DMF or dDMF - anhydrous dimethylformamide;
DMSO - dimethyl sulfoxide;
h or hrs - hours;
MeCN or dMeCN - anhydrous acetonitrile;
MeOH - methanol;
MS - probe mass spectroscopy;
NMR - proton nuclear magnetic resonance;
TEA - triethanolamine;
THF or dTHF - anhydrous tetrahydrofuran;
PTSA - para-toluenesulfonic acid; and
V/V - ratio of solvents was based on volume to volume.
Part 1 - Preparation of Propargyl Alcohols (PA) 1-23
PA-1
[0173] Step 1 of Example 1 in
US 5,458,814 was followed to prepare 1,1-bis(4-methoxyphenyl)-2-propyn-1-ol. The product was used
without further purification.
PA-2
Step 1
[0174] The procedure of step 1 of Example 7 of
US 7,465,415B2 was followed except that (4-hydroxyphenyl)(4-methoxyphenyl)methanone was used instead
of (4-fluorophenyl)(4-hydroxyphenyl)methanone to produce (4-(2-hydroxyethoxy)phenyl)(4-methoxyphenyl)methanone.
MS analysis supported the molecular weight of the product.
Step 2
[0175] The procedure of step 1 of Example 5 of
US 7,465,415B2 was followed except that (4-(2-hydroxyethoxy)phenyl)(4-methoxyphenyl)methanone used
in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-methoxyphenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-3
Step 1
[0176] In a 0.5L single neck flask bis(4-fluorophenyl)methanone (20g) was dissolved in DMSO
(40 mL), piperidine 3-methanol (9.6g) was added and then TEA (11.5 mL) was added.
The reaction mixture was stirred at 70 °C. After 20 hrs the reaction was cooled to
room temperature, water (0.8L) was added and resulting mixture was extracted with
DCM (2 times with 300 mL each time). The organic phase was collected, washed with
water (4 times with 300 mL each time) and the solvent evaporated to produce the product
(25g). MS analysis supported the molecular weight of the product (4-fluorophenyl)(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)methanone.
Step 2
[0177] The procedure of step 1 of Example 5 of
US 7,465,415B2 was followed except that the product of Step 1 (4-fluorophenyl)(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)methanone
was used in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce
1-(4-fluorophenyl)-1-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)prop-2-yn-1-ol. The
product was used without further purification.
PA-4
[0178] Steps 2 to 3 of example 7
US 7,465,415B2 were followed except that (4-fluorophenyl)(4-methoxyphenyl)methanone was used in
place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-methoxyphenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-5
[0179] Steps 1 to 3 of Example 7 in
US 7,465,415B2 were followed to prepare 1-(4-(2-hydroxyethoxy)-phenyl-1-(4-morpholinophenyl)-2-propyn-1-ol.
The product was used without further purification.
PA-6
[0180] Step 1 of Example 5 in
US 7,465,415B2 was followed to prepare 1-(4-fluorophenyl)-1-(4'-(2-hydroxyethoxy)phenyl)-2-propyn-1-ol.
The product was used without further purification.
PA-7
Step 1
[0181] Into a 0.5L reaction flask dihydroxybenzophenone (15 g) was suspended in water (150
mL) and a solution of NaOH (10.9 g in 120mL) was added while stirring. 2-Chloroethanol
(31.7 mL) was added. The resulting mixture was heated to reflux for 2 days. The mixture
was cooled to room temperature and filtered. The resulting solid was collected, dissolved
in THF (200 mL) and washed once with KOH 1M (300 mL). The organic layer was collected
and the solvents evaporated to produce 8.5 g of product. MS analysis supported the
molecular weight of bis(4-(2-hydroxyethoxy)phenyl)methanone.
Step 2
[0182] Into a 0.5L reaction flask was added THF (200 mL), product from Step 1, bis(4-(2-hydroxyethoxy)phenyl)methanone
and 3,4-dihydro-2H-pyran (DHP, 5.5mL). PTSA (57 mg) was added and the reaction mixture
stirred 12 hrs at room temperature. Then, the solvent was evaporated, the residue
dissolved in DCM (200 mL), extracted with aqueous 1% K
2CO
3 (one time with 150 mL) and brine (100 mL)). After evaporation of the solvent the
product (7.1 g) was collected. MS analysis supported the molecular weight of the product
bis(4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)phenyl)methanone.
Step 3
[0183] The product of Step 2 was added to a 1L reaction flask with 100 mL of DMF. The mixture
was cooled to 5 °C and was bubbled with acetylene gas for 10 min. A slurry of sodium
acetylide (18 % weight in Xylene/mineral oil from Aldrich, 7 mL) was added all at
once. The reaction mixture was stirred for 0.5 hrs and then the ice bath was removed.
After 10 hrs the mixture was poured into a flask containing ice (150g) and stirred
for 10 minutes. EtOAc (300 mL) was added and the mixture phase separated. During the
phase separation a saturated solution of NH
4Cl (250 mL) was added. The recovered organic layer was washed with water (2 times
with 150 mL each time). The resulting solution was concentrated by rotary evaporation
to provide 21 g of product. MS analysis supported the molecular weight of the product
1,1-bis(4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)phenyl)prop-2-yn-1-ol.
PA-8
[0184] Steps 1 to 2 of PA-3 were followed except that 4-hydroxy piperidine was used instead
of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(4-hydroxypiperidin-1-yl)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA 9
[0185] Steps 1 to 2 of PA-3 were followed except that piperidine 2-methanol was used instead
of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(2-(hydroxymethyl)piperidin-1-yl)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-10
[0186] Steps 1 to 2 of PA-3 were followed except that (4-fluorophenyl)(phenyl)methanone
was used instead of bis(4-fluorophenyl)methanone to produce 1-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-1-phenylprop-2-yn-1-ol.
The product was used without further purification.
PA-11
[0187] Steps 1 to 2 of PA-3 were followed except that piperazine-1-carbaldehyde was used
instead of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(4-formylpiperazin-1-yl)phenyl)prop-2-yn-1-ol.
MS analysis supported the molecular weight of the product.
PA-12
[0188] The procedure of Step 1 of Example 5 of
US 7,465,415B2 was followed except that (4-bromophenyl)(phenyl)methanone used in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone
to produce 1-(4-bromophenyl)-1-phenylprop-2-yn-1-ol. The product was used without
further purification.
PA-13
[0189] Steps 1 to 2 of PA-3 were followed except that 2-(piperazin-1-yl)ethanol was used
instead of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-14
[0190] Steps 1 to 2 of PA-3 were followed except that morpholin-2-ylmethanol was used instead
of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(2-(hydroxymethyl)morpholino)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-15
Step 1
[0191] In a dried flask under a nitrogen atmosphere, 4-methoxybenzophenone (32g) was dissolved
in acetic acid (250 mL) and then Br
2 (20 mL) was slowly added. The solution was stirred at room temperature for 48 hrs.
Then the mixture was diluted with DCM (250 mL) and washed with 5 weight % aqueous
K
2CO
3 (200 mL) and then with saturated aqueous K
2CO
3 (500 mL). The resulting organic phase was collected and washed with 1M aqueous solution
of NaHSO
3 (300 mL) and then with brine (200 mL). The organic phase was recovered, dried over
Mg
2SO
4 and filtered. After evaporation of the solvent, 38g of product was collected. MS
analysis supported the molecular weight of the product (3-bromo-4-methoxyphenyl)(phenyl)methanone.
Step 2
[0192] The procedure of Step 1 of Example 5 of
US 7,465,415B2 was followed except that (3-bromo-4-methoxyphenyl)(phenyl)methanone was used in place
of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-fluorophenyl)-1-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-16
Step 1
[0193] The procedure of Step 1 of PA-15 was used except that (4-fluorophenyl)(4-methoxyphenyl)methanone
was utilized instead of 4-methoxybenzophenone to obtain (3-bromo-4-methoxyphenyl)(4-fluorophenyl)methanone.
Step 2
[0194] Steps 2 to 3 of Example 7 of
US 7,465,415B2 were followed except that ((3-bromo-4-methoxyphenyl)(4-fluorophenyl)methanone was
used in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(3-bromo-4-methoxyphenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-17
[0195] Steps 2 to 3 of Example 7 of
US 7,465,415B2 were followed except that (4-fluorophenyl)(4-methoxyphenyl)methanone was used in
place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone and morpholin-2-ylmethanol
was used instead of morpholine to produce 1-(4-(2-(hydroxymethyl)morpholino)phenyl)-1-(4-methoxyphenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-18
[0196] Step 1 to 2 of PA-3 were followed except that piperidin-4-ylmethanol was used instead
of piperidine 3-methanol to produce 1-(4-fluorophenyl)-1-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-19
Step 1
[0197] Into a 0.5L reaction flask was added DMF (200 mL), dihydroxybenzophenone (15g) and
K
2CO
3 (29g). The resulting mixture was stirred under nitrogen atmosphere and allylbromide
(48mL) was added. The reaction was stirred for 12 hrs at 75 °C. The mixture was filtered
through filter paper and the filtrate collected. DCM (250 mL) was added, and the mixture
was washed with water (5 times with 400 mL each time). The resulting organic layer
was collected and the solvents evaporated to produce 19 g of product. MS analysis
supported the molecular weight of bis(4-(allyloxy)phenyl)methanone.
Step 2
[0198] The product of step 1 was added to a 1L reaction flask with 100 mL of DMF. The mixture
was cooled to 5 °C with an ice bath and bubbled with acetylene gas for 10 min. A slurry
of sodium acetylide (18 % weight in Xylene/mineral oil from Aldrich, 22 mL) was added
all at once. The reaction mixture was stirred for 0.5 hrs and then the ice bath was
removed. After 10 hrs the mixture was poured into a flask containing ice (150 g) and
stirred for 10 minutes. EtOAc (300 mL) was added and the mixture phase separated.
During the phase separation a saturated solution of NH
4Cl (250 mL) was added. The recovered organic layer was washed with water (2 times
with 150 mL each time). The resulting solution was concentrated by rotary evaporation
to provide 21 g of product. The product 1,1-bis(4-(allyloxy)phenyl)prop-2-yn-1-ol
was used without further purification. The product was used without further purification.
PA-20
Step1
[0199] The procedure of Step 1 of PA-19 was followed except that (4-fluorophenyl)(4-hydroxyphenyl)methanone
was used instead of dihydroxybenzophenone to obtain (4-(allyloxy)phenyl)(4-fluorophenyl)methanone.
MS analysis supported the molecular weight of the product.
Step 2
[0200] Steps 2 to 3 of Example 7 of
US 7,465,415B2 were followed except that (4-(allyloxy)phenyl)(4-fluorophenyl)methanone was used
in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-(allyloxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-21
[0201] Steps 2 to 3 of Example 13 in
US2006/0228557A1 were followed to produce 1-phenyl-1-(4-(2-hydroethoxy)phenyl)-2-propyn-1-ol. product
was used without further purification.
PA-22
Step 1
[0202] In a 500 mL dry flask, the product of Step1 of PA-2 (4-(2-hydroxyethoxy)phenyl)(4-methoxyphenyl)methanone
(8g) was dissolved in dry DMF (100mL) and NaH (5.6g, 55 % powder) was added. The mixture
was stirred for 1h under
[0203] Nitrogen atmosphere and then allyl bromide (14.8 mL) was slowly added. After 12 hrs
the reaction was quenched by addition of 50 mL of water. The resulting mixture was
extracted with DCM(200 mL) and the collected organic phase washed with water (5 times
with 250 mL each time). The solvent was evaporated to collect the residue. MS analysis
supports the molecular weight of the product (4-(2-(allyloxy)ethoxy)phenyl)(4-methoxyphenyl)methanone
(10g).
Step 2
[0204] The procedure of Step 1 of Example 5 of
US 7,465,415B2 was followed except that (4-(2-(allyloxy)ethoxy)phenyl)(4-methoxyphenyl)methanone
used in place of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-(2-(allyloxy)ethoxy)phenyl)-1-(4-methoxyphenyl)prop-2-yn-1-ol.
The product was used without further purification.
PA-23
Step 1
[0205] Into a 0.5L reaction flask was added DMF (200 mL), (4-hydroxyphenyl)(4-methoxyphenyl)methanone
(15g) and K
2CO
3 (27g). The resulting mixture was stirred under nitrogen atmosphere and butylbromide
(25mL) was added. The reaction was stirred for 12 hrs at 75 °C. The mixture was filtered
through filter paper and the filtrate collected. DCM (250 mL) was added, and the mixture
was washed with water (5 times with 400 mL each time). The resulting organic layer
was collected and the solvents evaporated to produce 17 g of product. MS analysis
supported the molecular weight of (4-butoxyphenyl)(4-methoxyphenyl)methanone.
Step 2
[0206] The procedure of step 1 of Example 5 of
US 7,465,415B2 was followed except that (4-butoxyphenyl)(4-methoxyphenyl)methanone used in place
of (4-fluorophenyl)(4-(2-hydroxyethoxy)phenyl)methanone to produce 1-(4-butoxyphenyl)-1-(4-methoxyphenyl)prop-2-yn-1-ol.
The product was used without further purification.
Part 2 - Preparation of Naphthols (N) 1-27
N-1
[0207] Steps 1 to 5 of Example 1 in
US2006/0228557A1 were followed to produce 2,3-dimethoxy-7,7-dimethyl-9-bromo-7H-benzo[C]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-2
[0208] Steps 1 to 6 in Example 1 in
US2006/0228557A1 were followed to produce 2,3-dimethoxy-7,7-dimethyl-9-cyano-7H-benzo[C]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-3
[0209] Step 1 in Example 2 in
US2006/0228557A1 was followed to produce 2,3-dimethoxy-7,7-dimethyl-9-carboxy-7H-benzo[C]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-4
[0210] Step 4 in Example 7 in
US7465415B2 was followed to produce 7,7-dimethyl-7H-benzo[c]fluoren-5-ol. MS analysis supported
the molecular weight of the product.
N-5
[0211] Steps 3 to 6 in Example 1 in
US7527754B2 were followed to produce 3,9-difluoro-7,7-dimethyl-7H-benzo[c]fluoren-5-ol. MS analysis
supported the molecular weight of the product.
N-6
[0212] The product of Step 5 of Example 4 in
US 5645767 (10 g) was dissolved in dTHF (100 mL) in a 1L reaction flask. The resulting solution
was cooled to 0 °C in an ice bath. MeMgBr (65 mL of 1.4M in THF) was added through
an addition funnel and the reaction mixture maintained in the ice bath for 1 h and
then refluxed. After 3 h at reflux the reaction mixture was cooled to room temperature
and quenched by adding small aliquots of saturated aqueous NH
4Cl (5 times with 10 mL each time). The mixture was poured into a flask containing
ice (150g). The resulting mixture was extracted with EtOAc (250 mL). The recovered
organic phase was washed with brine (100mL) and then dried over Mg
2SO
4. After filtration and evaporation of the solvent the product 3,7,9-trimethyl-7H-benzo[c]fluorene-5,7-diol
was collected (10.4 g). MS analysis supported the molecular weight of the product.
N-7
[0213] The procedure of Step 1 of Example 5 in
US 2006/0228557A1 was used except that 4-trifluoromethylphenylboronic acid was used instead of 4-fluorophenylboronic
acid to produce 2,3-dimethoxy-7,7-dimethyl-9-(4-(trifluoromethyl)phenyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-8
Step 1
[0214] The product of N-2 (10g) 2,3-dimethoxy-7,7-dimethyl-9-cyano-7H-benzo[C]fluoren-5-ol,
DHP (5 mL), PTSA (0.1g) and DCM (250 mL) were combined in a 0.5L reaction flask under
a nitrogen atmosphere. The mixture was stirred for 4 h and then poured into saturated
aqueous Na
2CO
3 (150 mL). The organic phase was collected and dried over Mg
2SO
4. After filtration and evaporation of the solvent, the product 2,3-dimethoxy-7,7-dimethyl-5-((tetrahydro-2H-pyran-2-yl)oxy)-7H-benzo[c]fluorene-9-carbonitrile
(12g) was collected and used in the next step without purification.
Step 2
[0215] The product of step 1 (12 g) was dissolved in tert-Butanol (200 mL) in a reaction
flask and then KOH (4.8g) and 1-bromoexane (10g) were added. The mixture was refluxed
for 6 hrs and cooled down to room temperature. After evaporation of the solvent the
recovered residue was dissolved in EtOAc (400 mL) and washed with water (3 times with
150 mL each time). The resulting organic phase was collected and the solvent evaporated
to provide the product N-hexyl-2,3-dimethoxy-7,7-dimethyl-5-((tetrahydro-2H-pyran-2-yl)oxy)-7H-benzo[c]fluorene-9-carboxamide
(12g) which was used as is for the next step.
Step 3
[0216] The product of Step 2 (12g) was dissolved in MeOH (250 mL) in a reaction flask and
HCl (37%, 0.5mL) was added. The mixture was heated to reflux for 3 hrs and cooled
down to room temperature. The solvent was evaporated by rotary evaporation and the
recovered residue dissolved in DCM (200 mL), washed with water (100 mL) and then with
brine (100 mL). The resulting organic phase was separated and after evaporation of
the solvent the product (10g) 2,3-dimethoxy-7,7-dimethyl-9-hexylcarbamoyl -7H-benzo[C]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-9
[0217] In a dried reaction flask, piperidine-3-methanol (3 g) and the product of N-8 (3g)
were dissolved in dTHF (60 mL), the solution was cooled in an ice bath and n-BuLi
(2M in cyclohexane, 35 mL) was slowly added using a syringe. The resulting mix was
stirred 15 min in the ice bath and then refluxed for 3.5 hrs. The mixture was stirred
overnight at room temperature. The reaction was quenched with water (25 mL) and saturated
aqueous NH
4Cl (40 mL). The mixture was extracted with EtOAc (100 mL) and the organic layer collected.
After evaporation of the solvent, the product (3.4g) was collected. NMR analysis showed
the product to have a structure consistent with 2-(3-(hydroxymethyl)piperidin-1-yl)-,3-dimethoxy-7,7-dimethyl-9-hexylcarbamoyl
-7H-benzo[C]fluoren-5-ol.
N-10
[0218] The procedure of Step 6 of Example 5 in
US7557208 was followed except that piperidine was used instead of morpholine to produce 3-methoxy-7,7-dimethyl-2-(piperidin-1-yl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-11
[0219] Steps 1 to 6 of Example 1 in
US2008/0103301A1 were followed to produce 2,3-dimethoxy-7,7-dimethyl-9-(trifluoromethyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-12
[0220] Step 1 of Example 9 in
US2006/0228557A1 was followed to produce 2,3-dimethoxy-7,7-dimethyl-9-(phenylethynyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-13
Step 1
[0221] The procedure of Step 1 of Example 5 in
US 2006/0228557A1 was used except that 2-trifluoromethylphenylboronic acid was used instead of 4-fluorophenylboronic
acid to produce 2,3-dimethoxy-7,7-dimethyl-9-(2-(trifluoromethyl)phenyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
Step 2
[0222] The procedure of Step 6 Example 5 in
US7557208 was used except that 3-dimethoxy-7,7-dimethyl-9-(2-(trifluoromethyl)phenyl)-7H-benzo[c]fluoren-5-ol
was used instead of 2,3-dimethoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol to produce
3-methoxy-7,7-dimethyl-2-(piperidin-1-yl)-9-(2-(trifluoromethyl)phenyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-14
[0223] The procedure of Step 6 of Example 5 in
US7557208 was used except that piperidine 3-methanol was used instead of morpholine to produce
2-(3-(hydroxymethyl)piperidin-1-yl)-3-methoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-15
[0224] The procedure of Step 1 of Example 5 in
US 2006/0228557A1 was used except that 4-cyanophenylboronic acid was used instead of 4-fluorophenylboronic
acid to produce 9-(4-cyanophenyl)-2,3-dimethoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-16
[0225] The procedure of Step 6 of Example 5 in
US7557208 was used except that the product from Steps 1 to 6 of Example 1 in
US2008/0103301A1 was used instead of 2,3-dimethoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol and N,N-diethylamine
instead of piperidine was used to produce 2-(diethylamino)-3-methoxy-7,7-dimethyl-9-(trifluoromethyl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-17
[0226] The procedure of Step 6 of Example 5 in
US7557208 was used except that the product from Step 1 of Example 6 from
US 2006/0228557A1 2,3-dimethoxy-7,7-dimethyl-9-phenyl-7H-benzo[c]fluoren-5-ol was used instead of 2,3-dimethoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol
to produce 3-methoxy-7,7-dimethyl-9-phenyl-2-(piperidin-1-yl)-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-18
[0227] The procedure of N-21 was followed except that morpholine was used instead of piperidine
to produce 3-methoxy-7,7-dimethyl-2-morpholino-9-phenyl-7H-benzo[c]fluoren-5-ol. MS
analysis supported the molecular weight of the product.
N-19
[0228] The product of N-3 (1.5g) was dissolved in dTHF (50 mL) in a reaction flask and cooled
to 5 °C in an ice bath. Then the solution of BH
3-THF complex 1M in THF (12 mL) was slowly added and the resulting mixture was stirred
at room temperature under a nitrogen atmosphere for 12 hrs. Water (30 mL) was added
and the resulting mixture was extracted with EtOAc (100 mL). After evaporation of
the solvent, the product 9-(hydroxymethyl)-2,3-dimethoxy-7,7-dimethyl-7H-benzo[c]fluoren-5-ol
was collected (1.2g) and used without further purification.
N-20
Step 1
[0229] The procedure of Steps 1 to 5 of Example 1 in
US 5645767 were followed except that bis(4-methoxyphenyl)methanone was used in place of 4,4'
dimethylbenzophenone to produce 5-hydroxy-3,9-dimethoxy-7H-benzo[c]fluoren-7-one.
Step 2
[0230] The product of Step 1 (5 g) was dissolved in dTHF (70 mL) in a reaction flask. The
resulting solution was cooled to 0 °C in an ice bath.
n-BuLi (2.5M in Hexanes, 20 mL) was added and the reaction mixture maintained in the
ice bath for 1 h and then warmed up to room temperature. After 2 h the reaction mixture
was quenched by adding small aliquots of saturated aqueous NH
4Cl (40 mL). The mixture was poured into a flask containing ice (100g). The resulting
mixture was extracted with EtOAc (150 mL). The recovered organic phase was washed
with brine (100mL) and then dried over Mg
2SO
4. After filtration and evaporation of the solvent the product 7-butyl-3,9-dimethoxy-7H-benzo[c]fluorene-5,7-diol
was collected (5.5 g). MS analysis supported the molecular weight of the product.
N-21
Step 1
[0231] A mixture of the product of Step 5 of Example 4 in
US 5645767 (20g) 3,9-dimethyl-5-hydroxy-7H-benzo[C]-fluoren-7-one, hydrazine hydrate (50-60%,
130g), anhydrous K
2CO
3 (168g) and diethylene glycol (600 mL) in a 2L reaction flask was heated to reflux
(approx 190 °C) for 6 hrs. The solution was cooled to room temperature and water (350
mL) was added. The resulting mixture was poured into aqueous HCl (6M, 400 mL) and
extracted with EtOAc (2 times with 500 mL each time). The organic phase was collected
and washed with brine (250 mL). After evaporation of the solvent the product 3,9-dimethyl-7H-benzo[c]fluoren-5-ol
(15g) was collected.
Step 2
[0232] Product from Step 1 (5 g) was dissolved in dry diethyl ether (150 mL) in a reaction
flask and the resulting solution cooled to -50 °C in a bath of dry ice in acetone.
n-BuLi (2.5M in Hexanes, 17 mL) was slowly added. The mixture was stirred for 10 minutes
in the cold bath and then 1 h at room temperature. The reaction mixture was poured
into crushed dry ice (30g). Water was added (40 mL) and the solution brought to neutral
pH using diluted HCl. The mixture was extracted with EtOAc (300 mL) and the organic
phase collected. Evaporation of the solvent yielded the product 5-hydroxy-3,9-dimethyl-7H-benzo[c]fluorene-7-carboxylic
acid (4.5g) which was used in the next step without further purification.
Step 3
[0233] The product of Step 2 (4.5g) was dissolved in MeOH (200 mL) and 3 drops of H
2SO
4 were added. The mixture was heated to reflux for 3 hrs and cooled to room temperature.
After evaporation of the solvent, the resulting residue was dissolved in DCM (150
mL) and washed with brine (50 mL). The organic layer was collected and the solvent
evaporated to afford the product methyl 5-hydroxy-3,9-dimethyl-7H-benzo[c]fluorene-7-carboxylate
(4.5g). MS analysis supported the molecular weight of the product.
N-22
Step 1
[0234] Bromo(3-methoxyphenyl)magnesium (1M in THF, 98 mL) was poured into a dry 1L flask
and the mix cooled in an ice bath. Bis[2-(N,N-dimethylamino)-ethyl] ether (18.6 mL)
was added in one portion while stirring. After 25 min the solution was slowly added
to a chilled solution of 4-biphenyl carbonyl chloride (21 g) in dTHF (40 mL). After
10 min the ice bath was removed and the reaction was mixed at room temperature for
12 hrs. Water (150 mL) was added to the reaction mixture, and the pH adjusted to 5
with HCl conc. (10 mL). The mixture was extracted using EtOAc (2 times with 300 mL
each time). The recovered organic fraction was then washed with water (200 mL), brine
(200 mL) and dried over Mg
2SO
4. After filtration and evaporation of the solvent the product (28g) was collected.
MS analysis supported the molecular weight of [1,1'-biphenyl]-4-yl(3-methoxyphenyl)methanone.
Step 2
[0235] Steps 1 to 5 of Example 1 in
US2006/0228557A1 were followed except that [1,1'-biphenyl]-4-yl(3-methoxyphenyl)methanone was used
in place of 3,4-dimethoxy-4'-bromobenzophenone to produce 2-methoxy-7,7-dimethyl-9-phenyl-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-23
[0236] Steps 1 to 5 in Example 1 in
US2006/0228557A1 were followed except that [1,1'-biphenyl]-4-yl(3-methoxyphenyl)methanone was used
in place of 3,4-dimethoxy-4'-bromobenzophenone and in Step 4 ethyl lithium was used
instead of methyl magnesium chloride to produce 7,7-diethyl-2-methoxy-9-phenyl-7H-benzo[c]fluoren-5-ol.
MS analysis supported the molecular weight of the product.
N-24
Step 1
[0237] Into a 1 L reaction flask containing acetic anhydride (600 mL) was added 7,7-dimethyl-7H-benzo[c]fluoren-5-ol
(150 g) followed by the addition of, 4-dimethylaminopyridine( DMAP) (0.2 g). The reaction
mixture was heated to 130°C and maintained at this temperature for 2 to 3 hours. The
resulting reaction mixture was cooled to 120°C and maintained at this temperature
overnight and cooled to room temperature prior to being poured into ice water and
stirred for 2 hours. An off-white solid formed and was collected by filtration. The
recovered solid was washed with water, and then with MeOH/water (v/v, 50/50). The
product 7,7-dimethyl-7H-benzo[c]fluoren-5-yl acetate was air-dried to yield 175 g
solid and was used in the next step without further purification.
Step 2
[0238] Into a 1 L reaction flask containing 400 mL of DMF was added the product of Step
1 (120 g) followed by the addition of N-bromosuccinimide (NBS, 82 g). The reaction
mixture was heated to 90°C, spiked to 120°C briefly and returned to about 95°C and
was heated at this temperature for 4 hours. Additional NBS was added (8 g) and the
reaction mixture was heated for 2 more hours. The resulting reaction mixture was poured
into water and was extracted with EtOAc. The recovered organic layer was washed with
water (3 x 200 mL), dried over MgSO
4 and concentrated under vacuum to provide product. The product was slurried in MeOH
and the solid was recovered by filtration, washed with MeOH (3 x 200 mL) and dried
to provide a light yellowish solid (107 g). The product 9-bromo-7,7-dimethyl-7H-benzo[c]fluoren-5-yl
acetate was used in the next step without purification.
Step 3
[0239] Into a 1 L reaction flask containing MeOH (500 mL) was added the product of Step
2 (107 g) followed by the addition of conc. HCl, 37% (3 g). The reaction mixture was
heated to reflux for 2 hours. The solvents were removed from the resulting reaction
mixture to yield about 100 g solid. The recovered solid was slurried in about 250
mL of DCM /Hexanes (v/v, 50/50) for 10 minutes at room temperature. The slurry was
filtered and the recovered solid was washed with DCM/Hexanes (v/v, 5/5) to provide
about 47 g of product. NMR analysis showed the product to have a structure consistent
with 7,7-dimethyl-9-bromo-7H-benzo[c]fluoren-5-ol.
Step 4
[0240] The product of Step 3 (3 g) and 4-methoxy phenyl boronic acid (2 g) were added to
a 0.5 L reaction flask containing a solution of dimethoxyethane (150 mL) and water
(50 mL) followed by the addition of K
2CO
3 (3.7 g) and triphenylphosphine (1.15g). The resulting solution was bubbled with nitrogen
for 10 minutes and then palladium acetate (0.2 g) was added to the reaction mixture.
The reaction mixture was heated to reflux under a nitrogen atmosphere. After 4h, the
reaction mixture was cooled to room temperature and poured into 400 mL of water followed
by extraction with EtOAc (2 x 150 mL). The recovered organic layers were combined
and washed with brine (200 mL). This organic layer was dried over Mg
2SO
4 and, after filtration and evaporation of the solvents yielded the product (3.5 g)
which was used in the next step without purification. MS analysis supported the molecular
weight of the product 9-(4-methoxyphenyl)-7,7-dimethyl-7H-benzo[c]fluoren-5-ol.
N-25
[0241] The procedure of Step 4 of N-30 was followed except that 4-dimethylaminophenyl boronic
acid instead of 4-methoxy phenyl boronic acid was used to produce 9-(4-(dimethylamino)phenyl)-7,7-dimethyl-7H-benzo[c]fluoren-5-ol.
The product was used without purification.
N-26
[0242] The procedure of Step 4 of N-30 was followed except that 2-methoxy phenyl boronic
acid instead of 4-methoxy phenyl boronic acid was used to produce 9-(2-methoxyphenyl)-7,7-dimethyl-7H-benzo[c]fluoren-5-ol.
The product was used without purification.
N-27
Step 1
[0243] Steps 2 to 5 of Example 10 in
US 2006/0228557A1 were followed except that [1,1'-biphenyl]-4-yl(3-methoxyphenyl)methanone was used
in place of 3,4-dimethoxy-4'-phenhylbenzophenone to produce 2-methoxy-7-oxo-9-phenyl-7H-benzo[c]fluoren-5-yl
acetate.
Step 2
[0244] Product from Step1 (15 g) was dissolved in MeOH (200 mL) in a reaction flask and
HCl (36%, 0.5 mL) was added. The mixture was refluxed for 3 hrs and cooled to room
temperature. The solvent was evaporated, the resulting residue dissolved in DCM (150
mL) and washed with brine (80 mL). After evaporation of the solvent, the product 5-hydroxy-2-methoxy-9-phenyl-7H-benzo[c]fluoren-7-one
(14 g) was collected. The product was used without purification.
Part 3 - Preparation of Photochromic Intermediates - Comparative Examples (CE) 1-73
CE-1
[0245] Example 5 in
US 5645767 was followed to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-hydroxy-3H,13Hindeno[2,1-f]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-2
[0246] Example 2 at column 86, lines 30 to 51 in
US 7465415B2 was followed to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-3
[0247] The procedure of Example 2 at column 86, lines 30 to 51 in
US 7465415B2 was followed except that ethylene glycol was used in place of triethylene glycol
to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-hydroxyethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-4
[0248] The procedure from Example 2 at column 86, lines 30 to 51 in
US 7465415B2 was followed except that allyl alcohol was used in place of triethylene glycol to
produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(allyloxy)-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-5
Step 1
[0249] Into a 0.5L reaction flask the product N-6 (4.6g) and product PA-2 (6.2g) were dissolved
in DCM (300 mL). PTSA (0.15g) was added and the mixture was stirred at room temperature
for 4 hrs. The reaction mixture was washed with water (200 mL) and then the solvent
was evaporated. The resulting residue was purified by column chromatography eluting
with DCM/EtOAc (4/1, V/V) to provide the product (7.3g). NMR analysis showed the product
to have a structure consistent with 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-hydroxy-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
Step 2
[0250] The procedure from Example 2 at column 86, lines 30 to 51 in
US 7465415B2 was followed except that product from Step 1 was used in place of 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-hydroxy-3H,13H-indeno[2,1-f]
naphtho [1,2-b]pyran to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-6
[0251] The procedure of Example 2 in
US2006/0228557A1 was followed to produce 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11-carboxy-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-7
Step 1
[0252] The procedure of CE-4 was employed except that the product of Step 1 in CE-5 was
used instead of 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-hydroxy-3H,13H-indeno
[2,1-f] naphtho [1,2-b]pyran to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-(allyloxy)-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
Step 2
[0253] Into a 300 mL flask, the product from Step1 (0.8 g) was dissolved in DCM (13 mL)
and then ε-caprolactone monomer (1.7 mL) and aluminum isopropoxide catalyst (0.1 g)
were added. The reaction mixture was stirred at room temperature for 14 hrs. Aqueous
HCl (5%, 10 mL) was added and after stirring for 30 minutes the mixture was washed
with water (20 mL). The resulting organic phase was collected and the solvent evaporated.
The residue was filtered through a silica plug and then collected. After evaporation
of the solvent, the product was dissolved in DCM (5mL) and precipitated by adding
hexanes (60 mL). After filtration the final product (0.6g) was collected. NMR analysis
showed the product to have a structure consistent with the starting material in which
5-6 caprolacton units polymerized.
CE-8
Step 1
[0254] Into a 0.5L reaction flask, product N-21 (4.5g) and product PA-4 (4.6 g) were dissolved
in DCM (300 mL). PTSA (0.10g) was added and the mixture was stirred at room temperature
for 12 hrs. The reaction mixture was washed with water (200 mL) and the solvent evaporated.
The resulting residue was purified by column chromatography eluting with DCM/EtOAc
(5/1, V/V) to afford the product (8.0g). The product 3-(4-morpholinophenyl)-3-(4-methoxyphenyl)-
6,11 -dimethyl-13-(methoxycarbonyl)-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran was used
without further purification in the next step.
Step 2
[0255] Into a dry 0.5L reaction flask, the product of Step 1 (8.0g) was dissolved in dry
acetone (250 mL) and dry K
2CO
3 (10 g) was added. The mixture was stirred and 11-bromo -1-undecanol (10g) was added.
The mixture was heated to reflux and after 15 hrs cooled to room temperature. After
filtration, the filtrate was collected and the solvent evaporated. The residue was
purified by column chromatography eluting with DCM/ EtOAc 5/1. The fractions containing
the product were collected to provide the product (8.0g). NMR analysis showed the
product to have a structure consistent with 3-(4-morpholinophenyl)-3-(4-methoxyphenyl)-
6,11-dimethyl-13-(11- hydroxyundecyl)-13-(methoxycarbonyl)-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
CE-9
Step 1
[0256] The procedure described in Step 7 of Example 10 in
US 2006/0228557 was followed except that compound N-20 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11-phenyl-7H-benzo-[C]
fluoren-5-ol to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-butyl-13-hydroxy-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0257] The procedure from Example 2 at column 86, lines 30 to 51 in
US 7465415B2 was followed except that product from Step 1 was used in place of 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-hydroxy-3H,13H-indeno
[2,1-f] naphtho [1,2-b]pyran and ethylene glycol was used in place of triethylene
glycol to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-butyl-13-(2-hydroxyethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-10
[0258] The procedure described in Step 4 of Example 13 of
US2006/0228557A1 was followed except that product N-5 was used in place of 3-methoxy-9-bromo-7,7-dimethy-7H-benzo[C]
fluoren-5-ol to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-phenyl- 6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-11
[0259] The procedure used in Step 1 of CE-5 was followed except that product N-8 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-hexylcarbamoyl-13,13-dimethyl-3H,13H
indeno[2',3':3,4]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-12
[0260] The procedure of Step 5 of Example 7 of
US7465415B2 was followed to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-morpholinophenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-13
[0261] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-14
[0262] The procedure used in Step 1 of CE-5 was followed except that product N-25 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)
-11- (4-(dimethylamino)phenyl) -13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-15
[0263] The procedure used in Step 1 of CE-5 was followed except that product N-19 was used
in place of product N-6 and product PA-22 instead of product PA-2 to produce 3-(4-(2-(allyloxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-(hydroxymethyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-16
[0264] The procedure used in Step 1 of CE-5 was followed except that product N-10 was used
in place of product N-6 to 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-17
[0265] The procedure used in Step 1 of CE-5 was followed except that product N-24 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-11-(4-methoxyphenyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-18
[0266] The procedure used in Step 1 of CE-5 was followed except that product N-25 was used
in place of product N-6 and product PA-6 instead of product PA-2 to produce produce
3-(4-(2-hydroxyethoxy)phenyl)-3-(4-fluorophenyl) -11- (4-(dimethylamino)phenyl) -13,13-dimethyl-3H,13H
indeno[2',3':3,4]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-19
[0267] The procedure used in Step 1 of CE-5 was followed except that product N-26 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-11-(2-methoxyphenyl)-13,13-dimethyl-3H,13Hindeno[2',3':3,4]
naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-20
[0268] The procedure used in Step 1 of CE-5 was followed except that product N-9 was used
in place of product N-6 and product PA-22 instead of product PA-2 to produce 3-(4-(2-(allyloxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-11-hexylcarbamoyl
-13,13-dimethyl-3H,13H indeno[2',3':3,4]naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
CE-21
[0269] The procedure described in Step 2 of CE-7 was followed except that product CE-47
was used in place of 2-(4-(13-(allyloxy)-3-(4-methoxyphenyl)-6,11,13-trimethyl-3,13-dihydrobenzo[h]indeno[2,1-f]chromen-3-yl)phenoxy)ethanol.
NMR analysis shows a product with a structure consistent with the starting material
in which 9 caprolactone units polymerized at the hydroxyl functionality.
CE-22
[0270] The procedure described in Step 7 of Example 10 in
US 2006/0228557A1 was followed except that compound N-19 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11phenyl-7H-benzo-[C]fluoren-5-ol
to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11-(hydroxymethyl) -13,13-dimethyl-3H,13Hindeno[2',3':3,4]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-23
[0271] The procedure of Example 7 of
US 2006/0228557A1 was followed to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11-(4-(hydroxymethyl)phenyl)
-13,13-dimethyl-3H,13H indeno[2',3':3,4]naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
CE-24
[0272] The procedure described in Step 7 of Example 10 in
US 2006/0228557A1 was followed except that compound N-14 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11phenyl-7H-benzo-[C]fluoren-5-ol
to produce 3,3-(di(4-methoxyphenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-13,13-dimethyl-3H,13Hindeno[2',3':3,4]
naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-25
[0273] The procedure of Step 1 of Example 12 of
US 2006/0228557A1 was followed. to produce 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11-bromo-13,13-dimethyl-3H,13H
indeno[2',3':3,4]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-26
[0274] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-3 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-27
[0275] The procedure used in Step 1 of CE-5 was followed except that product N-22 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-28
[0276] Into a 0.5L reaction flask, the product of Step 1 from CE-5 (2.9g) was dissolved
in MeOH (100 mL) and then PTSA (40 mg) was added. The mixture heated to 50 °C for
10 hrs. The reaction mixture was poured into water (200 mL) and filtered to collect
the solid product (2.5g). NMR analysis showed the product to have a structure consistent
with 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)- 6,11,13-trimethyl-13-methoxy-3H,13Hindeno[2,1-f]naphtho[1,2-b]pyran.
CE-29
[0277] In a 0.3L reaction flask, the product CE-28 (1.5g) and succinnic anhydride (2.0 g)
were dissolved in toluene (50 mL). 4-DMAP (30 mg) was added and the mixture heated
to reflux for 4 hrs. The reaction mixture was cooled to room temperature and filtered.
The filtrate was purified by column chromatography on silica gel eluting with hexanes/
DCM (1/1, V/V) and then with MeCN/DCM (1/4, V/V). Fractions containing product were
combined and evaporated to provide the product (1.46g). NMR analysis showed the product
to have s structure consistent with 3-((2-((3-carboxypropanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11,13-trimethyl-13-methoxy-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
CE-30
[0278] The procedure used in Step 1 of CE-5 was followed except that product N-5 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
CE-31
[0279] The procedure used for the preparation of CE-29 was used except that CE-30 was used
instead of CE-28 to produce 3-((2-((3-carboxypropanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-32
[0280] The procedure of Step 7 of Example 1 in
US 7527754B2 was used except that product PA-10 was used in place of 1-(fluorophenyl)-1-(4-piperidinophenyl)-2-propyn-1ol
to produce 3-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-33
[0281] The procedure used in Step 1 CE-5 was followed except that product N-4 was used in
place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-34
[0282] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-18 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-morpholino-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-35
[0283] The procedure used in Step 1 of CE-5 was followed except that product N-11 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-(trifluoromethyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-36
[0284] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-3 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-37
[0285] The procedure used for the preparation of CE-29 was used except that CE-13 was used
instead of CE-28 to produce 3-((2-(3-carboxypropanoyl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-38
[0286] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-8 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(4-hydroxypiperidin-1-yl)phenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-39
[0287] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-8 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(4-hydroxypiperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-40
Step1
[0288] The procedure described in Step 7 of Example 10 in
US 2006/0228557 was followed except that the product from Step1 of N-20 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11phenyl-7H-benzo-[C]fluoren-5-ol
to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-oxo-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
Step 2
[0289] A mixture of product of Step 1 (4g), hydrazine hydrate (50-60%, 12g), anhydrous K
2CO
3 (14g) and diethylene glycol (80 mL) in a 1L reaction flask was heated to reflux (approx
190 °C) for 5 hrs. The solution was cooled to room temperature and water (150 mL)
was added. The resulting mixture was poured into aqueous HCl (6M, 50 mL) and extracted
with EtOAc (2 times with 150 mL each time). The resulting organic phase was collected
and washed with brine (100 mL). After evaporation of the solvent the product 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy
-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 3
[0290] Product from Step 2 (3.2 g) was dissolved in dry diethyl ether (100 mL) in a reaction
flask and the resulting solution cooled to -50 °C in a bath of dry ice in acetone.
n-BuLi (2.5M in Hexanes, 2.7 mL) was slowly added. The mixture was stirred for 10 minutes
in the cold bath and then 45 minutes at room temperature. Iodomethane (1.4 mL) was
added and the mixture stirred for 2 hrs. The reaction mixture was quenched with saturated
aqueous NH
4Cl (30 mL). EtOAc (100 mL) was added and the mixture phase separated. The organic
layer was collected, washed with brine (50 mL) and then dried over Mg
2SO
4. After filtration and evaporation of the solvent the product (3.1g) was collected.
NMR analysis showed the product to have a structure consistent with 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 4
[0291] Product from Step 3 (3.1 g) was dissolved in dry diethyl ether (100 mL) in a reaction
flask and the resulting solution cooled to -50 °C in a bath of dry ice in acetone.
n-BuLi (2.5M in Hexanes, 2.5 mL) was slowly added. The mixture was stirred for 10 minutes
in the cold bath and then 1 h at room temperature. The reaction mixture was poured
into crushed dry ice (10g). Water was added (30 mL) and the solution brought to neutral
pH using diluted HCl. The mixture was then extracted with EtOAc (150 mL) and the organic
phase collected. Evaporation of the solvent yielded the product 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-hydoxycarbonyl-13-methyl-3H,13H
indeno-[2,1-f]naphtho[1,2-b]pyran (3g) which was used in the next step without further
purification.
Step 5
[0292] The product of Step 4 (3 g) was dissolved in ethanol (150 mL) in a reaction flask
and 2 drops of H
2SO
4 were added. The mixture was heated to reflux for 3 hrs and then cooled to room temperature.
After evaporation of the solvent, the resulting residue was dissolved in DCM (100
mL) and washed with brine (50 mL). The organic layer was collected and the solvent
evaporated to provide the product 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-ethoxycarbonyl-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran (3.1 g). the product was used in the next step without
further purification.
Step 6
[0293] The product of Step 5 (3.1g) was dissolved in dTHF (90 mL) in a reaction flask and
the resulting solution cooled to 0 °C in an ice bath. Lithium aluminum hydride (LAH)
was added portion wise (3 portions of 70 mg each). The mixture was stirred for 10
minutes in the ice bath and then 2 hrs at room temperature. The reaction mixture was
quenched with saturated aqueous NH
4Cl (30 mL). EtOAc (150 mL) was added and the mixture phase separated. The organic
layer was collected, washed with brine (50 mL) and then dried over Mg
2SO
4. After filtration and evaporation of the solvent the product (2.9 g) was collected.
NMR analysis showed the product to have a structure consistent with 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-hydroxymethyl-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
CE-41
Step1
[0294] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-16 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(3-bromo-4-(methoxyphenyl)-3-(4-morpholinophenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0295] To a solution of product from Step 1 (0.7g) in THF (40mL) and water (30 mL) in a
reaction flask, KF (0.9g) and the vinylboronic pinacol ester (0.5 mL) were added while
stirring at room temperature. The mixture was degassed for 10 min and then bis(triphenylphosphine)palladium(II)
dichloride (0.14g) was added. The mixture was refluxed for 12 hrs. The reaction was
cooled to room temperature and EtOAc (100 mL) was added. The mixture phase separated.
The resulting organic phase was collected and washed with brine. After evaporation
of the solvent, the residue was collected and purified by column chromatography on
silica gel eluting with hexanes/ DCM (4/1, V/V). The fractions containing the product
were collected to provide the product (0.4 g). NMR analysis showed the product to
have a structure consistent with 3-(3-vinyl-4-(methoxyphenyl)-3-(4-morpholinophenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran.
CE-42
[0296] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-17 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(2-(hydroxymethyl)morpholino)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-43
[0297] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-13 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-3-(4-fluorophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-44
[0298] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-20 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(allyloxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-45
Step1
[0299] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-11 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(4-formylpiperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0300] The product from Step 1 (3.5g) was dissolved in 1,4-dioxane (35 mL) in a reaction
flask, and water (25 mL) was added. The mixture was refluxed until the material was
dissolved and HCl (36%, 4 mL) was added. After 2 hrs of refluxing the mixture was
cooled and poured into a 1L beaker containing aqueous KOH (0.5M, 150 mL). EtOAc (300
mL) was added and the mixture phase separated. The resulting organic phase was washed
with brine (100 mL) and after evaporation of the solvent yielded the product (3.2g).
NMR analysis showed the product to have a structure consistent with 3-(4-fluorophenyl)-3-(4-(piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran.
Step 3
[0301] The procedure used for the preparation of CE-29 was used except that the product
from Step 2 was used instead of CE-28 to produce -(4-fluorophenyl)-3-(4-(4-(3-carboxypropanoyl)piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-46
[0302] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-18 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-47
[0303] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-17 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(piperidin-1-yl)
-11-phenyl-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
CE-48
[0304] The procedure of of Step 5 of Example 7 of
US7465415B2 was followed except that product N-7 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-14 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(2-(hydroxymethyl)morpholino)phenyl)-3-(4-fluorophenyl)-6,7-dimethoxy-11-(4-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-49
[0305] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-13 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-3-(4-fluorophenyl) -13,13-dimethyl-3H,
3H indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-50
[0306] The procedure used in Step 1 of CE-5 was followed except that product N-23 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-diethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-51
[0307] The procedure used in Step 1 of CE-5 was followed except that product N-15 was used
in place of product N-6 to 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-(4-cyanophenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-52
[0308] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-9 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-fluorophenyl)-3-(4-(2-(hydroxymethyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-53
[0309] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-13 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(piperidin-1-yl)
-11-(2-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-54
[0310] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-7 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-3 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(2-(hydroxymethyl)piperidin-1-yl)phenyl)-3-(4-fluorophenyl)-6,7-dimethoxy-11-(4-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-55
[0311] The procedure used in Step 1 of CE-5 was followed except that product N-7 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-(4-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-56
[0312] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-12 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-3 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-(2-(hydroxymethyl)piperidin-1-yl)phenyl)-3-(4-fluorophenyl)-6,7-dimethoxy-11-(phenylethynyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-57
[0313] The procedure described in Step 5 of Example 7 of
US7465415B2 was followed except that product PA-12 was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-phenyl-3-(4-bromophenyl) -13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-58
[0314] The procedure used in Step 1 of CE-5 was followed except that product N-2 was used
in place of product N-6 and product PA-6 instead of product PA-2 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-fluorophenyl)
-6,7-dimethoxy-11- cyano -13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-59
[0315] The procedure used in Step 1 of CE-5 was followed except that product N-2 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)
-6,7-dimethoxy-11- cyano -13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-60
[0316] The procedure used in Step 1 of CE-5 was followed except that product N-16 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(diethylamino)-11-(trifluoromethyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-61
Step1
[0317] Procedure of Step 7 of Example 1 in
US 7527754B2 was used except that product PA-15 was used in place of 1-(fluorophenyl)-1-(4-piperidinophenyl)-2-propyn-1ol
to produce 3-phenyl-3-(3-bromo-4-methoxyphenyl)- 6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0318] The procedure described in Step 2 of CE-41 was followed except that product of Step
1 was used in place of 4-(4-(3-(3-bromo-4-methoxyphenyl)-13,13-dimethyl-3,13-dihydrobenzo[h]indeno[2,1-f]chromen-3-yl)phenyl)morpholine
to produce produce 3-phenyl-3-(3-vinyl-4-methoxyphenyl)- 6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-62 and CE-63
[0319] Product CE-61 (1.0 g) was dissolved in dTHF (50 mL) in a reaction flask, and the
solution stirred under a nitrogen atmosphere. A solution of BH
3-THF complex (1M in THF, 0.9 mL) was added and the mixture was stirred for 2 hrs at
room temperature. Ethanol (1.5 mL), 0.7 mL of NaOH (aqueous 6M, 0.7 mL) and H
2O
2 (aqueous 30%, 1.3 mL) were added and the mixture heated to reflux for 1 h. The mixture
was diluted with EtOAc (100 mL) and brine (50 mL). The resulting organic layer was
collected and purified by column chromatography on silica gel eluting with DCM/EtOAc
(20/1, V/V). Two products were collected. NMR analysis showed that the less polar
product (0.1g) had a structure consistent with CE-63: 3-phenyl-3-(3-(1-hydroxyethyl)-4-methoxyphenyl)-
6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran and the more
polar one had a structure consistent with CE-62: 3-phenyl-3-(3-(2-hydroxyethyl)-4-methoxyphenyl)-
6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
CE-64
Step1
[0320] The procedure described in Step 7 of Example 10 in
US 2006/0228557 was followed except that the product from Step1 of N-20 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11phenyl-7H-benzo-[C]
fluoren-5-ol to produce 3,3-(di(4-methoxyphenyl)-7-methoxy-11-phenyl-13-oxo-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0321] Steps 2 to 5 of CE-40 were followed except that 3,3-(di(4-methoxyphenyl)-7-methoxy-11-phenyl-13-oxo-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran was used in place of 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-oxo-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran to produce 3,3-di(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxymethyl-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-65
[0322] Into a 0.5L reaction flask product N-4 (1.6 g) and product PA-7 (3.0 g) were dissolved
in 1,2-dichloroethane (100 mL). PTSA (0.22 g) was added and the mixture was stirred
at room temperature for 12 hrs. The solvent was evaporated and the resulting residue
dissolved in MeOH (80 mL) and PTSA (0.5 g) was added. The mixture was heated to reflux
for 12 hrs. After that the reaction was cooled to room temperature, the solvent evaporated,
the residue dissolved in THF (100 mL), EtOAc (200 mL) was added and the solution washed
with water (100 mL) and brine (100 mL). After evaporation of the solvents, the residue
was purified by column chromatography eluting with methylene chloride/EtOAc (4/1,
V/V) to provide the product (0.8 g) 3,3-bis(4-(2-hydroxyethoxy)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-66
Step 1
[0323] In a dried 0.5L reaction flask under a nitrogen atmosphere, 4,4'-di-tert-butyl-2,2'dipyridyl
(0.124g) and (1,5-cyclooctadiene) (methoxy)iridinium(I) dimer (0.15g) were added.
Hexanes (60mL), dimethyl isophthalate (3g) and pinacolborane (2.5mL) were charged.
The mixture was stirred at room temperature under a nitrogen atmosphere for 12 hrs.
Water was added (20 mL) and the mixture was extracted with EtOAc (200 mL). The organic
phase was collected, washed with brine (80 mL) and dried over Mg
2SO
4. The residue was collected and purified by column chromatography on silica gel eluting
with hexanes/DCM (1/2, V/V). The fractions containing the product were collected to
provide the product (1.6g). MS analysis supported the molecular weight of dimethyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isophthalate.
Step 2
[0324] The procedure of Step 2 of Example 12 in
US 2006/0228557A1 was used except that product from Step 1 was used instead of 4-phenylboronic acid
to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11- (3,5-bis(methoxycarbonyl)phenyl)
-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
Step 3
[0325] The product of Step 2 (0.3g) was dissolved in dTHF (70 mL) in a reaction flask, and
the mixture cooled to 0 °C with an ice bath. Vitride (65 % solution on toluene, 2.5
mL) was slowly added. The ice bath was removed and the mixture stirred at room temperature
for 12 hrs. Water (6 mL) and aqueous KOH (4M, 1 mL) were added and the mixture extracted
with EtOAc (150 mL). The resulting organic phase was collected, washed with brine
(50 mL) and then the solvent evaporated to provide the product (0.3g). MS and NMR
analysis supported the product to be 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11- (3,5-bis(hydroxymethyl)phenyl)
-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran.
CE-67
[0326] The procedure used in Step 1 of CE-5 was followed except that product N-9 was used
in place of product N-6 and product PA-19 instead of product PA-2 to produce 3,3-di(4-(allyloxy)phenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-11-hexylcarbamoyl
-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis
CE-68
[0327] The procedure described in CE-65 was followed except that N-5 was used in place of
N-4 to produce 3,3-bis(4-(2-hydroxyethoxy)phenyl)-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-69
[0328] The procedure used for the preparation of CE-29 was used except that the product
CE-2 was used instead of CE-28 to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-((3-carboxypropanoyl)oxy)ethoxy)ethoxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-70
Step 1
[0329] In a dried 0.5L reaction flask under a nitrogen atmosphere, product CE-69 (2.1g)
was dissolved in dMeCN (50 mL) and then
N-Hydroxysuccinimide (NHS, 0.38 g) was added. The solution was cooled to 0 °C in an
ice bath and then
N,N'-dicyclohexylcarbodiimide (DCC, 0.68 g) dissolved in dMeCN (10 mL) was slowly added.
The reaction mixture was stirred for 1h at 0 °C and the ice bath removed. After 12
hrs the reaction mixture was filtered and the solid discarded. The liquid phase was
concentrated and purified by column chromatography on silica gel eluting with DCM/EtOAc
(1/1, V/V) to collect the product (3 g) NMR supported the product to be 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-((4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutanoyl)oxy)ethoxy)ethoxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
Step 2
[0330] The product of Step 1 (3 g) was dissolved in pyridine (10 mL) in a reaction flask
and 2,2'-iminodiethanol (0.9 g) was added. The mixture was stirred at room temperature
for 2 days and the solvent was evaporated and MeCN (30 mL) was added. After filtration
the solid was discarded, the filtrate collected and the solvent evaporated. The resulting
product was dissolved in DCM (100 mL) washed with water (100 mL) and purified by column
chromatography on silica gel eluting with DCM/MeOH (4/1, V/V) to collect the product
(2.6 g). NMR analysis showed the product to have a structure consistent with 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((16-hydroxy-14-(2-hydroxyethyl)-10,13-dioxo-3,6,9-trioxa-14-azahexadecyl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
CE-71
[0331] The procedure used in Step 1 of CE-5 was followed except that product N-14 was used
in place of product N-6 to produce 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-72
[0332] The procedure used for the preparation of CE-29 was used except that the product
CE-5 was used instead of CE-28 to produce 3-((2-((3-carboxypropanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-((3-carboxypropanoyl)oxy)ethoxy)ethoxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-73
[0333] The procedure described in CE-65 was followed except that N-10 was used in place
of N-4 to produce 3,3-bis(4-(2-hydroxyethoxy)phenyl)-6-methoxy-7-(piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-74
Step1
[0334] The procedure described in Step 7 of Example 10 in
US 2006/0228557 was followed except that the product of Step 5 of Example 4 in
US 5645767 was used in place of 2,3-dimethoxy-7-hydroxy-7-ethyl-11phenyl-7H-benzo-[C] fluoren-5-ol
to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethyl-13-oxo-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
Step 2
[0335] Steps 2 to 5 of CE-40 were followed except that 3,3-(di(4-methoxyphenyl)-6,11-dimethyl-13-oxo-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran was used in place of 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-oxo-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethyl-13-hydroxymethyl-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
CE-75
[0336] The procedure described in Comparative Example 4 in
US 2006/0228557 was followed to produce 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
CE-76
[0337] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that 1,1-diphenyl-2-propyn-1-ol was used in place of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3,3-diphenyl-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The
structure was supported by NMR analysis.
CE-77
[0338] The procedure described in CE-62 was followed except that product CE41 was used in
place of CE61 to collect only the major component. NMR analysis supported the product
to be 3-(4-morpholinophenyl)-3-(3-(2-hydroxyethyl)-4-methoxyphenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
CE-78
[0339] The procedure of Step 5 of Example 7 of
US7465415B2 was followed except that product N-22 was used instead of 4,7,7-dimethyl-5-hydroxy-7Hbenzo[C]fluorene
and product PA-23 instead of 1-(4-(2-hydroxyethoxy)phenyl)-1-(4-morpholinophenyl)prop-2-yn-1-ol
to produce 3-(4-butoxyphenyl)-3-(4-methoxyphenyl)-7-methox-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Part 4 - Preparation of Examples (E) 1-87
E-1
[0340] In a 300 mL dried single neck flask CE-2 (1.0g) was dissolved in DCM (50 mL) and
the resulting solution cooled to 0 °C under a nitrogen atmosphere. TEA (0.3mL) and
4-DMAP (18 mg) were successively added. A solution of [tris(trimethylsiloxy)silylethyl]dimethyl-chlorosilane
(0.8mL) in DCM (10 mL) was added drop wise. The ice bath was removed and after 12
h aqueous HCl (5%, 30 mL) was added. The mixture phase separated and the recovered
organic layer was washed with water (100 mL). After evaporation of the solvent, the
resulting residue was purified by plug column chromatography on silica gel eluting
with hexanes/DCM (2/1, V/V) and then with hexanes/DCM (1/10, V/V). The fractions containing
the product were collected to provide the product (1.1 g). NMR analysis showed the
product to have a structure consistent with 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2,7,7-tetramethyl-4,4-bis((trimethylsilyl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,
13H indeno[2,1-f]naphtho[1,2-b]pyran.
E-2
[0341] The procedure described in Step 1 to 2 for the preparation of CE-70 was followed
except that 3-aminopropylmethylbis(trimethylsiloxy)-silane was used in place of 2,2'-iminodiethanol
to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2,4-trimethyl-9,12-dioxo-4-((trimethylsilyl)oxy)-3,13,16,19-tetraoxa-8-aza-2,4-disilahenicosan-21-yl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-3
[0342] In a 300 mL dried single neck flask CE-2 (1.0g) was dissolved in DCM (50 mL) and
the resulting solution cooled to 0 °C under a nitrogen atmosphere. TEA (0.46 mL) and
4-DMAP (18 mg) were successively added. A solution of tris(trimethylsiloxy)dimethyl-chlorosilane
(1.1mL) in DCM (10 mL) was added drop wise. The ice bath was removed and after 12
h aqueous HCl (5%, 30 mL) was added. The mixture phase separated and the recovered
organic layer was washed with water (100 mL). After evaporation of the solvent, the
resulting residue was purified by plug column chromatography on silica gel eluting
with hexanes/DCM (2/1, V/V) and then with hexanes/DCM (1/10, V/V). The fractions containing
the product were collected to provide the product (1.3 g). NMR analysis showed the
product to have a structure consistent with 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2-dimethyl-4,4-bis((trimethylsilyl)oxy)-3,5,8,11-tetraoxa-2,4-disilatridecan-13-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
E-4
[0343] The procedure described for E-1 was followed except that [bis(nonafluorohexyldimethylsiloxy)methyl]-silylethyldimethylchlorosilane
was used in place of [tris(trimethylsiloxy)silylethyl]dimethyl-chlorosilane to produce
3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((13-((dimethyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyl)oxy)-18,18,19,19,20,20,21,21,21-nonafluoro-10,10,13,15,15-pentamethyl-3,6,9,14-tetraoxa-10,13,15-trisilahenicosyl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-5
[0344] In a dried flask under a nitrogen atmosphere, CE-69 (1.2g) was dissolved in DCM (50
mL) then 3-[hydroxy(polyethyleneoxy)propyl]-heptamethyltrisiloxane (0.8mL) and 4-DMAP
(17mg) were added. The solution was cooled to 0°C in an ice bath and DCC (0.34 g)
dissolved in DCM (10 mL) was slowly added to the reaction mixture. The reaction mixture
was kept for 90 min at 0°C and then the ice bath was removed. After 10 hrs the solvent
was evaporated and the resulting residue purified by column chromatography on silica
gel eluting with DCM/EtOAc (2/1, V/V) to provide the product (0.4 g). NMR and MS analysis
supported the product to contain mainly 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2,4-trimethyl-21,24-dioxo-4-((trimethylsilyl)oxy)-3,8,11,14,17,20,25,28,31-nonaoxa-2,4-disilatritriacontan-33-yl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
E-6
[0345] The procedure described for E-1 was followed except that CE-3 was used in place of
CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-7
[0346] The procedure described for E-2 was used except that CE-3 was used instead of CE-2
to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-((4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)oxy)ethoxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-8
[0347] The procedure described for E-1 was followed except that CE-1 was used in place of
CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-9
[0348] In a dried flask, CE-4 (1.4 g) was dissolved in toluene (15 mL) and bis(trimethylsiloxy)methylsilane
(0.7 mL) was added. Platinum (0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex
(solution in xylene, Pt ∼2 %, 4 drops) were added. The reaction mixture was stirred
at room temperature. After 24 hrs the solvent was evaporated and the resulting residue
purified by column chromatography on silica gel eluting with DCM /Hexanes (3/2, V/V)
to provide the product (1 g). NMR analysis showed the product to have a structure
consistent with 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran.
E-10
[0349] The procedure described for E-3 was followed except that CE-8 was used in place of
CE-2 to produce 3-(4-morpholinophenyl)-3-(4-methoxyphenyl)- 6,11-dimethyl-13-(11-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)undecyl)-13-(methoxycarbonyl)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-11
[0350] The procedure described in E-9 was followed except that CE-7 was used in place of
CE-4. NMR analysis showed the product to be consistent with the structure of 3-(4-(2-hydroxyethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran with 5-6 units of caprolactone monomers polymerized
at the hydroxyl functionality.
E-12
Step 1
[0351] The procedure described for E-1 was followed except that trivinylchlorosilane was
used in place of [tris(trimethylsiloxy)silylethyl]dimethyl-chlorosilane to produce
3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((3,3-divinyl-4,7,10-trioxa-3-siladodec-1-en-12-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Step 2
[0352] The procedure used in E-9 was followed except that the product of Step 1 was used
instead of CE-4 and the stoichiometry adjusted to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((7,7-bis(2-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)ethyl)-2,2,4-trimethyl-4-((trimethylsilyl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-13
[0353] The procedure described for E-3 was followed except that CE-9 was used in place of
CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-butyl-13-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-14
[0354] The procedure described for E-3 was followed except that CE-40 was used in place
of CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethoxy-13-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-15
[0355] The procedure described for E-3 was followed except that CE-74 was used in place
of CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,11-dimethyl-13-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-16
[0356] The procedure described for E-3 was followed except that CE-64 was used in place
of CE-2 to produce 3,3-di(4-methoxyphenyl)-7-methoxy-11-phenyl-13-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)-13-methyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-17
[0357] The preparation described for E-2 was used except that CE-6 was used instead of CE-2
to produce 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)carbamoyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-18
[0358] The procedure described for E-3 was followed except that CE-22 was used in place
of CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-19
[0359] The procedure described for E-3 was followed except that CE-23 was used in place
of CE-2 to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11-(4-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)phenyl)
-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
E-20
[0360] The procedure described for E-1 was followed except that CE-24 was used in place
of CE-2 to produce 3,3-(di(4-methoxyphenyl)-6-methoxy-7-(3-((((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)methyl)piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-21
[0361] In a dried 0.3 L reaction flask, CE-25 (1.9 g) was dissolved in dTHF (20 mL). The
mix was cooled at -75 °C using a dry ice-acetone bath and stirred under dry nitrogen.
n-BuLi (2M in cyclohexane, 1.9 mL) was added and after 1min tris(trimethylsiloxy)dimethyl-chlorosilane
(1.6 mL) was added. The reaction mixture was left to react in the cold bath for 20
min and then at room temperature for 12 hrs. Water was added (20 mL) and the mixture
extracted with EtOAc (50 mL). The recovered organic phase was washed with brine (30
mL) and the solvent evaporated. The resulting residue was purified by column chromatography
on silica gel eluting with hexanes/DCM (4/1, V/V) to provide the product (0.7 g).
NMR analysis showed the product to have a structure consistent with 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran.
E-22
[0362] The procedure of E-21 was followed except that [tris(trimethylsiloxy)silylethyl]dimethyl-chlorosilane
was used in place of tris(trimethylsiloxy)dimethyl-chlorosilane to produce 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-11-((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-23
[0363] The procedure described for E-3 was followed except that CE-26 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(3-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-24
[0364] The procedure described for E-3 was followed except that CE-13 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-25
[0365] The procedure described for E-3 was followed except that CE-27 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-26
[0366] The preparation described for E-2 was used except that CE-29 was used instead of
CE-2 to produce 3-(4-(2-((4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-methoxy-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-27
[0367] The procedure described for E-1 was followed except that CE-30 was used in place
of CE-2 to produce 3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-28
[0368] The preparation described for E-2 was used except that CE-31 was used instead of
CE-2 to produce 3-(4-(2-((4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-29
[0369] The procedure described for E-3 was followed except that CE-30 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-30
[0370] The procedure described for E-3 was followed except that CE-32 was used in place
of CE-2 to produce 3-phenyl-3-(4-(3-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-
6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-31
[0371] The procedure described for E-3 was followed except that CE-33 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
E-32
[0372] The procedure described for E-3 was followed except that CE-34 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-morpholino
-11-phenyl-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-33
[0373] The procedure described for E-3 was followed except that CE-35 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-(trifluoromethyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-34
[0374] The procedure described for E-3 was followed except that CE-36 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(3-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-35
[0375] The procedure described for E-3 was followed except that CE-10 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-36
[0376] The procedure described for E-3 was followed except that CE-11 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6,7-dimethoxy-11- hexylcarbamoyl-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-37
[0377] The procedure used in E-9 was followed except that CE-15 was used instead of CE-4
to produce 3-(4-(2-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,7-dimethoxy-11-
(hydroxymethyl)-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-38
[0378] The preparation described for E-2 was used except that CE-37 was used instead of
CE-2 to produce 3-(4-(2-((4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-39
[0379] The procedure described for the preparation of E-31 was followed except that Tri-t-terbutoxychlorosilane
was used in place of tris(trimethylsiloxy)dimethyl-chlorosilane to produce 3-(4-(-(2-((tri-tert-butoxysilyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-40
[0380] The procedure described for E-3 was followed except that CE-12 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-41
[0381] The procedure described for E-3 was followed except that CE-16 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6-methoxy-7-(piperidin-1-yl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-42
[0382] The procedure described for E-3 was followed except that CE-17 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-11-(4-methoxyphenyl) -13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The
structure was supported by NMR analysis.
E-43
[0383] The procedure described for E-3 was followed except that CE-14 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-11-(4-(dimethylamino)phenyl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-44
[0384] The procedure described for E-3 was followed except that CE-18 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-fluorophenyl)
-11-(4-(dimethylamino)phenyl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-45
[0385] The procedure described for E-3 was followed except that CE-19 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-11-(2-methoxyphenyl) -13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The
structure was supported by NMR analysis.
E-46
[0386] The procedure described for E-3 was followed except that CE-39 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(4-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)piperidin-1-yl)phenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-47
[0387] The procedure described for E-3 was followed except that CE-40 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(4-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-48
[0388] The procedure described for E-3 was followed except that CE-47 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(4-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-49
[0389] The procedure used in E-9 was followed except that CE-21 was used instead of CE-4.
NMR analysis showed the product to be consistent with the structure of 3-(4-(2-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-11-hexylcarbamoyl-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran with 9 units of caprolactone monomers polymerized
at the hydroxyl functionality.
E-50
[0390] The procedure described for E-3 was followed except that CE-42 was used in place
of CE-2 to produce 3-(4-(2-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)morpholino)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-51
[0391] The procedure described for E-3 was followed except that CE-43 was used in place
of CE-2 to produce 3-(4-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethyl)piperazin-1-yl)phenyl)-3-(4-fluorophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-52
[0392] The procedure used in E-9 was followed except that CE-44 was used instead of CE-4
and to produce 3-(4-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-53
[0393] The preparation described for E-2 was used except that CE-45 was used instead of
CE-2 to produce 3-(4-fluorophenyl)-3-(4-(4-(4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-54
[0394] The procedure used in E-9 was followed except that CE-20 was used instead of CE-4
and to produce 3-(4-(2-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-11-
hexylcarbamoyl -13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-55
[0395] The procedure described for E-1 was followed except that CE-13 was used in place
of CE-2 to produce 3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-56
[0396] The procedure described for E-1 was followed except that CE-26 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-7-methoxy-11-pheny]-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-57
[0397] The procedure described for E3 was followed except that CE-47 was used in place of
CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(piperidin-1-yl)-11-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-58
[0398] The procedure described for E-3 was followed except that CE-48 was used in place
of CE-2 to produce 3-(4-(2-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)morpholino)phenyl)-3-(4-fluorophenyl)-6,7-dimethoxy-11-(4-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-59
[0399] The procedure described for E-3 was followed except that CE-49 was used in place
of CE-2 to produce 3-(4-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethyl)piperazin-1-yl)phenyl)-3-(4-fluorophenyl)-7-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-60
[0400] The procedure described for E-3 was followed except that CE-50 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-7-methoxy-11-phenyl-13,13-diethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-61
[0401] The procedure described for E-3 was followed except that CE-51 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6,7-dimethoxy-11-(4-cyanophenyl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-62
[0402] The procedure described for E-3 was followed except that CE-52 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(2-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-63
[0403] The procedure described for E-3 was followed except that CE-53 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-morpholinophenyl)-6-methoxy-7-(piperidin-1-yl)-11-(2-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-64
[0404] The procedure described for E-3 was followed except that CE-54 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(3-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-6,7-dimethoxy-11-(4-
(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran.
The structure was supported by NMR analysis.
E-65
[0405] The procedure described for E-3 was followed except that CE-55 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6,7-dimethoxy-11-(4-(trifluoromethyl)phenyl)-13,13-dimethyl-3H,13H indeno[2,1-f]
naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-66
[0406] The procedure described for E-3 was followed except that CE-56 was used in place
of CE-2 to produce 3-(4-fluorophenyl)-3-(4-(3-(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)piperidin-1-yl)phenyl)-6,7-dimethoxy-11-(phenylethynyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-67
[0407] The procedure describe for the preparation of E-22 was followed except that CE-57
was used in place of CE-25 to produce 3-4-((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)phenyl-3-phenyl-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-68
[0408] The procedure described for E-3 was followed except that CE-58 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-fluorophenyl)
-6,7-dimethoxy-11-cyano-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The
structure was supported by NMR analysis.
E-69
[0409] The procedure described for E-3 was followed except that CE-59 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6,7-dimethoxy-11-cyano-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The
structure was supported by NMR analysis.
E-70
[0410] The procedure described for E1 was followed except that CE-28 was used in place of
CE-2 to produce 3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-
6,11,13-trimethyl-13-methoxy -3H,13H indeno[2,1-f]naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-71
[0411] The procedure described for E-3 was followed except that CE-60 was used in place
of CE-2 to produce 3-(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)
-6-methoxy-7-(diethylamino)-11-(trifluoromethyl)-13,13-dimethyl-3H,13H indeno[2,1-f]
naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-72
[0412] The procedure used in E-9 was followed except that CE-61 was used instead of CE-4
to produce 3-(3-(2-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)ethyl)-4-methoxy)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-73
[0413] The procedure described for E-3 Was followed except that CE-62 was used in place
of CE-2 to produce 3-(3-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethyl)-4-methoxy)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-74
[0414] The procedure described in E-73 was followed except that tris(trimethylsiloxy)silane
was used instead of bis(trimethylsiloxy)methylsilane to produce 3-(3-(2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)-4-methoxy)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-75
[0415] The procedure described for E-3 was followed except that CE-63 was used in place
of CE-2 to produce 3-(3-(1-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethyl)-4-methoxy)phenyl)-3-phenyl-6,11-difluoro-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-76
[0416] The procedure used in E-9 was followed except that CE-41 was used instead of CE-4
to produce 3-(3-(2-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)ethyl)-4-methoxy)phenyl)-3-(4-morpholinophenyl)
-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
E-77
[0417] The procedure described for E-1 was followed except that CE-5 was used in place of
CE-2 and the stochiometry of the reaction adjusted to produce 3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2,7,7-tetramethyl-4,4-bis((trimethylsilyl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-78
[0418] The procedure described for E-3 was followed except that CE-65 was used in place
of CE-2 and the stochiometry of the reaction adjusted to produce 3,3-bis(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)
-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
E-79
[0419] The procedure described for E-3 was followed except that CE-66 was used in place
of CE-2 and the stoichiometry of the reaction adjusted to produce 3,3-(di(4-methoxyphenyl)-6,7-dimethoxy-11-(3,5-bis(((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)methyl)phenyl)
-13,13-dimethyl-3H,13H indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported
by NMR analysis.
E-80
[0420] The procedure used in E-9 was followed except that CE-67 was used instead of CE-4
and the stoichiometry adjusted to produce 3,3-bis(4-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)phenyl)-6-methoxy-7-(3-(hydroxymethyl)piperidin-1-yl)-11-
hexylcarbamoyl -13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-81
[0421] The procedure described for E-3 was followed except that CE-68 was used in place
of CE-2 and the stoichiometry of the reaction adjusted to produce 3,3-bis(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)
-6,11-difluoro-13,13-dimethyl-3H,13H indeno[2,1-f] naphtho[1,2-b]pyran. The structure
was supported by NMR analysis.
E-82
[0422] The procedure described for E-1 was followed except that CE-69 was used in place
of CE-2 and the stoichiometry of the reaction adjusted to produce 3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13-((11-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethyl)-2,2,7,7-tetramethyl-12,15-dioxo-4,4-bis((trimethylsilyl)oxy)-3,8,16,19,22-pentaoxa-11-aza-2,4,7-trisilatetracosan-24-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-83
[0423] The procedure described for E-3 was followed except that CE-73 was used in place
of CE-2 and the stoichiometry of the reaction adjusted to produce 3,3-bis(4-(2-((1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)oxy)ethoxy)phenyl)-6-methoxy-7-(piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-84
[0424] The preparation described for E-2 was used except that CE-72 was used instead of
CE-2 and the stoichiometry of the reaction adjusted to produce 3-(4-(2-((4-((3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propyl)amino)-4-oxobutanoyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6,11,13-trimethyl-13-((2,2,4-trimethyl-9,12-dioxo-4-((trimethylsilyl)oxy)-3,13,16,19-tetraoxa-8-aza-2,4-disilahenicosan-21-yl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-85
[0425] The procedure described for E-1 was followed except that CE-71 was used in place
of CE-2 and the stoichiometry of the reaction adjusted to produce 3-(4-(2-(((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)ethoxy)phenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(3-((((2-(1,1,1,5,5,5-hexamethyl-3-((trimethylsilyl)oxy)trisiloxan-3-yl)ethyl)dimethylsilyl)oxy)methyl)piperidin-1-yl)-13,13-dimethyl-3H,13H
indeno[2',3':3,4] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-86
[0426] The procedure used for the preparation of E-39 was followed except that CE-65 was
used in place of CE-33 and the stoichiometry of the reagents adjusted to produce 3,3-bis(4-(2-((tri-tert-butoxysilyl)oxy)ethoxy)phenyl)-13,13-dimethyl-3H,13H
indeno[2,1-f] naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
E-87
[0427] The procedure described for E-1 was followed except that Tri-t-terbutoxychlorosilane
was used in place of [tris(trimethylsiloxy)silylethyl]dimethyl-chlorosilane to produce
3,3-(di(4-methoxyphenyl)-6,11,13-trimethyl-13 -((4,4-di-tert-butoxy-2,2-dimethyl-3,5,8,11-tetraoxa-4-silatridecan-13-yl)oxy)-3,8,11,14-tetraoxa-2,4,7-trisilahexadecan-16-yl)oxy)-3H,13H
indeno[2,1-f]naphtho[1,2-b]pyran. The structure was supported by NMR analysis.
Part 4 - Photochromic Performance Testing of Examples (E) and Comparative Examples
(CE)
Part A - Test Square Preparation
[0428] Testing was done with the compounds described in Examples 1-87 and Comparative Examples
1-5, 7-24, 26-30, 32-36, 38-40, 42-56, 58-60, 62, 64, 66, 67, 69, 71 and 74-77 in
the following manner. A quantity of compound calculated to yield a 1.5×10
-3 molal solution was added to a flask containing 50 grams of a monomer blend of 4 parts
ethoxylated bisphenol A dimethacrylate (BPA 2EO DMA), 1 part poly(ethylene glycol)
600 dimethacrylate, and 0.033 weight percent 2,2'-azobis(2-methyl propionitrile) (AIBN).
Each compound was dissolved into the monomer blend by stirring and gentle heating,
if necessary. After a clear solution was obtained, the sample was degassed in a vacuum
oven for 5-10 minutes at 25 torr. Using a syringe, the sample was poured into a flat
sheet mold having an interior dimension of 2.2 mm+/-0.3 mm × 6 inch (15.24 cm) × 6
inch (15.24 cm). The mold was sealed and placed in a horizontal airflow, programmable
oven to ramp from 40° C. to 95°C. over a 5 hour interval, hold the temperature at
95° C. for 3 hours, ramp down to 60° C. over a 2 hour interval and then hold at 60°
C. for 16 hours. After curing, the mold was opened, and the polymer sheet was cut
into 2 inch (5.1 cm) test squares using a diamond blade saw.
Part B - Response Testing
[0429] Prior to response testing on an optical bench, the test squares from Part A were
conditioned by exposing them to 365 nm ultraviolet light for 10 minutes at a distance
of about 14 cm from the source in order to pre-activate the photochromic compounds
in samples. The UVA irradiance at the sample surface was measured with a Licor Model
Li-1800 spectroradiometer and found to be 22.2 Watts per square meter. The samples
were then placed under a halogen lamp (500 W, 120V) for about 10 minutes at a distance
of about 36 cm from the lamp in order to bleach, or inactivate, the photochromic compounds
in the samples. The illuminance at the sample was measured with the Licor spectroradiometer
and found to be 21.9 Klux. The samples were then kept in a dark environment for at
least 1 hour prior to testing in order to cool and continue to fade back to a ground
state.
[0430] The optical bench was fitted with an Newport Model #67005 300-watt Xenon arc lamp,
and Model 69911 power supply, Vincent Associates (model VS25S2ZM0R3 with VMM-D4 controller)
high-speed computer controlled shutter, a Schott 3 mm KG-2 band-pass filter, which
removed short wavelength radiation, neutral density filter(s) to attenuate light from
the xenon lamp, a fused silica condensing lens for beam collimation, and a fused silica
water cell/sample holder for maintaining sample temperature in which the test sample
to be tested was inserted. The temperature in the water cell was controlled with a
pumped water circulation system in which the water passed through copper coils that
were placed in the reservoir of a chiller unit. The water cell used to hold test samples
contained fused silica sheets on the front and back facings in order to eliminate
spectral change of the activation or monitoring light beams. The filtered water passing
through the water cell was maintained at 22±1°C (72° F.±2°) for photochromic response
testing. A Newport Model 689456 Digital Exposure Timer was used to control the intensity
of the xenon arc lamp during activation of the sample.
[0431] A broadband light source for monitoring response measurements was positioned in a
perpendicular manner to a surface of the cell assembly. Increased signal of shorter
visible wavelengths was obtained by collecting and combining separately filtered light
from a 100-Watt tungsten halogen lamp (controlled by a Lambda UP60-14 constant voltage
powder supply) with a split-end, bifurcated fiber optical cable. Light from one side
of the tungsten halogen lamp was filtered with a Schott KG1 filter to absorb heat
and a Hoya B-440 filter to allow passage of the shorter wavelengths. The other side
of the light was either filtered with a Schott KG1 filter or unfiltered. The light
was collected by focusing light from each side of the lamp onto a separate end of
the split-end, bifurcated fiber optic cable, and subsequently combined into one light
source emerging from the single end of the cable. A 10.16 cm (4") light pipe was attached
to the single end of the cable to insure proper mixing. After passing through the
sample, the light was refocused into a 5.08 cm (2-inch) integrating sphere and fed
to an Ocean Optics S2000 spectrophotometer by fiber optic cables. Ocean Optics SpectraSuite
and PPG proprietary software were used to measure response and control the operation
of the optical bench.
[0432] Irradiance for response testing of the samples on the optical bench was established
at the sample surface using an International Light Research Radiometer, Model IL-1700
with a detector system comprising a Model SED033 detector, B Filter and diffuser.
The output display of the radiometer was corrected (factor values set) against a Licor
1800-02 Optical Calibration Calibrator in order to display values representing Watts
per square meter UVA. The irradiance at the sample point for initial response testing
was set at to 3.0 Watts per square meter UVA and approximately 8.6 Klux illuminance.
During sample response testing, if a sample darkened beyond an acceptable detection
capability limit, the irradiance was lowered to 1.0 Watts per square meter UVA or
the sample was remade at a one-half concentration in the copolymer. Adjusting the
output of the filtered xenon arc lamp was accomplished by increasing or decreasing
the current to the lamp through the controller and/or by adding or removing neutral
density filters in the light path. The test samples were exposed to the activation
light at 31° normal to its surface while being perpendicular to the monitoring light.
[0433] Samples were activated in the 73° F(22.8°C) controlled water cell for 30 minutes,
then allowed to fade under room light conditions until the change in optical density
of the activated sample faded to ¼ of its highest dark (saturated) state or for a
maximum of 30 minutes of fade.
[0434] Change in optical density (ΔOD) from the bleached state to the darkened state was
determined by establishing the initial transmittance, opening the shutter from the
Xenon lamp to provide ultraviolet radiation to change the test lens from the bleached
state to an activated (i.e., darkened) state. Data was collected at selected intervals
of time, measuring the transmittance in the activated state, and calculating the change
in optical density according to the formula: ΔOD=log(% Tb/% Ta), where % Tb is the
percent transmittance in the bleached state, % Ta is the percent transmittance in
the activated state and the logarithm is to the base 10.
[0435] The λ
max-vis in the visible light range is the wavelength in the visible spectrum at which the
maximum absorption of the activated form of the photochromic compound occurs. The
λ
max-vis was determined by testing the photochromic test square in a Varian Cary 4000 UV-Visible
spectrophotometer or comparable equipment.
[0436] The ΔOD/Min, which represents the sensitivity of the photochromic compound's response
to UV light, was measured over the first five (5) seconds of UV exposure, then expressed
on a per minute basis. The saturation optical density (ΔOD at saturation) was taken
under identical conditions except UV exposure was continued for a total of 30 minutes.
The fade half life is the time interval in seconds for the ΔOD of the activated form
of the photochromic compound in the test squares to reach one half the ΔOD measured
after thirty minutes, or after saturation or near-saturation was achieved, at room
temperature after removal of the source of activating light, e.g., by closing the
shutter. Results are listed in Table I. Double lines in Table 1 were used to separate
the individual groups of examples and their respective comparative examples.
TABLE 1 - Photochromic Performance Test Results
| E- #'s & CE-#'s |
λmax-vis (nm) |
Sensitivity (ΔOD/Min) |
ΔOD at saturation |
T ½ (sec) |
| E-8 |
566 |
0.714 |
0.945 |
123 |
| CE-1 |
575 |
0.27 |
0.5 |
119 |
| E-1 |
572 |
0.552 |
0.652 |
84 |
| E-3 |
572 |
0.636 |
0.666 |
74 |
| E-4 |
572 |
0.534 |
0.627 |
83 |
| E-12 |
567 |
0.762 |
0.636 |
56 |
| E-87 |
566 |
0.594 |
0.657 |
76 |
| CE-2 |
570 |
0.49 |
0.64 |
104 |
| E-6 |
572 |
0.558 |
0.592 |
74 |
| E-7 |
572 |
0.582 |
0.673 |
85 |
| CE-3 |
572 |
0.486 |
0.641 |
97 |
| E-9 |
572 |
0.57 |
0.778 |
112 |
| CE-4 |
572 |
0.456 |
0.723 |
130 |
| E-77 |
573 |
0.648 |
0.679 |
74 |
| E-84 |
572 |
0.666 |
0.72 |
80 |
| CE-5 |
572 |
0.516 |
0.676 |
99 |
| E-17 |
577 |
0.348 |
0.551 |
129 |
| CE-11 |
577 |
0.29 |
0.51 |
157 |
| E-11 |
567 |
0.636 |
0.707 |
91 |
| CE-7 |
572 |
0.492 |
0.742 |
124 |
| E-10 |
596 |
0.546 |
0.515 |
58 |
| CE-8 |
595 |
0.45 |
0.49 |
79 |
| E-13 |
595 |
0.696 |
0.519 |
56 |
| CE-9 |
599 |
0.57 |
0.58 |
90 |
| E-35 |
560 |
0.648 |
0.871 |
129 |
| CE-10 |
558 |
0.558 |
0.861 |
159 |
| E-36 |
576 |
0.36 |
0.58 |
124 |
| CE-11 |
577 |
0.29 |
0.51 |
157 |
| E-40 |
586 |
0.66 |
0.76 |
78 |
| CE-12 |
588 |
0.486 |
0.617 |
86 |
| E-24 |
580 |
0.69 |
1.101 |
173 |
| E-38 |
583 |
0.684 |
1.057 |
160 |
| E-55 |
584 |
0.672 |
1.01 |
170 |
| CE-13 |
584 |
0.642 |
1.006 |
151 |
| E-43 |
591 |
0.84 |
0.911 |
173 |
| CE-14 |
593 |
0.732 |
0.813 |
158 |
| E-37 |
576 |
0.324 |
0.663 |
247 |
| CE-15 |
577 |
0.306 |
0.74 |
306 |
| E-41 |
571 |
0.108 |
0.432 |
344 |
| CE-16 |
571 |
0.09 |
0.415 |
389 |
| E-42 |
572 |
0.75 |
0.888 |
136 |
| CE-17 |
573 |
0.636 |
0.795 |
138 |
| E-44 |
586 |
0.888 |
1.077 |
285 |
| CE-18 |
589 |
0.672 |
0.866 |
262 |
| E-45 |
567 |
0.672 |
0.883 |
140 |
| CE-19 |
572 |
0.594 |
0.827 |
148 |
| E-54 |
487 |
1.128 |
1.711 |
225 |
| CE-20 |
488 |
0.942 |
1.627 |
233 |
| E-49 |
481 |
1.026 |
1.279 |
153 |
| CE-21 |
482 |
1.008 |
1.473 |
182 |
| E-18 |
577 |
0.384 |
0.77 |
222 |
| CE-22 |
578 |
0.33 |
0.77 |
274 |
| E-19 |
584 |
0.438 |
0.74 |
214 |
| CE-23 |
586 |
0.36 |
0.70 |
264 |
| E-20 |
590 |
0.09 |
0.403 |
410 |
| CE-24 |
590 |
0.09 |
0.405 |
405 |
| E-21 |
580 |
0.408 |
0.784 |
266 |
| E-22 |
576 |
0.396 |
0.772 |
214 |
| CE-75 |
576 |
0.34 |
0.73 |
285 |
| E-23 |
589 |
0.828 |
1.336 |
187 |
| E-56 |
590 |
0.69 |
1.245 |
198 |
| CE-26 |
595 |
0.642 |
1.126 |
203 |
| E25 |
556 |
0.684 |
1.165 |
229 |
| CE-27 |
557 |
0.636 |
1.1 |
237 |
| E-70 |
572 |
0.552 |
0.76 |
110 |
| CE-28 |
572 |
0.45 |
0.696 |
124 |
| E-26 |
572 |
0.57 |
0.763 |
105 |
| CE-29 |
572 |
0.498 |
0.761 |
124 |
| E-27 |
572 |
0.582 |
0.497 |
54 |
| E-28 |
566 |
0.60 |
0.518 |
55 |
| E-29 |
567 |
0.606 |
0.492 |
51 |
| CE-30 |
568 |
0.50 |
0.51 |
67 |
| E-30 |
616 |
0.714 |
0.749 |
69 |
| CE-32 |
618 |
0.55 |
0.70 |
89 |
| E-31 |
557 |
0.66 |
0.878 |
104 |
| E-39 |
558 |
0.648 |
0.868 |
109 |
| CE-33 |
558 |
0.57 |
0.84 |
115 |
| E-32 |
607 |
0.456 |
0.893 |
247 |
| CE-34 |
607 |
0.366 |
0.736 |
236 |
| E-33 |
572 |
0.312 |
0.432 |
90 |
| CE-35 |
572 |
0.24 |
0.37 |
98 |
| E-34 |
593 |
0.78 |
1.021 |
92 |
| CE-36 |
600 |
0.61 |
0.94 |
107 |
| E-46 |
586 |
0.744 |
1.302 |
202 |
| CE-38 |
591 |
0.582 |
1.05 |
215 |
| E-47 |
588 |
0.738 |
1.001 |
104 |
| CE-39 |
593 |
0.612 |
0.92 |
114 |
| E-14 |
596 |
0.792 |
0.896 |
164 |
| CE-40 |
596 |
0.57 |
0.827 |
216 |
| E-76 |
587 |
0.636 |
0.836 |
105 |
| CE-77 |
588 |
0.57 |
0.717 |
93 |
| E-50 |
579 |
0.756 |
1.036 |
162 |
| CE-42 |
583 |
0.402 |
0.679 |
189 |
| E-51 |
580 |
0.738 |
1.309 |
236 |
| CE-43 |
580 |
0.546 |
1.098 |
284 |
| E-52 |
584 |
0.522 |
0.795 |
169 |
| CE-44 |
583 |
0.57 |
0.912 |
179 |
| E-53 |
580 |
0.666 |
1.054 |
131 |
| CE-45 |
580 |
0.57 |
1.041 |
153 |
| E-48 |
592 |
0.762 |
0.977 |
92 |
| CE-46 |
596 |
0.588 |
0.866 |
110 |
| E-57 |
597 |
0.444 |
0.92 |
296 |
| CE-47 |
599 |
0.378 |
0.818 |
298 |
| E-58 |
601 |
0.498 |
0.793 |
180 |
| CE-48 |
604 |
0.396 |
0.707 |
196 |
| E-59 |
583 |
0.72 |
1.079 |
117 |
| CE-49 |
583 |
0.552 |
0.982 |
142 |
| E-60 |
557 |
0.78 |
1.031 |
152 |
| CE-50 |
557 |
0.678 |
0.952 |
162 |
| E-61 |
581 |
0.516 |
0.616 |
153 |
| CE-51 |
581 |
0.43 |
0.59 |
186 |
| E-62 |
596 |
0.786 |
0.96 |
87 |
| CE-52 |
598 |
0.552 |
0.787 |
118 |
| E-63 |
571 |
0.408 |
0.814 |
249 |
| CE-53 |
572 |
0.378 |
0.802 |
247 |
| E-64 |
612 |
0.564 |
0.751 |
134 |
| CE-54 |
618 |
0.414 |
0.613 |
147 |
| E-65 |
580 |
0.414 |
0.657 |
174 |
| CE-55 |
580 |
0.354 |
0.591 |
191 |
| E-66 |
618 |
0.576 |
0.678 |
125 |
| CE-56 |
622 |
0.462 |
0.619 |
140 |
| E-67 |
538 |
0.666 |
1.709 |
756 |
| CE-76 |
532 |
0.41 |
1.5 |
723 |
| E-68 |
572 |
0.342 |
0.44 |
105 |
| CE-58 |
572 |
0.31 |
0.45 |
116 |
| E-69 |
578 |
0.354 |
0.368 |
67 |
| CE-59 |
578 |
0.31 |
0.37 |
78 |
| E-71 |
590 |
0.114 |
0.267 |
178 |
| CE-60 |
590 |
0.078 |
0.219 |
197 |
| E-72 |
561 |
0.642 |
0.906 |
137 |
| E-73 |
560 |
0.696 |
0.943 |
136 |
| E-74 |
562 |
0.654 |
0.913 |
135 |
| E-75 |
557 |
0.66 |
0.91 |
140 |
| CE-62 |
561 |
0.576 |
0.872 |
157 |
| E-16 |
556 |
0.762 |
0.907 |
117 |
| CE-64 |
558 |
0.648 |
0.89 |
158 |
| E-78 |
556 |
0.726 |
0.873 |
95 |
| E-86 |
557 |
0.708 |
0.885 |
105 |
| CE-33 |
558 |
0.57 |
0.84 |
115 |
| E-79 |
583 |
0.384 |
0.611 |
206 |
| CE-66 |
584 |
0.228 |
0.451 |
255 |
| E-80 |
488 |
0.942 |
1.396 |
193 |
| CE-67 |
488 |
0.912 |
1.688 |
260 |
| E-81 |
572 |
0.66 |
0.472 |
42 |
| CE-30 |
568 |
0.50 |
0.51 |
67 |
| E-2 |
572 |
0.636 |
0.668 |
76 |
| E-5 |
573 |
0.678 |
0.665 |
70 |
| E-82 |
572 |
0.546 |
0.645 |
83 |
| CE-69 |
567 |
0.516 |
0.62 |
85 |
| E-85 |
481 |
0.3 |
1.117 |
350 |
| CE-71 |
482 |
0.246 |
1.07 |
375 |
| E-83 |
571 |
0.12 |
0.435 |
307 |
| CE-16 |
571 |
0.09 |
0.415 |
389 |
| E-15 |
565 |
0.702 |
0.796 |
99 |
| CE-74 |
566 |
0.552 |
0.811 |
138 |
Part 6 - Preparation and Testing of Polyurethane Coatings with E-25 and CE-78
Part 6A - Preparation of Coating A containing CE-78
[0437] The following materials were added in the order described to a suitable vessel equipped
with an agitator. Weight percent listed below is based on the total weight of the
coating formulation.
CHARGE 1
[0438]
| MATERIAL |
WEIGHT PERCENT |
| CE-78 |
1.0071 |
| IRGANOX® 245(1) |
0.3357 |
| TINUVIN® 144(2) |
0.3357 |
| NMP(3) |
24.8350 |
(1) An antioxidant/stabilizer available from Ciba Specialty Chemicals Corp.
(2) A light stabilizer of the hindered amine class reported to have CAS# 63843-89-0
and is available from Ciba Specialty Chemicals.
(3) N-methylpyrrolidinone (biotechnical grade) available from Aldrich of Milwaukee,
Wisconsin. |
CHARGE 2
[0439]
| MATERIAL |
WEIGHT PERCENT |
| BYK® 333(4) |
0.0400 |
| K-KAT® 348(5) |
0.5307 |
| A-187(6) |
2.6504 |
(4) A polyether modified dimethylpolysiloxane compolymer, which is available from
BYK-Chemie of Wallingford, Connecticut.
(5) A urethane catalyst reported to be a bismuth carboxylate available from King Industries
Inc.
(6) A gamma-glycidoxypropyl trimethoxysilane, which is available from Osi Specities
of Paris, France. |
CHARGE 3
[0440]
| MATERIAL |
WEIGHT PERCENT |
| Poly(meth)acrylic Polyol(7) |
16.2907 |
| PC-1122(8) |
15.9854 |
| DESMODUR® PL 340(9) |
9.8230 |
| HDI Biuret BI-7960(10) |
28.1663 |
(7) A poly(meth)acrylic polyol produced by following the procedure of Composition
D of Example 1 in U.S. Patent 6,187,444 except that in Charge 2, the styrene was replaced with methyl methacrylate and 0.5
% by weight, based on the total monomer weight, of triphenyl phosphite was added.
(8) Polycarbonate diol sold by Stahl, USA.
(9) A blocked aliphatic polyisocyanate based on IPDI available from Bayer US.
(10) A blocked hexamethylene diisocyanate available from Baxenden Chemical Co. of
Lancashire, England. |
[0441] Charge 1 was added to the vessel and mixed for approximately 30 minutes to dissolve
the solids. Charge 2 was added to the solution and the resulting mixture was stirred
for approximately 5 minutes. The materials of Charge 3 were added in the order listed
to a separate container and mixed prior to adding it to the vessel containing Charges
1 and 2. The resulting mixture was stirred for 1 hour.
Part 6B- Preparation of Coating B containing E-25
[0442] The following materials were added in the order described to a suitable vessel equipped
with an agitator.
CHARGE 1
[0443]
| MATERIAL |
WEIGHT PERCENT |
| E-25 |
1.4387 |
| IRGANOX® 245(1) |
0.4796 |
| TINUVIN® 144(2) |
0.4796 |
| NMP(3) |
24.1156 |
CHARGE 2
[0444]
| MATERIAL |
WEIGHT PERCENT |
| BYK® 333(4) |
0.0400 |
| K-KAT® 348(5) |
0.5307 |
| A-187(6) |
2.6504 |
CHARGE 3
[0445]
| MATERIAL |
WEIGHT PERCENT |
| Poly(meth)acrylic Polyol(7) |
16.2907 |
| PC-1122(8) |
15.9854 |
| IPDI PL 340(9) |
9.8230 |
| HDI Biuret BI-7960(10) |
28.1663 |
[0446] Charge 1 was added to the vessel and mixed for approximately 30 minutes to dissolve
the solids. Charge 2 was added to the solution and the resulting mixture was stirred
for approximately 5 minutes. The materials of Charge 3 were added in the order listed
to a separate container and mixed prior to adding it to the vessel containing Charges
1 and 2. The resulting mixture was stirred for 1 hour.
Part 6C - Preparation of a Protective Coating Formulation (PCF)
[0447] The PCF (Hard Coat) was prepared as follows: Charge 1 was added to a clean dry beaker
and placed in an ice bath at 5°C with stirring. Charge 2 was added and an exotherm
raised the temperature of the reaction mixture to 50°C. The temperature of the resulting
reaction mixture was cooled to 20-25°C and Charge 3 was added with stirring. Charge
4 was added to adjust the pH from about 3 to about 5.5. Charge 5 was added and the
solution was mixed for half an hour. The resulting solution was filtered through a
nominal 0.45 micron capsule filter and stored at 4°C until use.
Charge 1
[0448]
| glycidoxypropyltrimethoxysilane |
32.4 grams |
| methyltrimethoxysilane |
345.5 grams |
Charge 2
[0449]
| Solution of deionized water (DI) with nitric acid (nitric acid lg/7000g) |
292 grams |
Charge 3
[0450]
| DOWANOL® PM solvent |
228 grams |
Charge 4
[0451]
| TMAOH (25% tetramethylamonium hydroxide in MeOH) |
0.45 grams |
Charge 5
[0452]
| BYK®-306 surfactant |
2.0 grams |
Part 6D- Preparation of Coated Lenses
[0453] Finished single vision polycarbonate lenses having a diameter of 70 mm obtained from
Gentex Optics were used. The test lenses were treated with a corona discharge from
a Tantec EST-Electrical Service Treatment unit operating at 500 Watts and 54 kVA for
45 seconds. Coating A and Coating B were each applied by spin-coating separately to
corona treated lens and cured at 125°C for 60 minutes. The resulting cured coatings
were approximately 20 microns thick. The coated test lenses were treated by corona
discharge from a 3DT Flexidyne unit operating at 20 Hertz and 0.70 kilowatts for 35
seconds.
[0454] The hard coat solution (approximately 2 mL) prepared in Part 6C was spin coated at
a rate of 2,550 revolutions per minute (rpm) for 10 seconds onto the cured coated
substrates. Post curing of the coated substrates was completed at 60°C for 30 minutes.
Part 6E - Photochromic Performance Testing
[0455] The photochromic performance of E-25 and CE-78 in the aforementioned coating compositions
was performed as follows. The coated lenses prepared above were tested for photochromic
response on the Bench for Measuring Photochromics ("BMP") optical bench made by Essilor,
Ltd. France. The optical bench was maintained at a constant temperature of 73.4°F
(23°C) during testing.
[0456] Prior to testing on the optical bench, each of the coated lenses were exposed to
365-nanometer ultraviolet light for about 10 minutes at a distance of about 14 centimeters
to activate the photochromic materials. The UVA (315 to 380nm) irradiance at the lens
was measured with a LICOR® Model Li-1800 spectroradiometer and found to be 22.2 watts
per square meter. The lens was then placed under a 500 watt, high intensity halogen
lamp for about 10 minutes at a distance of about 36 centimeters to bleach (inactivate)
the photochromic materials. The illuminance at the lens was measured with the LICOR®
spectroradiometer and found to be 21.9 Klux. The lenses were then kept in a dark environment
at room temperature (from 70 to 75°F, or 21 to 24°C) for at least 1 hour prior to
testing on an optical bench. Prior to optical bench measurement, the lenses were measured
for ultraviolet absorbance at 390 nanometers.
[0457] The BMP optical bench was fitted with two 150-watt ORIEL® Model #66057 Xenon arc
lamps at right angles to each other. The light path from Lamp 1 was directed through
a 3mm SCHOTT® KG-2 band-pass filter and appropriate neutral density filters that contributed
to the required UV and partial visible light irradiance level. The light path from
Lamp 2 was directed through a 3mm SCHOTT® KG-2 band-pass filter, a SCHOTT® short band
400 nm cutoff filter and appropriate neutral density filters in order to provide supplemental
visible light illuminance. A 5.08 cm x 5.08 cm (2 inch x 2 inch) 50% polka dot beam
splitter, at 45° to each lamp is used to mix the two beams. The combination of neutral
density filters and voltage control of the Xenon arc lamp were used to adjust the
intensity of the irradiance. Proprietary software i.e., BMPSoft version 2.1e was used
on the BMP to control timing, irradiance, air cell and sample temperature, shuttering,
filter selection and response measurement. A ZEISS® spectrophotometer, Model MCS 501,
with fiber optic cables for light delivery through the lens was used for response
and color measurement. Photopic response measurements, as well as the response at
four select wavelengths, were collected on each lens.
[0458] The power output of the optical bench, i.e., the dosage of light that the lens was
exposed to, was adjusted to 6.7 Watts per square meter (W/m
2) UVA, integrated from 315-380 nm and 50 Klux illuminance, integrated from 380-780
nm. Measurement of this power setpoint was made using an irradiance probe and the
calibrated Zeiss spectrophotometer. The lens sample cell was fitted with a quartz
window and self-centering sample holder. The temperature in the sample cell was controlled
at 23° C. through the software with a modified Facis, Model FX-10, environment simulator.
Measurement of the sample's dynamic photochromic response and color measurements was
made using the same Zeiss spectrophotometer, with fiber optic cables for light delivery
from a tungsten halogen lamp and through the sample. The collimated monitoring light
beam from the fiber optic cable was maintained perpendicular to the test sample while
passing through the sample and directed into a receiving fiber optic cable assembly
attached to the spectrophotometer. The exact point of placement of the sample in the
sample cell was where the activating xenon arc beam and the monitoring light beam
intersected to form two concentric circles of light. The angle of incidence of the
xenon arc beam at the sample placement point was ≈30° from perpendicular.
[0459] Response measurements, in terms of a change in optical density (ΔOD) from the unactivated
or bleached state to the activated or colored state were determined by establishing
the initial unactivated transmittance, opening the shutter from the Xenon lamp(s)
and measuring the transmittance through activation at selected intervals of time.
Change in optical density was determined according to the formula: ΔOD = log (10)(%Tb/%Ta),
where %Tb is the percent transmittance in the bleached state, %Ta is the percent transmittance
in the activated state. Optical density measurements were based on photopic optical
density.
[0460] The results of this testing are presented below in Table 2, wherein the ΔOD at saturation
is after 15 minutes of activation and the Fade Half Life ("T1/2") value is the time
interval in seconds for the ΔOD of the activated form of the photochromic material
in the coating to reach one half the fifteen-minute ΔOD at 73.4°F (23°C), after removal
of the activating light source. The ΔOD/Min, which represents the sensitivity of the
photochromic compound's response to UV light, was measured over the first five (5)
seconds of UV exposure, then expressed on a per minute basis.
Table 2 - Photochromic Performance Results for E-25 & CE-78
| E- #'s & CE-#'s |
Sensitivity (ΔOD/Min) |
ΔOD at saturation |
T½ (sec) |
| E-25 |
0.39 |
0.80 |
144 |
| CE-78 |
0.34 |
0.71 |
144 |
[0461] The present invention has been described with reference to specific details of particular
embodiments thereof. It is not intended that such details be regarded as limitations
upon the scope of the invention except insofar as to the extent that they are included
in the accompanying claims.